CareDx, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:

☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒	Definitive Proxy Statement
☐	Definitive Additional Materials
☐	Soliciting Material under §240.14a-12

CareDx, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒	No fee required.
☐	Fee paid previously with preliminary materials.
☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

2025

Notice of Annual Meeting

and Proxy Statement

Message from the

Company’s Management

April 25, 2025

Dear CareDx Stockholder,

John W Hanna

President & CEO

2024 was a transformational year for CareDx, Inc.

At our investor day in October, we laid out a three-year plan to achieve $500 million in revenue and $100

million in adjusted EBITDA in 2027, establishing a best-in-class financial profile and delivering on our mission

to create life-changing solutions that enable transplant patients to thrive.

I am proud of the significant strides we have made and appreciate your support as a stockholder.

Together, we will continue to make a positive impact and drive toward our vision of a world where every

patient receives the transplant they need to live longer, fuller lives.

Sincerely,

John W. Hanna | President and CEO

CAREDX, INC. 8000 Marina Boulevard, 4th Floor Brisbane, CA 94005

Notice of Annual Meeting of Stockholders

To Be Held at 10:00 a.m. Pacific Time on Thursday, June 12, 2025

Dear Stockholder:

You are cordially invited to attend the 2025 annual meeting of stockholders (the “Annual Meeting”) of CareDx, Inc., a

Delaware corporation (“CareDx,” “we”, “us”, “our”, or the “Company”). The Annual Meeting will be held on Thursday,

June 12, 2025 at 10:00 a.m. Pacific Time, virtually via live webcast at http://www.virtualshareholdermeeting.com/

CDNA2025, for the following purposes, as more fully described in the accompanying proxy statement:

Our Board of Directors has fixed the close of business on April 15, 2025 as the record date for the Ann ual Meeting.

To elect two Class II directors to serve until the 2026 annual meeting of stockholders or until their successors are

duly elected and qualified;

To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our

fiscal year ending December 31, 2025;

To approve, on an advisory basis, the compensation of our named executive officers;

To approve an amendment to our 2024 Equity Incentive Plan to increase the available shares reserved

thereunder; and

To conduct any other business properly brought before the Annual Meeting and any adjournments or

postponements thereof.

Only stockholders of record on April 15, 2025 are entitled to notice of and to vote at the Annual Meeting. Further

information regarding voting rights and the matters to be voted upon are more fully described in the accompanying

proxy statement.

On or about April 25, 2025 we expect to mail our stockholders a Notice of Internet Availability of Proxy Materials (the

“Notice”) containing instructions on how to access our proxy statement and our annual report. The Notice provides

instructions on how to vote via the Internet or by telephone and includes instructions on how to receive a paper copy

of our proxy materials by mail. The accompanying proxy statement and our annual report can be accessed directly at

http://investors. CareDxinc .com/financial-information/annual-reports.

YOUR VOTE IS IMPORTANT. Whether or not you plan to attend the Annual Meeting, we urge you to

submit your vote via the Internet, telephone or mail as soon as possible so that your shares can be

voted at the Annual Meeting in accordance with your instructions.

Thank you for your continued support of CareDx.

By order of the Board of Directors,

/s/ Michael D. Goldberg | Chairman of the Board of Directors | Brisbane, California | April 25, 2025

Table of Contents

Questions And Answers About The Annual Meeting ................................................................................	1
Proposal No. 1 Election Of Directors ..........................	8
Nominees .........................................................................	8
Vote Required; Board Recommendation ....................	8
Board of Directors and Corporate Governance .......	9
Directors with Terms Expiring at the Annual Meeting-Nominees for Director ....................................	10
Continuing Directors .......................................................	12
Considerations in Evaluating Director Nominees ......	20
Director Independence ..................................................	20
Board Leadership Structure ..........................................	20
Board Diversity of Skills and Expertise .......................	21
Legal Proceedings with Directors ................................	21
Agreements with Directors ............................................	21
Board and Committee Meetings ...................................	21
Compensation Committee Interlocks and Insider Participation .....................................................................	24
Stockholder Recommendations for Nominations to the Board of Directors ....................................................	25
Communications with the Board of Directors .............	26
Corporate Governance Guidelines and Code of Business Conduct and Ethics .......................................	26
Clawback Policy ..............................................................	26
Insider Trading Policy ....................................................	26
Non-Employee Director Stock Ownership Policy ......	27
Executive Officer Stock Ownership Policy ..................	27
Board of Directors’ Role in Risk Oversight .................	27
Director Compensation ..................................................	28
Proposal No. 2 Ratification of Appointment of Independent Registered Public Accounting Firm ...	32
Fees Paid to the Independent Registered Public Accounting Firm ..............................................................	32
Auditor Independence ....................................................	32
Audit and Finance Committee Policy on Pre- Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm ..............................................................	32
Vote Required; Board Recommendation ....................	33
Audit and Finance Committee Report ........................	33
Proposal No. 3 Advisory Vote on Executive Compensation ...................................................................	34
Vote Required; Board Recommendation ....................	34

Proposal No. 4 Approval of 2024 Equity Incentive Plan ......................................................................................	35
Shares Reserved Under the 2024 Plan ......................	35
Important Considerations ..............................................	35
Information on Equity Compensation Plans as of March 31, 202 5 ...............................................................	36
Taking Action to Reduce Burn Rate and Dilution ......	36
Key Features and Governance Practices ...................	38
Summary of the 2024 Plan ............................................	39
Form S-8 Registration Statement ................................	45
New Plan Benefits ..........................................................	45
Federal Income Tax Consequences ............................	45
Vote Required; Board Recommendation ....................	47
Executive Officers ............................................................	48
Legal Proceedings with Executive Officers ................	49
Executive Compensation ...............................................	50
Compensation Discussion and Analysis .....................	50
I. Executive Summary ................................................	50
II. Compensation Philosophy ....................................	52
III. Compensation Determination Process ..............	52
IV. Pay Components ..................................................	55
Compensation Committee Report ................................	61
Summary Compensation Table ....................................	62
Grants of Plan-Based Awards ......................................	63
Outstanding Equity Awards at Fiscal Year-End .........	64
Option Exercises and Stock Vested ............................	68
Pension Benefits .............................................................	69
Pay Ratio Disclosure ......................................................	71
Pay Versus Performance ..............................................	72
Equity Compensation Plan Information .......................	76
Security Ownership of Certain Beneficial Owners and Management ..............................................................	77
Related Party Transactions ...........................................	79
Indemnification Agreements .........................................	79
Rule 10b5-1 Sales Plans ...............................................	79
Policies and Procedures for Related Party Transactions ....................................................................	79
Other Matters .....................................................................	80
Delinquent Section 16(a) Reports ................................	80
Available Information ......................................................	80
Note About Forward-Looking Statements ..................	80
Householding ..................................................................	80
Company Website ..........................................................	81
Appendix A – 2024 Equity Incentive Plan ..................	A - 1
Appendix B – Amendment No.1 to the 2024 Equity Incentive Plan ...................................................................	B - 1

CareDx, Inc.Proxy Statement For 2025

Annual Meeting of Stockholders

To Be Held at 10:00 a.m. Pacific Time on Thursday, June 12, 2025

We sent you this proxy statement and the enclosed proxy card because the Board of Directors (“Board of Directors”)

of CareDx, Inc. (sometimes referred to as “we”, “CareDx” or the “Company”) is soliciting your proxy to vote at the

Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) and any postponements, adjournments or

continuations thereof. The Annual Meeting will be held on Thursday, June 12, 2025 at 10:00 a.m. Pacific Time,

virtually via live webcast at http://www.virtualshareholdermeeting.com/CDNA2025. You are invited to attend the

Annual Meeting and we request that you vote on the proposals described in this proxy statement. However, you do

not need to attend the Annual Meeting to vote your shares. Instead, you may complete, sign and return the enclosed

proxy card or submit your proxy through the Internet or by telephone according to the instructions contained in the

enclosed proxy card.

The Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access this proxy

statement and our annual report is first being mailed on or about April 25, 2025 to all stockholders entitled to receive

notice of and to vote at the Annual Meeting.

Questions and Answers About the Annual

Meeting

The information provided in the “question and answer” format below addresses certain frequently asked questions but

is not intended to be a summary of all matters contained in this proxy statement. Please read the entire proxy

statement carefully before voting your shares.

What matters am I voting on?

You will be voting on:

• the election of two Class II directors to hold office until the 2026 annual meeting of stockholders or until their

successors are duly elected and qualified;

• a proposal to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting

firm for our fiscal year ending December 31, 2025;

• a proposal to approve, on an advisory basis, the compensation of our named executive officers;

• a proposal to approve an amendment to our 2024 Equity Incentive Plan (the “2024 Plan”) to increase the

available shares reserved thereunder; and

• any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.

How does our Board of Directors recommend that I vote?

Our Board of Directors recommends that you vote:

• FOR the election of each of the two directors nominated by our Board of Directors and named in this proxy

statement as Class II directors to serve for a one-year term;

• FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting

firm for our fiscal year ending December 31, 2025;

• FOR the approval of the compensation paid to our named executive officers as disclosed in this proxy statement;

and

• FOR the approval of an amendment to our 2024 Plan to increase the available shares reserved thereunder.

Will there be any other items of business on the agenda?

If any other items of business or other matters are properly brought before the Annual Meeting, your proxy gives

discretionary authority to the persons named on the proxy card concerning those items of business or other matters.

The persons named on the proxy card intend to vote the proxy in accordance with their best judgment. Our Board of

Directors does not intend to bring any other matters to be voted on at the Annual Meeting, and we are not currently

aware of any matters that may be properly presented by others for consideration at the Annual Meeting.

Who is entitled to vote at the Annual Meeting?

Holders of our common stock at the close of business on April 15, 2025, the record date for the Annual Meeting (the

“Record Date”), are entitled to notice of and to vote at the Annual Meeting. Each stockholder is entitled to one vote

for each share of our common stock held as of the Record Date. Stockholders are not permitted to cumulate votes

with respect to the election of directors.

As of the Record Date, there were 55,596,737 shares of common stock outstanding and entitled to vote.

What is the difference between holding shares as a stockholder of record and as a beneficial owner?

Stockholder of Record: Shares Registered in Your Name. If, at the close of business on the Record Date, your

shares were registered directly in your name with Computershare Trust Company, N.A., our transfer agent, then you

are the stockholder of record for such shares. As the stockholder of record, you may vote either electronically at the

Annual Meeting or by proxy.

Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee. If, at the close of business

on the Record Date, your shares were held, not in your name, but rather in a stock brokerage account or by a bank or

other nominee on your behalf, then you are considered the beneficial owner of shares held in “street name.” As the

beneficial owner, you have the right to direct your broker, bank or other nominee how to vote your shares by following

the voting instructions your broker, bank or other nominee provides. If you do not provide your broker, bank or other

nominee with instructions on how to vote your shares, your broker, bank or other nominee may, in its discretion, vote

your shares with respect to routine matters but may not vote your shares with respect to any non-routine matters.

Please see “What if I do not specify how my shares are to be voted?” for additional information.

Do I have to do anything in advance if I plan to attend the Annual Meeting?

The Annual Meeting will be a virtual audio meeting of stockholders, which will be conducted via live audio webcast.

You are entitled to participate in the Annual Meeting only if you were a holder of our common stock as of the close of

business on the Record Date or if you hold a valid proxy for the Annual Meeting.

To participate in the Annual Meeting, you will need the control number included on your proxy card or the Notice. The

live audio webcast will begin promptly at 10:00 a.m. Pacific Time. We encourage you to access the meeting prior to

the start time. Online check-in will begin at 9:45 a.m. Pacific Time and you should allow ample time for the check-in

procedures.

How can I get help if I have trouble checking in or listening to the meeting online?

If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the

technical support number that will be posted on the log-in page at http://www.virtualshareholdermeeting.com/

CDNA2025.

How do I vote and what are the voting deadlin es?

Stockholder of Record: Shares Registered in Your Name. If you are a stockholder of record, you can vote in one of

the following ways:

• You may vote via the Internet or by telephone. To vote via the Internet or by telephone, follow the instructions

provided in the Notice. If you vote via the Internet or by telephone, you do not need to return a proxy card by mail.

Internet and telephone voting are available 24 hours a day. Votes submitted through the Internet or by telephone

must be received by 11:59 p.m. Eastern Time on June 11, 2025 at 1-800-690-6903, or the Internet at

www.proxyvote.com.

• You may vote by mail. If you have received printed proxy materials by mail and would like to vote by mail, you

need to complete, date and sign the proxy card that accompanies this proxy statement and promptly mail it to the

tabulation agent in the enclosed postage-paid envelope so that it is received no later than June 11, 2025. You do

not need to put a stamp on the enclosed envelope if you mail it from within the United States. The persons named

in the proxy card will vote the shares you own in accordance with your instructions on the proxy card you mail.

• You may vote electronically at the Annual Meeting. If you plan to attend the Annual Meeting, please log into

http://www.virtualshareholdermeeting.com/CDNA2025 as a “Stockholder” using the control number available on

your proxy card or the Notice, and vote during the Annual Meeting following the instructions at http://

www.virtualshareholdermeeting.com/CDNA2025.

• Note: If you vote via the Internet, return a proxy card by mail or vote electronically at the Annual Meeting, but do not

give any instructions on a particular matter to be voted on at the Annual Meeting, Michael D. Goldberg, John W.

Hanna and Abhishek Jain, the persons who have been designated as proxy holders by our Board of Directors, will

vote the shares you own in accordance with the recommendations of our Board of Directors. Our Board of

Directors recommends that you vote FOR the election of each of the two directors nominated by our Board of

Directors and named in this proxy statement as Class II directors to serve for a one-year term (Proposal No. 1),

FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting

firm for our fiscal year ending December 31, 2025 (Proposal No. 2), FOR the approval of the compensation paid to

our named executive officers as disclosed in this proxy statement (Proposal No. 3), and FOR the approval of an

amendment to our 2024 Equity Incentive Plan (Proposal No. 4) to increase the available shares reserved

thereunder.

Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee. If you are the beneficial

owner of shares held of record by a broker, bank or other nominee, you will receive voting instructions from your

broker, bank or other nominee. You must follow the voting instructions provided by your broker, bank or other

nominee in order to instruct your broker, bank or other nominee how to vote your shares. The availability of Internet

and telephone voting options will depend on the voting process of your broker, bank or other nominee. As

discussed above, if you are a beneficial owner, you may not vote your shares electronically at the Annual Meeting

unless you obtain a legal proxy from your broker, bank or other nominee.

Can I change my vote or revoke my proxy?

Stockholder of Record: Shares Registered in Your Name. If you are a stockholder of record, you may revoke your

proxy or change your proxy instructions at any time before your proxy is voted at the Annual Meeting by:

• entering a new vote by Internet or telephone;

• signing and returning a new proxy card with a later date;

• delivering a written notice of revocation to our Corporate Secretary prior to the Annual Meeting; or

• attending the Annual Meeting and voting electronically.

Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee. If you are the beneficial

owner of your shares, you must contact the broker, bank or other nominee holding your shares and follow their

instructions to change your vote or revoke your proxy.

What is the effect of giving a proxy?

Proxies are solicited by and on behalf of our Board of Directors. John W. Hanna and Abhishek Jain have been

designated as proxy holders by our Board of Directors. When a proxy is properly dated, executed and returned, the

shares represented by the proxy will be voted at the Annual Meeting in accordance with the instructions of the

stockholder. If no specific instructions are given, however, the shares will be voted in accordance with the

recommendations of our Board of Directors. If any matters not described in this proxy statement are properly

presented at the Annual Meeting, the proxy holders will use their own judgment to determine how to vote your shares.

If the Annual Meeting is postponed or adjourned, the proxy holders can vote your shares on the new meeting date,

unless you have properly revoked your proxy, as described above.

What if I do not specify how my shares are to be voted?

Stockholder of Record: Shares Registered in Your Name . If you are a stockholder of record and you submit a proxy

but you do not provide voting instructions, your shares will be voted:

• FOR the election of each of the two directors nominated by our Board of Directors and named in this proxy

statement as Class II directors to serve for a one-year term (Proposal No. 1);

• FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting

firm for our fiscal year ending December 31, 2025 (Proposal No. 2);

• FOR the approval of the compensation paid to our named executive officers as disclosed in this proxy

statement (Proposal No. 3);

• FOR the approval of an amendment to our 2024 Equity Incentive Plan (Proposal No. 4) to increase the available

shares reserved thereunder; and

• In the discretion of the named proxy holders regarding any other matters properly presented for a vote at the

Annual Meeting.

Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee. If you are a beneficial

owner and you do not provide your broker, bank or other nominee that holds your shares with voting instructions, then

your broker, bank or other nominee will determine if it has discretion to vote on each matter. Brokers do not have

discretion to vote on non-routine matters. Proposal No. 1 (election of directors), Proposal No. 3 (approval of the

compensation of our named executive officers), and Proposal No. 4 (approval of an amendment to our 2024 Equity

Incentive Plan to increase the available shares reserved thereunder) are non-routine matters, while Proposal No. 2

(ratification of appointment of independent registered public accounting firm) is a routine matter. As a result, if you do

not provide voting instructions to your broker, bank or other nominee, then your broker, bank or other nominee may

not vote your shares with respect to Proposal No. 1, Proposal No. 3, or Proposal No. 4, which would result in a

“broker non-vote,” but may, in its discretion, vote your shares with respect to Proposal No. 2. For additional

information regarding broker non-votes, see “What are the effects of abstentions and broker non-votes?” below.

What is a quorum?

A quorum is the minimum number of shares required to be present at the Annual Meeting for the meeting to be

properly held under our amended and restated bylaws (the “Bylaws”) and Delaware law. A majority of the shares of

common stock outstanding and entitled to vote, at the Annual Meeting or by proxy, constitutes a quorum for the

transaction of business at the Annual Meeting. As noted above, as of the Record Date, there were a total

of 55,596,737 shares of common stock outstanding, which means that 27,798,370 shares of common stock must be

represented virtually or by proxy at the Annual Meeting to have a quorum. If there is no quorum, either the chairman

or chairwoman of the meeting or a majority of the shares present at the Annual Meeting may adjourn the meeting to a

later date.

What are the effects of abstentions and broker non-votes?

An abstention represents a stockholder’s affirmative choice to decline to vote on a proposal. If a stockholder

indicates on its proxy card or vote over the Internet or by telephone that such stockholder wishes to abstain from

voting such stockholder’s shares, or if a broker, bank or other nominee holding its customers’ shares of record causes

abstentions to be recorded for shares, these shares will be considered present and entitled to vote at the Annual

Meeting. As a result, abstentions will be counted for purposes of determining the presence or absence of a quorum

and will also count as votes against a proposal in cases where approval of the proposal requires the affirmative vote

of a majority of the shares present and entitled to vote at the Annual Meeting (e.g., Proposal No. 2, Proposal No. 3,

and Proposal No. 4). However, because the outcome of Proposal No. 1 will be determined by a plurality vote (see the

next question below for an explanation of what a plurality vote means), abstentions will have no impact on the

outcome of such proposal as long as a quorum exists.

A broker non-vote occurs when a broker, bank or other nominee holding shares for a beneficial owner does not vote

on a particular proposal because the broker, bank or other nominee does not have discretionary voting power with

respect to such proposal and has not received voting instructions from the beneficial owner of the shares. Broker

non-votes are not considered votes cast or entitled to vote on a proposal and therefore will be counted for purposes of

calculating whether a quorum is present at the Annual Meeting, but will not have any effect on the results of

Proposals Nos. 1 through 4.

How many votes are needed for approval of each proposal and how are votes counted?

• Proposal No. 1: The election of Class II directors requires a plurality vote of the shares of our common stock

present virtually or by proxy at the Annual Meeting and entitled to vote thereon to be approved. This means that

the two nominees who receive the most FOR votes will be elected. You may (i) vote FOR all nominees,

(ii) WITHHOLD your vote as to all nominees, or (iii) vote FOR all nominees except for those specific nominees from

whom you WITHHOLD your vote. Any shares not voted FOR a particular nominee (whether as a result of voting

withheld or a broker non-vote) will not be counted in such nominee’s favor and will have no effect on the outcome of

the election. If you WITHHOLD your vote as to all nominees, you will be deemed to have abstained from voting on

Proposal No. 1, and such abstention will have no effect on the outcome of the proposal.

• Proposal No. 2: The ratification of the appointment of Deloitte & Touche LLP requires an affirmative vote of a

majority of the shares of our common stock present virtually or by proxy at the Annual Meeting and entitled to vote

thereon to be approved. You may vote FOR, AGAINST or ABSTAIN. If you ABSTAIN from voting on Proposal No.

2, the abstention will have the same effect as a vote AGAINST the proposal.

• Proposal No. 3: The approval, on an advisory basis, of the compensation of our named executive officers requires

an affirmative vote of a majority of the shares of our common stock present virtually or by proxy at the Annual

Meeting and entitled to vote thereon to be approved. You may vote FOR, AGAINST or ABSTAIN. If you ABSTAIN

from voting on Proposal No. 3, the abstention will have the same effect as a vote AGAINST the proposal. As an

advisory vote, this proposal is not binding. However, our Board of Directors and Compensation and Human Capital

Committee will consider the outcome of the vote when making future compensation decisions for our named

executive officers.

• Proposal No. 4: The approval of an amendment to our 2024 Equity Incentive Plan to increase the available shares

reserved thereunder requires an affirmative vote of a majority of the shares of our common stock present virtually or

by proxy at the Annual Meeting and entitled to vote thereon to be approved. You may vote FOR, AGAINST or

ABSTAIN. If you ABSTAIN from voting on Proposal No. 4, the abstention will have the same effect as a vote

AGAINST the proposal.

How are proxies solicited for the Annual Meeting and who is paying for such solicitation?

Our Board of Directors is soliciting proxies for use at the Annual Meeting by means of the proxy materials. We will

bear the entire cost of proxy solicitation, including the preparation, assembly, printing, mailing and distribution of the

proxy materials. Copies of solicitation materials will also be made available upon request to brokers, banks and other

nominees to forward to the beneficial owners of the shares held of record by such brokers, banks or other nominees.

The original solicitation of proxies may be supplemented by solicitation by telephone, electronic communication, or

other means by our directors, officers, employees or agents. No additional compensation will be paid to these

individuals for any such services, although we may reimburse such individuals for their reasonable out-of-pocket

expenses in connection with such solicitation. We have retained Innisfree M&A Incorporated to help us solicit proxies.

We will pay Innisfree M&A Incorporated $25,000 plus reasonable expenses for its services.

If you choose to access the proxy materials and/or vote over the Internet, you are responsible for Internet access

charges you may incur. If you choose to vote by telephone, you are responsible for telephone charges you may

incur.

Why did I receive the Notice instead of a full set of proxy materials?

In accordance with the rules of the Securities and Exchange Commission (the “SEC”), we have elected to furnish our

proxy materials, including this proxy statement and our annual report, primarily via the Internet. Stockholders may

request to receive proxy materials in printed form by mail or electronically by e-mail by following the instructions

contained in the Notice. We encourage stockholders to take advantage of the availability of our proxy materials on

the Internet to help reduce the environmental impact of our annual meetings of stockholders.

What does it mean if I received more than one Notice?

If you receive more than one Notice, your shares may be registered in more than one name or in different accounts.

Please follow the voting instructions on each Notice to ensure that all of your shares are voted.

Who will count the votes?

The votes will be counted, tabulated and certified by Broadridge Financial Solutions, Inc.

Is my vote confidential?

Proxies, ballots and voting tabulations are handled on a confidential basis to protect your voting privacy. This

information will not be disclosed either within CareDx or to third parties, except as necessary to meet applicable legal

requirements, to allow for the tabulation of votes and certification of the vote, or to facilitate a successful proxy

solicitation.

Do CareDx’s executive officers and directors have an interest in any of the matters to be acted upon at the

Annual Meeting?

Dr. Cohen and Mr. Riggsbee each have an interest in Proposal No. 1 (election of directors), as each nominee is

currently a member of our Board of Directors. Members of our Board of Directors and our executive officers do not

have any interest in Proposal No. 2 (ratification of appointment of independent registered public accounting firm). Our

executive officers have an interest in Proposal No. 3 (approval of the compensation of our named executive officers),

as compensation for our current and former executive officers is subject to this vote. Members of our Board of

Directors and our executive officers have an interest in Proposal No. 4 (approval of an amendment to our 2024 Equity

Incentive Plan to increase the available shares reserved thereunder), as each would be eligible to receive equity

awards under the plan.

Will members of the Board of Directors attend the Annual Meeting?

We encourage, but do not require, the members of our Board of Directors to attend the Annual Meeting. Those who

do attend will be available to answer appropriate questions from stockholders.

I share an address with another stockholder, and we received only one paper copy of the proxy materials.

How may I obtain an additional copy of the proxy materials?

We are sending only one annual report and proxy materials to multiple stockholders who share the same address

unless we received contrary instructions from one or more of the stockholders. This practice, known as

“householding,” reduces our printing and mailing costs. Stockholders who participate in householding will continue to

be able to access and receive separate proxy cards. Upon written or oral request, we will promptly deliver a separate

copy of the proxy materials and annual report to any stockholder at a shared address to which we delivered a single

copy of any of these documents. To receive a separate copy, or, if you are receiving multiple copies, to request that

we only send a single copy of next year’s proxy materials and annual report, you may contact us as follows:

CareDx, Inc.

Attention: Corporate Secretary

8000 Marina Boulevard, 4th Floor

Brisbane, CA 94005

(415) 287-2300

Stockholders who hold shares in street name may contact their broker, bank or other nominee to request information

about householding.

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in

a Current Report on Form 8-K (“Form 8-K”) that we expect to file within four business days after the Annual Meeting.

If final voting results are not available to us by such date, we intend to file a Form 8-K to publish preliminary results

and, within four business days after the final results are known to us, file an amendment to the Form 8-K to publish

the final results.

What is the deadline to propose actions for consideration at next year’s annual meeting of stockholders or to

nominate individuals to serve as directors?

Stockholder Proposals

Stockholders may present proper proposals for inclusion in our proxy statement and for consideration at the next

annual meeting of stockholders by submitting their proposals in writing to our Corporate Secretary in a timely manner.

For a stockholder proposal to be considered for inclusion in our proxy statement for our 2026 annual meeting of

stockholders, our Corporate Secretary must receive the written proposal at our principal executive offices no later

than December 30, 2025. In addition, stockholder proposals must comply with the requirements of Rule 14a-8 under

the Securities Exchange Act of 1934, as amended (the “Exchange Act”), regarding the inclusion of stockholder

proposals in company-sponsored proxy materials. Stockholder proposals should be addressed to:

CareDx, Inc.

Attention: Corporate Secretary

8000 Marina Boulevard, 4th Floor

Brisbane, CA 94005

Our Bylaws also establish an advance notice procedure for stockholders who wish to present a proposal before an

annual meeting of stockholders but do not intend for the proposal to be included in our proxy statement. Our Bylaws

provide that the only business that may be conducted at an annual meeting is business that is brought (i) pursuant to

our proxy materials with respect to the annual meeting specified in the notice of meeting (or any supplement thereto),

(ii) by or at the direction of our Board of Directors, or (iii) properly before the annual meeting by a stockholder of

record entitled to vote at the annual meeting who has delivered timely written notice to our Corporate Secretary, which

notice must contain the information specified in our Bylaws.

To be timely for our 2026 annual meeting of stockholders, our Corporate Secretary must receive the written notice at

our principal executive offices:

• not earlier than February 13, 2026; and

• not later than March 15, 2026.

In the event that we hold our 2026 annual meeting of stockholders more than 30 days before or after the first

anniversary of the date of the Annual Meeting, then notice of a stockholder proposal that is not intended to be

included in our proxy statement must be received no earlier than the close of business on the 120th day before such

annual meeting and no later than the close of business on the later of the following two dates:

• the 90th day prior to such annual meeting; or

• the 10th day following the day on which public announcement of the date of such annual meeting is first made.

If a stockholder who has notified us of such stockholder’s intention to present a proposal at an annual meeting does

not appear to present such stockholder’s proposal at such annual meeting, we are not required to present the

proposal for a vote at such annual meeting.

In addition, pursuant to Rule 14a-19 of the Exchange Act (“Rule 14a-19”), the SEC’s universal proxy rule, notices of a

solicitation of proxies in support of director nominees other than our own nominees must be postmarked or

electronically submitted no later than April 13, 2026, and each nomination must comply with the SEC regulations

under Rule 14a-19, which requires, among other things, that such notice include a statement that such person intends

to solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election

of directors. If, however, the date of the 2026 annual meeting of stockholders is more than 30 days before or after

June 13, 2026, then the Rule 14a-19 deadline shall be the later of 60 calendar days prior to the date of the 2026

annual meeting of stockholders or the 10th calendar day following the day on which we first make a public

announcement of the date of our 2026 annual meeting of stockholders. A nomination that does not comply with the

requirements set forth in the Certificate of Incorporation and Bylaws will not be considered for presentation at the

annual meeting. We intend to file our proxy statement and white proxy card with the SEC in connection with our

solicitation of proxies for our 2026 annual meeting of stockholders.

Nomination of Director Candidates

You may propose director candidates for consideration by our Governance and Nominating Committee. Any such

recommendations should include the nominee’s name and qualifications for membership on our Board of Directors

and should be directed to our Corporate Secretary at the address set forth above. For additional information

regarding stockholder recommendations for director candidates, see “Board of Directors and Corporate Governance -

Stockholder Recommendations for Nominations to the Board of Directors.”

In addition, our Bylaws permit stockholders to nominate directors for election at an annual meeting of stockholders.

To nominate a director, the stockholder must provide the information required by our Bylaws. The stockholder must

also give timely notice to our Corporate Secretary in accordance with our Bylaws, which, in general, require that the

notice be received by our Corporate Secretary within the time period described above under “Stockholder Proposals”

for stockholder proposals that are not intended to be included in a proxy statement.

Availability of Bylaws

A copy of our Bylaws may be obtained by accessing our public filings on the SEC’s website at www.sec.gov. You may

also contact our Corporate Secretary at our principal executive office for a copy of the relevant Bylaw provisions

regarding the requirements for making stockholder proposals and nominating director candidates.

Proposal No. 1

Election of Directors

Our Board of Directors is currently composed of ten members. In accordance with our amended and restated

certificate of incorporation (the “Certificate of Incorporation”), our Board of Directors is currently divided into three

classes with staggered three-year terms. At the Annual Meeting, two Class II directors will be elected for a one-year

term to succeed the same class whose term is then expiring.

Each director’s term continues until the election and qualification of such director’s successor, or such director’s

earlier death, resignation, or removal. Any increase or decrease in the number of directors will be distributed among

the three classes so that, as nearly as possible, each class will consist of one-third of our directors. The current

classification of our Board of Directors may have the effect of delaying or preventing changes in control of our

company. However, our Certificate of Incorporation provides for the gradual elimination of the classification of our

Board of Directors over a three year period starting in 2025 and provides for the annual election of all directors

beginning at our 2027 annual meeting of stockholders.

One of our current directors, William A. Hagstrom, is not standing for re-election and will be stepping down from the

Board when his current term expires at the Annual Meeting. We would like to thank Mr. Hagstrom for his guidance

and valuable contributions during his decade of dedicated service on the Board of Directors.

Nominees

Our Governance and Nominating Committee has recommended, and our Board of Directors has approved, Fred E.

Cohen, M.D., D. Phil and R. Bryan Riggsbee as nominees for election as Class II directors at the Annual Meeting. If

elected, Dr. Cohen and Mr. Riggsbee will each serve as Class II directors until the 2026 annual meeting of

stockholders or until their successors are duly elected and qualified. Each of the nominees is currently a director of

our company. For information concerning the nominees, please see the section titled “Board of Directors and

Corporate Governance.”

If you are a stockholder of record and you sign your proxy card or vote over the Internet or by telephone but do not

give instructions with respect to the voting of directors, your shares will be voted FOR the re-election of Dr. Cohen

and Mr. Riggsbee. We expect that Dr. Cohen and Mr. Riggsbee will each accept such nomination; however, in the

event that a director nominee is unable or declines to serve as a director at the time of the Annual Meeting, the

proxies will be voted for any nominee who shall be designated by our Board of Directors to fill such vacancy. If you

are a beneficial owner of shares of our common stock and you do not give voting instructions to your broker, bank or

other nominee, then your broker, bank or other nominee will leave your shares unvoted on this matter.

Vote Required; Board Recommendation

The election of Class II directors requires a plurality vote of the shares of our common stock present virtually or by

proxy at the Annual Meeting and entitled to vote thereon to be approved. Abstentions and broker non-votes will have

no effect on this proposal.

OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ELECTION OF EACH OF THE TWO

DIRECTORS NOMINATED BY OUR BOARD OF DIRECTORS AND NAMED IN THIS PROXY STATEMENT AS

CLASS II DIRECTORS TO SERVE FOR A ONE-YEAR TERM.

BOARD OF DIRECTORS AND CORPORATE GOVERNANCE

Our business affairs are managed under the direction of our Board of Directors, which is currently composed of 10

members. Our Board of Directors is divided into three classes with staggered three-year terms. At the Annual

Meeting, a class of directors will be elected for a one-year term to succeed the same class whose term is then

expiring. As noted above, our Certificate of Incorporation provides for the gradual elimination of the classification of

our Board of Directors over a three year period starting in 2025 and provides for the annual election of all directors

beginning at our 2027 annual meeting of stockholders.

The following table sets forth the name, age as of April 15, 2025 and certain other information of each of our d irectors:

Name	Class	Age	Position	Director Since	Current Term Expires	Expiration of Term For Which Nominated
Directors with Terms Expiring at the Annual Meeting
Director Nominees
Fred E. Cohen, M.D., D. Phil (2)	II	68	Director	2003	2025	2026
R. Bryan Riggsbee (3)	II	54	Director	2024	2025	2026
Non-Continuing Director
William A. Hagstrom (1)(5)	II	67	Director	2015	2025	—
Continuing Directors
George W. Bickerstaff, III (1)(3)(4)	I	69	Director	2014	2027	—
Christine M. Cournoyer (1)(3)	I	73	Director	2019	2027	—
Hannah A. Valantine, M.D. (2)(4)	I	73	Director	2021	2027	—
Michael D. Goldberg	III	67	Chairman of the Board of Directors	2011	2026	—
John W. Hanna	III	45	Director	2024	2026	—
Peter Maag, Ph.D. (2)	III	58	Director	2012	2026	—
Arthur A. Torres (4)	III	78	Director	2021	2026	—

(1) M ember of our Compensation and Human Capital Committee

(2) Member of our Technology and Innovation Committee

(3) Member of our Audit and Finance Committee

(4) Member of our Governance and Nominating Committee

(5) Mr. Hagstrom is not standing for re-election

Directors with Terms Expiring at the Annual Meeting

Director Nominees

Professional Experience • Founder & Chairman, Monograph Capital Partners (2021 - Present) • Founder & Senior Managing Director, Vida Ventures (2017 - Present) • Senior Advisor & Partner, TPG (2001 - Present) • Professor (Cellular and Molecular Pharmacology), University of California, San Francisco (UCSF) (1988 - 2016)
Key Skills & Qualifications • Relevant Industry Experience: Dr. Cohen’s thought leadership in biotechnology as an elected member of the National Academy of Medicine of the National Academy of Sciences and fellow of the American College of Physicians, among other organizations, and experience as Professor of Cellular and Molecular Pharmacology at UCSF, is an asset to the Board in assessing the firm’s strategy. • Investment, Finance or Accounting Experience: As founder and Senior Managing Director of Vida Ventures and as a Partner and more recently a Senior Advisor at TPG, Dr. Cohen is well-versed in investment and financial matters specific to biotechnology companies. • Public Company Board or Governance Experience: Dr. Cohen has served on multiple public boards and committees including most recently at Progyny, Intellia Therapeutics and Urogen Pharma.
Other Boards • Director, Kyverna Therapeutics (2020 - Present) • Director, Progyny (Nasdaq: PGNY) (2019 - Present (service will conclude in June 2025)) • Director, Intellia Therapeutics (Nasdaq: NTLA) (2019 - Present) • Director, Urogen Pharma (Nasdaq: URGN) (2017 - 2024) • Director, Novotech (2017 - Present) • Director, Tandem Diabetes (Nasdaq: TNDM) (2013 - 2019) • Director, Biocryst (Nasdaq: BCRX) (2013 - 2019) • Director, Five Prime Therapeutics (Nasdaq: FPRX) (2013 - 2018) • Director, Veracyte (Nasdaq: VCYT) (2013 - 2019) • Director, Roka Biosciences (Nasdaq: ROKA) (2014 - 2017) • Director, Quintiles (NYSE: Q) (merged with IQVIA Holdings) (2013 - 2015)
Current Organizations • Member, American Academy of Arts and Sciences • Fellow, National Academy of Medicine • Fellow, American Medical Informatics Association
Previous Organizations • Trustee, Autistica • Fellow, American College of Physicians • Member, Association of American Physicians • Fellow, Western Association of Physicians • Member, American Society for Clinical Investigation
Education • Ph.D., Oxford University • M.D., Stanford University • B.S., Yale University

Fred E.

Cohen, M.D.,

D. Phil

Independent Director

Age: 68

Independent Director

since 2014

Committees :

• Technology and

Innovation Committee

Professional Experience • CFO, Myriad Genetics (Nasdaq: MYGN) (2014 – 2024) • Interim President and CEO, Myriad Genetics (Nasdaq: MYGN) (2020) • Senior Vice President, Corporate Finance, Laboratory Corporation of America (LabCorp) (NYSE: LH) (2004-2014)
Key Skills & Qualifications • Financial Planning and Analysis • Strategic Planning • Risk Management • Compliance and Regulatory Standards • Treasury • Certified Public Accountant licensed in the state of North Carolina
Current Organizations • N/A
Previous Organizations • Myriad Genetics • Laboratory Corporation of America (LabCorp) • General Electric • KPMG
Education • M.B.A., Northwestern University • B.A. (Political Science), University of North Carolina at Chapel Hill • B.A. (Accounting), North Carolina State University

R. Bryan

Riggsbee

Independent Director

Age: 54

Independent Director

since 2024

Committees:

• Audit & Finance

Committee (Chairman)

Continuing Directors

Professional Experience • Partner & MD, M.M. Dillon & Co. (2005 - Present) • Scientific Advisor, American Oriental Bioengineering (Nasdaq: AOBI) (2008 - 2012) • CFO, Novartis Pharma AG (2000 - 2005) • EVP & CFO, Workspace (1999 - 2000) • EVP & CFO, Uniscribe Professional Services (1998 - 1999) • EVP & CFO, Intellisource Group (1998) • Vice President (Finance), Cognizant (1997) • CFO, IMS Health (1990 - 1997) • Senior Vice President (Finance), Dun & Bradstreet (NYSE: DNB) (1985 - 1989) • Auditor & Engineer, General Electric (1978 - 1984)
Key Skills & Qualifications • Business and Operations Leadership Experience: Through various executive positions, including as CFO of Novartis Pharma, Mr. Bickerstaff has developed a deep understanding of business and operations in the healthcare sector. • Investment, Finance or Accounting Experience: Mr. Bickerstaff’s experience in investment banking at MM Dillon as well as more than a decade of experience in senior finance roles equip him with the necessary knowledge to advise on financial matters. • Public Company Board or Governance Experience: Mr. Bickerstaff has served on the boards of multiple public healthcare companies, including most recently at Innoviva, Sio Gene Therapies and Inovio Pharmaceuticals.
Other Boards • Director, InCarda Therapeutics (2020 - 2023) • Director, Innoviva (Nasdaq: INVA) (2017 - 2023) • Director, RoosterBio (2017 - 2020) • Chairman, Optical Academy (2017 - 2019) • Independent Chairman, Cardax (2016 - 2021) • Director, Aegis Health Analytics (2014 - 2016) • Director, Livwel Therapeutics (2008 - 2011) • Director, Sio Gene Therapies (Nasdaq: SIOX) (2018 - 2020) • Director, Inovio Pharmaceuticals (Nasdaq: INO) (2017 - 2018) • Director, Ariad Pharmaceuticals (Nasdaq: ARIA) (2016 - 2017) • Director, Viventia Bio Inc. (2015 - 2017) • Director, Cyclica Inc. (2010 - 2014) • Director, BMP Sunstone (Nasdaq: BJGP) (2008 - 2009) • Director, Vion Pharmaceuticals (Nasdaq: VION) (2005 - 2008) • Director, Amazys Holding (2005 - 2006)
Current Organizations • Founding Member, The Global Leaders • Chairman, International Vaccine Institute
Previous Organizations • Vice Chairman, International Centre for Missing & Exploited Children • Chairman, Global Oncology • Director, Center for Disease Dynamics, Economics & Policy Inc. • Director, Gavi, the Vaccine Alliance
Education • B.S., Rutgers University • B.A., Rutgers University

George W.

Bickerstaff, III

Independent Director

Age: 69

Independent Director

since 2014

Committees:

• Audit & Finance

• Governance &

Nominating

• Compensation and

Human Capital

Professional Experience • Professor of Medicine, Stanford School of Medicine (2000 - Present) • Chief Officer (Scientific Workforce Diversity), National Institutes of Health (2014 - 2020) • Senior Associate Dean for Diversity and Leadership, Stanford School of Medicine (2005 - 2014) • Assistant Professor of Medicine, Stanford School of Medicine (1987 - 2000) • Registrar, Hammersmith Hospitals NHS Trust
Key Skills & Qualifications • Relevant Industry Knowledge: Dr. Valantine has more than thirty-five years of expertise in transplant medicine. She is an international leader in the development and application of genomic-based diagnostics for acute rejection, having led the first ever randomized controlled trial of gene-expression profiling published in the New England Journal of Medicine, setting the stage for FDA approval. She further advanced the field by publishing the first application of donor-derived cell-free DNA as a sensitive and specific biomarker for heart transplant rejection, an approach that has become widely adopted across all other solid organ transplants. Her pioneering work across several platforms has enabled the advancement of a multi-modality approach to molecular diagnostics services. • ESG: Dr. Valantine’s experience in ESG matters spans more than two decades. She is nationally recognized for her transformative approaches to enhancing both gender and racial diversity among faculty. As the inaugural Senior Associate Dean for Diversity and Leadership at Stanford University School of Medicine, and then as the inaugural NIH Chief Officer for scientific workforce diversity, she has built and disseminated successful national programs to ensure both workforce diversity and health equity across the NIH research ecosystem.
Other Boards • Director, BridgeBio Pharma (Nasdaq: BBIO) (2021 - Present) • Director, Pacific Biosciences (Nasdaq: PACB) (2021 - Present)
Current Organizations • Founder & Principal, HAV • Member, National Academy of Medicine • Member, Stanford Cardiovascular Institute
Previous Organizations • President (Western State Affiliation), American Heart Association
Education • M.D., London University • Fellowship, Stanford University • M.B.B.S., London University

Hannah A.

Valantine,

M.D.

Independent Director

Age: 73

Independent Director

since 2021

Committees:

• Governance &

Nominating Committee

• Technology and

Innovation Committee

(Chairwoman)

Professional Experience • Vice President, QIAGEN N.V. (NYSE: QGEN) (2019) • Chairman & CEO, N-of-One (2012 - 2019) • Vice President (Clinical Analytics), Optum (part of UnitedHealth Group) (2010 - 2011) • President & COO, Picis (acquired by UnitedHealth Group) (2006 - 2010) • Managing Director (Solutions), Harte-Hanks (2005 - 2006) • CIO & Division Vice President, IBM (NYSE: IBM) (1995 - 2002) • SVP, CIO, Lotus Development (1994 - 1995)
Key Skills & Qualifications • Relevant Industry Knowledge: Ms. Cournoyer has extensive experience as an executive in the life sciences industry and healthcare technology, including at N- of-One, Optum and Picis. • M&A or Corporate Development Experience: Ms. Cournoyer has led or contributed to two transformative M&A transactions - while CEO at N-of-One, Ms. Cournoyer led the strategic sales process and successful sale to QIAGEN, and while at Picis, she contributed to Picis’ sale to UnitedHealth Group in an executive capacity. • Investment, Finance or Accounting Experience: Ms. Cournoyer managed P&L, raised capital and managed cash operations for different organizations including N-of-One, Picis and IBM, among others. • Risk Management: As a former CIO, Ms. Cournoyer has a deep understanding of IT controls and cyber security.
Other Boards • Chairman, Spok Holdings (Nasdaq: SPOK) (2022 - Present) • Director, Emerson Hospital (2012 - 2018) • Director, BJ’s Wholesale Club (NYSE: BJ) (2008 - 2011) • Director, GTEC (2003 - 2006) • Director, Lightbridge (Nasdaq: LTBR) (2002 - 2003) • Director, Stride Rite (Nasdaq: LRN) (2001 - 2007)
Current Organizations • Board of Advisors, Manning School of Business • Member, Madam Chair
Education • M.A., Northeastern University • B.S., University of Massachusetts Lowell

Christine M.

Cournoyer

Independent Director

Age: 73

Independent Director

since 2019

Committees:

• Audit & Finance

• Compensation &

Human Capital

(Chairwoman)

Professional Experience • CEO, Kyverna Therapeutics (Nasdaq: KYTX) (2022 - 2024) • Executive Chairman, CareDx (Nasdaq: CDNA) (2020 - 2021) • CEO & President, CareDx (Nasdaq: CDNA) (2012 - 2020) • Division President, Novartis Diagnostics AG (NYSE: NVS) (2009 - 2012) • CEO & Country President, Novartis AG, Germany (NYSE: NVS) (2006 - 2008) • CEO & Country President, Novartis AG, Korea (2003 - 2005) • Head of Division (Franchise Infectious Diseases), Novartis AG (2002 - 2003) • Head of Strategy (Pharma Division), Novartis AG (2001 - 2002) • Associate Principal, McKinsey & Company (1994 - 2001)
Key Skills & Qualifications • Business and Operations Leadership Experience: Dr. Maag’s 20+ years of executive management experience in the pharmaceutical and diagnostic industry including as former CEO of CareDx and as President of Diagnostics qualify him to advise the Board on matters specific to CareDx’s business and strategy. • Risk Management: Dr. Maag has deep expertise in risk management as he has served as a director of multiple healthcare companies, including Novartis, MiroMatrix Medical, and as the former Chairman and CEO of CareDx. • M&A or Corporate Development Experience: Dr. Maag served in positions at Novartis Pharma and Novartis Diagnostics including as Head of Strategy where he was instrumental in the global growth of the organization. During his tenure at CareDx, he has led multiple acquisitions and financial transactions.
Other Boards • Director, Kyverna Therapeutics (2022 - 2024) • Director, MiroMatrix Medical (2021 - 2023), MiroMatrix was acquired by United Therapeutics (Nasdaq: UTHR) in December 2023 • Director, Phoenix Pharmahandel (2012 - Present) • Director, MolecularMD (2012 - 2020) • Director, Chiron France (2009 - 2012) • Director, Novartis AG, Germany (2006 - 2008) • Director, Zuellig Pharma (2003 - 2005) • Director, Novartis, Korea (2003 - 2005)
Current Organizations • Director, Personalized Medicine Coalition • Director, BluLake Ventures LLC
Education • Ph.D., University of Berlin • MSc, University of Heidelberg, University of London

Peter K. Maag,

Ph.D.

Independent Director

Age: 58

Independent Director

since 2024

Committees:

• Technology and

Innovation Committee

Professional Experience • Partner, Mohr Davidow Ventures (2005 - 2011) • Founder & CEO, Axion (1987 - 1995) (acquired by Bristol-Myers Squibb, NYSE: BMS) • Partner, Sevin Rosen Management Company (1985 - 1987) • Director (Corporate Development), Cetus Corporation (1981 - 1985)
Key Skills & Qualifications • Relevant Industry Knowledge: Mr. Goldberg has a track record of leadership in healthcare, as the former CEO of Axion and a founding and a former Board member of the California Institute for Regenerative Medicine. Mr. Goldberg is also a former director of Cetus Corporation, which developed the foundational PCR technology for precision medicine. • Public Company Board or Governance Experience: As a director at multiple public companies, Mr. Goldberg has extensive experience working with management teams and Board members on business matters and governance policies. • Business and Operations Leadership Experience: Mr. Goldberg’s experience as founder and CEO of Axion, as well as Executive Chair at DNAnexus and Senior Executive and Venture Capital Investor with numerous companies in the Life Sciences industry, helps the Board develop and oversee our operations and business strategy.
Other Boards • Executive Chairman & Director, DNAnexus (2013 - Present) • Chairman; Director, former Chairman YorLabs (2018 - Present) • Chairman, iRhythm Technologies (Nasdaq: IRTC) (2007 - 2010) • Chairman, Crescendo Biosciences (2007 - 2010) (acquired by Myriad Genetics, Nasdaq: MYGN) • Director, eHealth (Nasdaq: EHTH) (1999 - 2021) • Director, Genomic Health (acquired by Exact Sciences, Nasdaq: EXAS) (2001 - 2007)
Previous Organizations • Founding Board Member, California Institute for Regenerative Medicine • Board Member, Western Association of Venture Capitalists • Advisory Board Member, Harvard Center for Genetics and Genomics • Advisory Board Member, Berkeley Center for Law and Technology • Advisory Board Member, UCSF Center for Translational and Policy Research on Personalized Medicine • Advisory Board Member, Stanford Distinguished Careers Institute • Trustee, National Childhood Cancer Foundation
Education • M.B.A., Stanford Graduate School of Business • B.A., Brandeis University

Michael

Goldberg

Chairman of the Board

of Directors

Age: 67

Independent Director

since 2011

Professional Experience • Director, San Francisco Municipal Transportation Agency (2017 - 2020) • President & Member, San Francisco Public Utilities Commission (2010 - 2014) • Vice President, Montgomery Asset Management • Member Covered California Board of Directors • Chairman, California Democratic Party (1996 - 2009) • Senator, California State Senate (1982 - 1994) • Chair, California Assembly Health Committee (1978 - 1994)
Key Skills & Qualifications • Regulatory and Legal Experience: Mr. Torres’ extensive career in politics and government and background in law qualifies him to advise on regulatory and governance matters. • Relevant Industry Knowledge: As Chair of the California Assembly Health Committee and California Senate Insurance Committee and the Vice Chair of One Legacy, an organ transplant foundation, Mr. Torres has the experience necessary to set strategy for our organization. • ESG: During his tenure in the California state legislature, Mr. Torres worked to provide a voice for his constituents as co-author of the California Clean Water Act and consultant on immigration reform, among other initiatives.
Current Organization • PFM, Board Member, Member Audit Committee • Lifeguard Health Networks, Member, Board of Directors
Previous Organizations • Vice Chair Emeritus, California Institute for Regenerative Medicine • Vice Chair, Emeritus, One Legacy, an Organ Transplant Foundation • University of California Regent Emeritus & President Emeritus, University of California Alumni Association • Alumni Regent Designate Emeritus, University of California • Board Member Emeritus, Covered California • Fellow, German Marshal Fund • JFK Teaching Fellow, Harvard University
Education • J.D., University of California Davis School of Law • B.A. (Government), University of California Santa Cruz

Arthur A.

Torres

Independent Director

Age: 78

Independent Director

since 2021

Committees:

• Governance &

Nominating Committee

(Chairman)

Professional Experience • President and Chief Executive Officer, CareDx, Inc. (2024 - Present) • Vice President, Corporate Development (Pacific Biosciences of California, Inc. (2023 – 2024) • CEO, Apton Biosystem, Inc. (2021 – 2023) • Chief Commercial Officer, Veracyte, Inc. (2011 – 2021)
Key Skills & Qualifications • Relevant Industry Knowledge: Mr. Hanna has over two decades of experience in the molecular diagnostics and life sciences tools industries. • Business and Operations Leadership Experience: Mr. Hanna previously served as CEO of Apton Biosystems, Inc. where he led the development of a high throughput next-generation sequencing (NGS) platform for liquid biopsy and other clinical applications. The company was acquired by Pacific Biosciences of California, Inc. in August 2023, where he served as Vice President of Corporate Development. Mr. Hanna previously spent ten years at Veracyte, Inc., an oncology diagnostics company in the fields of thyroid, lung, breast, and prostate cancer, where he held numerous roles including Chief Commercial Office and Vice President of Marketing. Prior to Veracyte, Mr. Hanna held leadership roles at Humana and IBM.
Current Organization • CareDx, Inc.
Previous Organizations • Pacific Biosciences of California, Inc. • Apton Biosystem, Inc. • Veracyte, Inc.
Education • M.B.A., University of Miami • B.S. (Political Science), Hampden Sydney College

John W.

Hanna

Director, President and

Chief Executive Officer

of CareDx

Age: 45

Director since 2024

Non-Continuing Directors

Professional Experience • Co-Founder and Chairman (2023 – Present) and CEO (2016 - 2023), Octave Biosciences • CEO, Crescendo Bioscience (acquired by Myriad Genetics, Nasdaq: MYGN) (2007 - 2014) • President, Alpha BioPartners • Co-Founder, Biolytx Pharmaceuticals • Co-Founder, Altheus Therapeutics • Initial CEO, Selexys Pharmaceuticals (2003 - 2004) • Interim CEO, Inoveon (2001 - 2003) • Chairman, President & CEO, Urocor (Nasdaq: UCOR) (1989 - 1999) • Division Vice President (Scientific Products Division), Baxter Travenol (1985 - 1989)
Key Skills & Qualifications • Investment, Finance or Accounting Experience: Mr. Hagstrom has deep knowledge of finance, capital formation and financial modeling through his track record as a founder and executive, including as the former President of Crescendo Bioscience, which was acquired by Myriad Genetics. • Business and Operations Leadership Experience: Mr. Hagstrom has extensive experience developing pipelines, infrastructure and commercial strategy at several companies in specialty and molecular diagnostics, as demonstrated by his tenure at Crescendo Bioscience and as the co-founder and CEO of Octave Biosciences. • Regulatory and Legal Experience: In addition to his experience as a founder, Mr. Hagstrom held multiple management and executive positions at large multinational healthcare companies where he managed the legal and regulatory risks specific to medical products companies.
Other Boards • Director, MetaSign Dx (2025 - Present) • Director, CoFactor Genomics (2018 – Present) • Director, Genalyte (2016 - 2019) • Director, Navican Genomics (2016 - 2017) • Executive Director, Crescendo Bioscience (2007 - 2014) • Director, Inoveon (2000 - 2003) • Director, Prometheus Labs (1998 - 2003) • Chairman, Urocor (Nasdaq: UCOR) (1989 - 1999) • Director, Zymetx (Nasdaq: ZMTX) (1994 - 1998) • Chairman, President & CEO, Urocor (Nasdaq: UCOR) (1989 - 1999)
Current Organization • Advisor, Astoria Biologica • Advisor, Biolytx Pharmaceuticals
Previous Organizations • Advisor, Convergent Genomics • Advisor, Guardant Health
Education • B.S., Bob Jones University

William A.

Hagstrom

Independent Director

Age: 67

Independent Director

since 2015

Committees:

• Compensation &

Human Capital

Committee

Considerations in Evaluating Director Nominees

Our Governance and Nominating Committee uses a variety of methods for identifying and evaluating director

nominees. In its evaluation of director candidates, our Governance and Nominating Committee will consider the

composition of our Board of Directors, including, without limitation, issues of character, integrity, judgment, diversity,

age, independence, skills, education, expertise, business acumen, business experience, length of service,

understanding of our business and other commitments. Members of our Board of Directors are expected to prepare

for, attend, and participate in all Board of Directors and applicable committee meetings. Our Governance and

Nominating Committee requires the following minimum qualifications to be satisfied by any nominee for a position on

our Board of Directors: (i) the highest personal and professional ethics and integrity, (ii) proven achievement and

competence in the nominee’s field and the ability to exercise sound business judgment, (iii) skills that are

complementary to those of the existing Board of Directors, (iv) the ability to assist and support management and

make significant contributions to our success, and (v) an understanding of the fiduciary responsibilities that are

required of a member of our Board of Directors and the commitment of time and energy necessary to diligently carry

out those responsibilities. Other than the foregoing, there are no stated minimum criteria for director nominees,

although our Governance and Nominating Committee may also consider such other factors as it may deem, from time

to time, are in our and our stockholders’ best interests.

Although our Board of Directors does not maintain a specific policy with respect to board diversity, our Board of

Directors believes that our Board of Directors should be a diverse body in terms of experiences and backgrounds,

and our Governance and Nominating Committee considers a broad range of factors in identifying new nominees. In

determining nominations of directors, our Governance and Nominating Committee may take into account the benefits

of varying viewpoints, industry experience, academic experience, and educational backgrounds. Our Governance

and Nominating Committee also considers these and other factors as it oversees the annual Board of Directors and

committee evaluations. After completing its review and evaluation of director candidates, our Governance and

Nominating Committee recommends to our full Board of Directors the director nominees for selection.

Director Independence

Our common stock is listed on the Nasdaq Global Market. Under the rules of The Nasdaq Stock Market LLC (the

“Nasdaq Rules”), independent directors must comprise a majority of a listed company’s Board of Directors. In

addition, the Nasdaq Rules require that, subject to specified exceptions, each member of a listed company’s audit,

compensation, and nominating and corporate governance committees be independent. Under the Nasdaq Rules, a

director will only qualify as an “independent director” if, in the opinion of the listed company’s Board of Directors, the

director does not have a relationship that would interfere with the exercise of independent judgment in carrying out

the responsibilities of a director.

Audit and Finance Committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the

Exchange Act and the Nasdaq Rules. In addition, Compensation and Human Capital Committee members must

satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act and the Nasdaq Rules.

Our Board of Directors has undertaken a review of the independence of each director and considered whether such

director has a material relationship with us that could compromise the director’s ability to exercise independent

judgment in carrying out the director’s responsibilities. As a result of this review, our Board of Directors has

determined that Mr. Goldberg, Mr. Bickerstaff, Dr. Cohen, Dr. Maag, Ms. Cournoyer, Mr. Hagstrom, Mr. Riggsbee,

Senator Torres and Dr. Valantine are “independent directors” as defined under the applicable rules and regulations of

the SEC and the Nasdaq Rules. Accordingly, all of the members, including the chairman or chairwoman, of each of

the Audit and Finance Committee, the Compensation and Human Capital Committee and the Governance and

Nominating Committee are independent directors.

Board Leadership Structure

Our Board of Directors has an independent Chairman, Mr. Goldberg, and we believe that having independent

leadership is an important component of our governance structure. Our independent Chairman has authority, among

other things, to preside over Board of Directors meetings, including meetings of the independent directors, and to call

special meetings of our Board of Directors. Accordingly, the independent Chairman has substantial ability to shape

the work of our Board of Directors. We currently believe that having an independent Chairman creates an

environment that is more conducive to objective evaluation and oversight of management’s performance, increasing

management accountability and improving the ability of our Board of Directors to monitor whether management’s

actions are in the best interests of our Company and our stockholders.

In addition, we believe that separation of the roles of Chairman and Chief Executive Officer enhances the

accountability of our Chief Executive Officer to our Board of Directors and encourages balanced decision making.

While our Chief Executive Officer is responsible for our day-to-day leadership and operations, our independent

Chairman provides guidance to our Board of Directors and sets the agenda for the meetings of the Board of Directors.

However, no single leadership model is right for all companies and at all times. Our Board of Directors recognizes

that, depending on the circumstances, other leadership models, such as combining the role of Chairman with the role

of Chief Executive Officer, might be appropriate. Accordingly, our Board of Directors periodically reviews its

leadership structure and will continue to evaluate and implement the leadership structure that it concludes most

effectively supports our Board of Directors in fulfilling its responsibilities.

Board Diversity of Skills and Expertise

The following is an overview of the collective experiences, qualifications and attributes of our Board of Directors.

Please see the sections titled “Directors with Terms Expiring at the Annual Meeting-Nominees for Director” and

“Continuing Directors” for individual details regarding the experience and expertise of each of our directors.

Director Skills / Qualifications	Goldberg	Bickerstaff	Cohen	Cournoyer	Hagstrom	Hanna	Maag	Riggsbee	Torres	Valantine	Board Composition
Relevant Industry Knowledge	•	•	•	•	•	•	•	•	•	•	10 of 10
Business and Operations Leadership Experience	•	•	•	•	•	•	•	•			8 of 10
Investment, Finance or Accounting Experience	•	•	•	•	•	•	•	•	•		9 of 10
Public Company Board or Governance Experience	•	•	•	•	•	•	•	•	•		9 of 10
Risk Management	•	•	•	•	•	•	•	•			8 of 10
M&A or Corporate Development Experience	•	•	•	•	•	•	•	•			8 of 10
Regulatory and Legal Experience	•	•	•	•	•	•	•	•	•		9 of 10
Female				•						•	2 of 10
Independent	•	•	•	•	•		•	•	•	•	9 of 10

Legal Proceedings with Directo rs

There are no legal proceedings related to any of the directors or director nominees that require disclosure pursuant to

Items 103 or 401(f) of Regulation S-K.

Agreements with Directors

None of the directors or nominees for director was selected pursuant to any arrangement or understanding, other

than compensation arrangements in the ordinary course of business.

Board and Committee Meetings

During fiscal year 2024, our Board of Directors held five meetings (including regularly scheduled and special

meetings), and took action by written consent. Each director attended at least 86% of the aggregate of (i) the total

number of meetings of our Board of Directors held during the period for which he or she served as a director, and (ii)

the total number of meetings held by the Audit & Finance Committee, Compensation & Human Capital Committee,

and Governance & Nomination Committee of our Board of Directors on which he or she served during the periods that

he or she served.

It is the policy of our Board of Directors to regularly have separate meeting times for independent directors without

management. Although we do not have a formal policy regarding attendance by members of our Board of Directors at

annual meetings of stockholders, we encourage, but do not require, our directors to attend. Mr. Goldberg attended

our 2024 annual meeting of stockholders.

Our Board of Directors has four standing committees: the Audit and Finance Committee, the Compensation and

Human Capital Committee, the Governance and Nominating Committee and the Technology and Innovation

Committee. The composition and responsibilities of each of the committees and the subcommittee of our Board of

Directors as of April 25, 2025 are described below. Members will serve on these committees (or the subcommittee)

until their resignation or until otherwise determined by our Board of Directors.

	Audit and Finance Committee	Governance and Nominating Committee	Compensation and Human Capital Committee
George W. Bickerstaff, III	X	X	X
Fred E. Cohen, M.D., D. Phil			X
Christine M. Cournoyer	X		X*
Michael D. Goldberg
William A. Hagstrom			X
Peter Maag, Ph.D.			X
R. Bryan Riggsbee	X*
Arthur A. Torres		X*
Hannah A. Valantine, M.D.		X	X*

X: Committee Member

*: Com mittee Chairman or Chairwoman

Audit and Finance Committee

We have a separately-designated standing audit and finance committee established in accordance with

Section 3(a)(58)(A) of the Exchange Act. Our Audit and Finance Committee is currently comprised of R. Bryan

Riggsbee, George W. Bickerstaff, III and Christine M. Cournoyer, each of whom is a non-employee member of our

Board of Directors. Mr. Riggsbee has served as the Chairman of our Audit and Finance Committee since his

appointment to our Board of Directors in March 2024. Our Board of Directors has determined that each of the

members of our Audit and Finance Committee satisfies the requirements for independence and financial literacy

under the rules and regulations of the SEC, including Rule 10A-3 under the Exchange Act and the Nasdaq Rules.

Our Board of Directors has determined that each of Messrs. Riggsbee, Bickerstaff, and Ms. Cournoyer qualifies as an

“audit committee financial expert” as defined by the applicable SEC rules and satisfies the financial sophistication

requirements of the Nasdaq Rules. This designation does not impose on Messrs. Riggsbee, Bickerstaff and Ms.

Cournoyer any duties, obligations or liabilities that are greater than those generally imposed on members of our Audit

and Finance Committee and our Board of Directors. Our Audit and Finance Committee is responsible for, among

other things:

• appointing, compensating and overseeing the work of our independent registered public accounting firm;

• reviewing the qualifications, performance and independence of our independent registered public accounting firm;

• pre-approving any audit and permissible non-audit services to be performed by our independent registered public

accounting firm;

• overseeing our internal accounting and financial controls, including procedures for the treatment of complaints on

accounting controls, internal accounting controls or auditing matters and procedures for the submission of

confidential, anonymous employee comments about questionable accounting or auditing matters;

• providing to our Board of Directors such information and materials as it may deem necessary to make our Board of

Directors aware of significant financial matters that require the attention of our Board of Directors;

• overseeing our financial and treasury policies and strategies, including our cash position, capital structure and

strategies, and insurance coverage;

• reviewing the terms and conditions of material financing plans and making recommendations to our Board of

Directors on such plans;

• reviewing our Board of Directors’ delegated authority to our officers and related spending and transaction authority

guidelines, matrices or policies;

• reviewing with our management and independent registered public accounting firm the organization and

performance of our internal audit function;

• reviewing and discussing with our management and the independent registered public accounting firm the results of

our annual audit, our quarterly financial statements and financial statements included in our publicly filed reports;

• reviewing and approving related party transactions;

• preparing and providing the Audit Committee report that the SEC requires in our annual proxy statements;

• reviewing our guidelines and policies with respect to risk assessment and risk management, including risks relating

to our accounting matters, financial reporting, legal and regulatory compliance and general business risks and the

steps taken by management to monitor and control these exposures;

• assisting with the resolution of any actual or potential conflicts of interest with respect to members of our Board of

Directors; and

• reviewing and evaluating, at least annually, the performance of the Audit and Finance Committee and its members.

Our Audit and Finance Committee operates under a written charter that satisfies the applicable rules and regulations

of the SEC and the Nasdaq Rules. A copy of the charter of our Audit and Finance Committee is available on our

website at www.caredx.com in the Corporate Governance section of our Investors webpage. During fiscal year 2024,

our Audit and Finance Committee held six standalone meetings and also took action by written consent.

Compensation and Human Capital Committee

Our Compensation and Human Capital Committee is comprised of Christine M. Cournoyer, George W. Bickerstaff, III

and William A. Hagstrom, each of whom is a non-employee member of our Board of Directors. Ms. Cournoyer serves

as the Chairwoman of our Compensation and Human Capital Committee. Our Board of Directors has determined

that each member of our Compensation and Human Capital Committee meets the requirements for independence

under the rules and regulations of the SEC, including Rule 10C-1 under the Exchange Act, and the Nasdaq Rules and

is a “non-employee director” within the meaning of Rule 16b-3 under the Exchange Act. Our Compensation and

Human Capital Committee is responsible for, among other things:

• reviewing and approving all salaries, incentive awards and bonuses, equity awards, severance arrangements,

change in control agreements and any other compensation and benefit plans for our Chief Executive Officer and all

other executive officers;

• administering our equity compensation plans and the issuance of stock options and other stock-related awards not

granted pursuant to a plan;

• reviewing, at least annually, our stock plans, performance goals, incentive awards and the overall composition and

coverage of its compensation plans;

• preparing and providing the annual report on executive compensation that the SEC requires in our annual proxy

statements;

• reviewing the results of any stockholder advisory vote on executive compensation and considering whether to

recommend adjustments to the our executive compensation policies and practices as a result of such vote;

• reviewing and recommending to our Board of Directors for approval the frequency with which we will conduct the

stockholder advisory vote on named executive officer compensation, taking into account the results of the most

recent stockholder advisory vote;

• evaluating risks arising from our compensation plans, policies and programs for our employees;

• developing and implementing policies with respect to the recovery of any excess compensation paid to our

executive officers based on erroneous data;

• evaluating and making recommendations to our Board of Directors about director compensation;

• overseeing our overall compensation philosophy, compensation plans and benefits programs;

• overseeing and reviewing our human capital management practices, including talent management and diversity,

equity and inclusion considerations in the context of our compensation plans, programs and pay equity practices;

and

• reviewing and evaluating, at least annually, the performance of the Compensation and Human Capital Committee

and its members.

Our Compensation and Human Capital Committee operates under a written charter that satisfies the applicable rules

and regulations of the SEC and the Nasdaq Rules. A copy of the charter of our Compensation and Human Capital

Committee is available on our website at www.caredx.com in the Corporate Governance section of our Investors

webpage. During fiscal year 2024, our Compensation and Human Capital Committee held three standalone meetings

and also took action by written consent.

Our Compensation and Human Capital Committee adopted an Equity Award Grant Policy, pursuant to which our

Compensation and Human Capital Committee delegated our Chief Executive Officer the power and authority,

separately but concurrently with the power and authority of our Compensation and Human Capital Committee, to

grant stock options, restricted stock awards and stock-settled stock appreciation rights under our 2024 Equity

Incentive Plan to our employees (other than executives and directors), consultants or advisors of our company that

are natural persons.

Compensation Committee Interlocks and Insider Participation

No member of our Compensation and Human Capital Committee in fiscal year 2024 was at any time during 2024 or at

any other time an officer or employee of ours, and none had or have any relationships with us that are required to be

disclosed under Item 404 of Regulation S-K. None of our executive officers has served as a member of the board of

directors, or as a member of the compensation or similar committee, of any entity that has one or more executive

officers who served on our Board of Directors or Compensation and Human Capital Committee during fiscal year

2024.

Governance and Nominating Committee

Our Governance and Nominating Committee is comprised of Arthur A. Torres, George W. Bickerstaff, III and Hannah

A. Valantine, M.D., each of whom is a non-employee member of our Board of Directors. Senator Torres serves as the

Chairman of our Governance and Nominating Committee. Our Board of Directors has determined that each member

of our Governance and Nominating Committee meets the requirements for independence under the Nasdaq Rules.

Our Governance and Nominating Committee is responsible for, among other things:

• reviewing and making recommendations regarding the composition and size of our Board of Directors and

determine the relevant criteria (including any minimum qualifications) for membership on our Board of Directors;

• overseeing our Board of Directors’ evaluation process, including conducting periodic evaluations of the

performance of our Board of Directors as a whole and each committee of our Board of Directors, and evaluating the

performance of members of our Board of Directors eligible for re-election;

• reviewing and recommending candidates for election to our Board of Directors (including candidates proposed by

our stockholders) at the annual meeting of stockholders in compliance with our policies and procedures for

consideration of Board of Directors candidates;

• reviewing disclosures about our nomination process in our annual proxy statement;

• reviewing and making recommendations about our corporate governance guidelines and overseeing compliance

with laws and regulations by our Board of Directors and its committees;

• overseeing and providing input to management on our risks, policies, strategies and programs related to matters of

sustainability, corporate social responsibility, corporate culture, corporate governance, Environmental, Social and

Governance (“ESG”) matters, as well as diversity, equity and inclusion (“DEI”) matters;

• overseeing our compliance program, including policies and practices designed to ensure our compliance with

applicable legal, regulatory and ethical requirements, except with respect to matters of financial compliance, which

are the responsibility of the Audit and Finance Committee;

• overseeing our response to regulatory actions and investigations (except for financial, accounting and internal

control matters, which are responsibilities of the Audit and Finance Committee) and investigating any matter within

the scope of its responsibilities that it determines appropriate;

• determining the manner in which stockholders may send communications to our Board of Directors, as well as the

process by which stockholder communications will be relayed to our Board of Directors and what our Board of

Directors’ response, if any, should be;

• reviewing governance-related stockholder proposals and recommending our Board of Directors’ responses;

• reviewing and approving conflicts of interest of our directors and corporate officers, other than related party

transactions reviewed by the Audit and Finance Committee; and

• reviewing and evaluating, at least annually, the performance of the Governance and Nominating Committee and its

members.

Our Governance and Nominating Committee operates under a written charter that satisfies the Nasdaq Rules. A

copy of the charter of our Governance and Nominating Committee is available on our website at www.caredx.com in

the Corporate Governance section of our Investors webpage. During fiscal year 2024, our Governance and

Nominating Committee held two standalone meetings and also took action by written consent.

Technology and Innovation Committee

Our Technology and Innovation Committee is comprised of Hannah A. Valantine, M.D., Fred E. Cohen, M.D., D. Phil

and Peter Maag, Ph.D., each of whom is a non-employee member of our Board of Directors. Dr. Valantine serves as

the Chairwoman of our Technology and Innovation Committee. Our Technology and Innovation Committee is

responsible for, among other things:

• meeting with our science and technology leaders to review our internal research and technology development

activities and providing input as it deems appropriate;

• reviewing technologies that we consider for licensing or acquisition and providing input as it deems appropriate;

• reviewing our development of our technical goals and research and development strategies and providing input as

it deems appropriate;

• periodically reporting to our Board of Directors regarding the Technology and Innovation Committee’s review and

assessment of our internal technology development, technology assessment, technology review and technical

goals and research and development strategies and any other matters as it deems appropriate; and

• reviewing and evaluating, at least annually, the performance of the Technology and Innovation Committee and its

members.

Our Technology and Innovation Committee operates under a written charter. During fiscal year 2024, our Technology

and Innovation Committee held three standalone meetings.

Stockholder Recommendations for Nominations to the Board of Directors

Our Governance and Nominating Committee will consider candidates for director recommended by stockholders

holding at least one percent of our fully diluted capitalization continuously for at least 12 months prior to the date of

the submission of the recommendation. Our Governance and Nominating Committee will evaluate such

recommendations in accordance with its charter, our Bylaws, our policies and procedures for director candidates, as

well as the regular director nominee criteria described above. This process is designed to ensure that our Board of

Directors includes members with diversity of experience, skills and experience, including appropriate financial and

other expertise relevant to our business. Stockholders wishing to recommend a candidate for nomination should

contact our Corporate Secretary in writing. Such recommendations must include:

• the candidate’s name;

• home and business contact information;

• detailed biographical data;

• relevant qualifications;

• a signed letter from the candidate confirming willingness to serve on our Board of Directors;

• information regarding any relationships between the candidate and CareDx; and,

• evidence of the recommending stockholder’s ownership of our common stock.

Such recommendations must also include a statement from the recommending stockholder in support of the

candidate, particularly within the context of the criteria for Board of Directors’ membership. Our Governance and

Nominating Committee has discretion to decide which individuals to recommend for nomination as directors.

A stockholder can nominate a candidate directly for election to our Board of Directors by complying with the

procedures in Section 2.4(ii) of our Bylaws and the rules and regulations of the SEC. Any eligible stockholder who

wishes to submit a nomination should review the requirements in our Bylaws on nominations by stockholders. Any

nomination should be sent in writing to our Corporate Secretary at CareDx, Inc., 8000 Marina Boulevard, 4th Floor,

Brisbane, California 94005. To be timely for our 2026 annual meeting of stockholders, our Corporate Secretary must

receive the nomination no earlier than February 13, 2026 and no later than March 15, 2026. The notice must state

the information required by Section 2.4(ii) of our Bylaws and otherwise must comply with applicable federal and state

law.

In addition, pursuant to Rule 14a-19, the SEC’s universal proxy rule, notices of a solicitation of proxies in support of

director nominees other than our own nominees must be postmarked or electronically submitted no later than April 13,

2026, and each nomination must comply with the SEC regulations under Rule 14a-19, which requires, among other

things, that such notice include a statement that such person intends to solicit the holders of shares representing at

least 67% of the voting power of shares entitled to vote on the election of directors. If, however, the date of the 2026

annual meeting of stockholders is more than 30 days before or after June 12, 2026, then the Rule 14a-19 deadline

shall be the later of 60 calendar days prior to the date of the 2026 annual meeting of stockholders or the 10th

calendar day following the day on which we first make a public announcement of the date of our 2026 annual meeting

of stockholders. A nomination that does not comply with the requirements set forth in the Certificate of Incorporation

and Bylaws will not be considered for presentation at the annual meeting. We intend to file a proxy statement and

white proxy card with the SEC in connection with our solicitation of proxies for our 2026 annual meeting of

stockholders.

Communications with the Board of Directors

Stockholders wishing to communicate with our Board of Directors or with an individual member of our Board of

Directors may do so by writing to our Board of Directors or to the particular member of our Board of Directors, and

mailing the correspondence to our Chief Financial Officer at CareDx, Inc., 8000 Marina Boulevard, 4th Floor,

Brisbane, California 94005. Our Chief Financial Officer will review all incoming stockholder communications

(excluding mass mailings, product complaints or inquiries, job inquiries, business solicitations and patently offensive

or otherwise inappropriate material), and if deemed appropriate, the stockholder communications will be forwarded to

the appropriate member or members of our Board of Directors, or if none is specified, to the Chairman of the Board of

Directors. This procedure does not apply to stockholder proposals submitted pursuant to Rule 14a-8 under the

Exchange Act.

Corporate Governance Guidelines and Code of Business Conduct and Ethics

Our Board of Directors has adopted Corporate Governance Guidelines. These guidelines address items such as the

qualifications and responsibilities of our directors and director candidates and corporate governance policies and

standards applicable to us in general. In addition, our Board of Directors has adopted a Code of Business Conduct

and Ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief

Financial Officer, and other executive and senior financial officers. The full text of our Corporate Governance

Guidelines and our Code of Business Conduct and Ethics is posted on our website at www.caredx.com in the

Corporate Governance section of our Investors webpage. We intend to post any amendments to our Code of

Business Conduct and Ethics, and any waivers of our Code of Business Conduct and Ethics for directors and

executive officers, on the same website.

Clawback Policy

Effective October 1, 2023, our Board of Directors adopted a restated compensation recovery (“clawback”) policy

pursuant to the listing standards approved by The Nasdaq Stock Market LLC implementing Rule 10D-1 under the

Exchange Act. The clawback policy is administered by our Compensation and Human Capital Committee and applies

to current and former executive officers of the Company as defined in Rule 10D-1 (each an “Affected Officer”). Under

the clawback policy, if the Company is required to prepare an accounting restatement to correct the Company’s

material noncompliance with any financial reporting requirement under securities laws, including restatements that

correct an error in previously issued financial statements that is material to the previously issued financial statements

or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in

the current period (collectively, a “Restatement”), the Company is obligated to recover erroneously awarded incentive-

based compensation received from the Company by Affected Officers. Incentive-based compensation includes any

compensation that is granted, earned or vested based in whole or in part on the attainment of a financial reporting

measure. Erroneously awarded incentive-based compensation is the amount of incentive-based compensation

received that exceeds the amount of incentive-based compensation that otherwise would have been received had it

been determined based on an applicable Restatement.

Insider Trading Policy

Our Board of Directors has adopted an insider trading policy. Our insider trading policy prohibits our directors, officers

(including our executive officers), employees and agents, as well as their immediate family members, from engaging

in short sales of our securities and from engaging in transactions in publicly-traded options and other derivative

securities with respect to our securities. This prohibition extends to any hedging or similar transactions designed to

decrease the risks associated with holding our securities. Our insider trading policy also restricts certain individuals,

including our directors and executive officers, from pledging our securities as collateral for loans absent pre-clearance

and the satisfaction of other conditions.

Non-Employee Director Stock Ownership Policy

Our Compensation and Human Capital Committee has adopted a stock ownership policy that is applicable to each of

our non-employee directors. Our Compensation and Human Capital Committee believes this policy is an important

tool in aligning the interests of our non-employee directors with the long-term interests of our stockholders.

This policy requires that our non-employee directors hold shares of our common stock with a value equal to at

least three times such director’s annual cash retainer for service on our Board of Directors (excluding service on any

committee of our Board of Directors). For purposes of calculating ownership under this policy, the following sources

are included: shares held in the director’s name; shares held in trust for the benefit of the director or their family;

shares held by the director jointly with, or separately by, certain family members of the director; shares held by the

director through a profit sharing or savings plan; the “in the money” portion of vested, but unexercised, stock options

or stock-settled stock appreciation rights; shares issued or vested pursuant to the achievement of the performance

conditions of a performance-based equity award even if such shares are subject to additional time-based vesting

requirements (the “Vested Performance Awards”); vested restricted stock units (“RSU” or “RSUs”) awards; deferred

share units; shares held by the director under any deferral plan; and restricted stock or phantom stock held by the

director.

The following shares do not count towards the requirements: (i) shares that directors have the right to acquire through

the exercise of stock options or stock appreciation rights that are not “in the money”, (ii) shares underlying stock

options or stock appreciation rights that have not yet vested or (iii) shares that may be issued pursuant to unvested

performance-based restricted stock units (“PRSUs”) or other performance-based equity awards (other than Vested

Performance Awards).

For purposes of these requirements, a director’s annual cash retainer shall be deemed to be the director’s annual

cash retainer earned by such director for the calendar year immediately preceding the applicable date of calculation.

To give our non-employee directors time to comply with our stock ownership policy, the policy provides that our non-

employee directors have until the later of our 2025 annual meeting of stockholders or the first annual meeting of

stockholders held after the date that is six years following their appointment as a director to comply with the stock

ownership provisions in the policy.

Executive Officer Stock Ownership Policy

Our Compensation and Human Capital Committee adopted a stock ownership policy that is applicable to each of our

executive officers. Our Compensation and Human Capital Committee believes this policy is an important tool in

aligning the interests of our executive officers with the long-term interests of our stockholders.

This policy requires that our executive officers hold shares of our common stock with a value equal to a multiple of

their base salary, as follows: 3X in the case of our Chief Executive Officer and 1X in the case of each of our other

executive officers. For purposes of calculating ownership under this policy, the following sources are included: shares

held in the executive officer’s name; shares held in trust for the benefit of the executive officer or their family; shares

held by the executive officer jointly with, or separately by, certain family members of the executive officer; shares held

by the executive officer through a profit sharing or savings plan; the “in the money” portion of vested, but unexercised,

stock options or stock-settled stock appreciation rights; Vested Performance Awards; vested RSU awards; deferred

share units; shares held by the executive officer under any deferral plan; and restricted stock or phantom stock held

by the executive officer.

The following shares do not count towards the requirements: (i) shares that the executive officers have the right to

acquire through the exercise of stock options or stock appreciation rights that are not “in the money”, (ii) shares

underlying stock options or stock appreciation rights that have not yet vested or (iii) shares that may be issued

pursuant to unvested PRSUs or other performance-based equity awards (other than Vested Performance Awards).

For purposes of these requirements, an executive officer’s base salary during any calendar year is deemed to be their

base salary as of the close of business on December 31st of the immediately preceding year. To give our executive

officers time to comply with our stock ownership policy, the policy provides that our executive officers have until the

later of our 2025 annual meeting of stockholders or the first annual meeting of stockholders held after the date that is

six years following the date such individual first becomes an executive officer to comply with the stock ownership

provisions in the policy.

Board of Directors’ Role in Risk Oversight

Risk is inherent with every business, and we face a number of risks, including strategic, financial, business and

operational, legal and compliance, and reputational risks. We have designed and implemented processes to manage

risk in our operations. Management is responsible for the day-to-day management of risks we face, while our Board

of Directors, as a whole and assisted by its committees, has responsibility for the oversight of risk management. In its

risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes

designed and implemented by management are appropriate and functioning as designed.

Our Board of Directors believes that open communication between management and our Board of Directors is

essential for effective risk management and oversight. Our Board of Directors meets with our Chief Executive Officer

and other members of the senior management team at quarterly meetings of our Board of Directors, where, among

other topics, they discuss strategy and risks facing us, as well as at such other times as they deem appropriate.

Moreover, our management regularly briefs our Board of Directors with respect to environmental and social risk,

information and cybersecurity risk, enterprise risk and other governance matters.

While our Board of Directors is ultimately responsible for risk oversight, our board committees assist our Board of

Directors in fulfilling its oversight responsibilities in certain areas of risk. Our Audit and Finance Committee assists

our Board of Directors in fulfilling its oversight responsibilities with respect to risk management in the areas of internal

control over financial reporting and disclosure controls and procedures, legal and regulatory compliance, and

discusses with management and the independent auditor guidelines and policies with respect to risk assessment and

risk management. Our Audit and Finance Committee also reviews our major financial risk exposures, including

liquidity risks, and the steps management has taken to monitor and control these exposures. In addition, our Audit

and Finance Committee monitors certain key risks on a regular basis throughout the fiscal year, such as risk

associated with internal control over financial reporting and liquidity risk, as well as cybersecurity risks as further

described below. Our Governance and Nominating Committee assists our Board of Directors in fulfilling its oversight

responsibilities with respect to the management of risk associated with board organization, membership and structure

and corporate governance. Our Compensation and Human Capital Committee assesses risks created by the

incentives inherent in our compensation and human capital policies. Finally, our full Board of Directors reviews

strategic and operational risk in the context of reports from the management team, receives reports on all significant

committee activities at each regular meeting, and evaluates the risks inherent in significant transactions.

With respect to cybersecurity risks, our Board of Directors and Audit and Finance Committee each receive regular

presentations and reports on developments in the cybersecurity space, including risk management practices, recent

developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat

environment, technological trends, and information security issues encountered by our peers and third parties. Our

Board of Directors and Audit and Finance Committee also receive prompt and timely information regarding any

cybersecurity risk that meets pre-established reporting thresholds. Annually, our Board of Directors and Audit and

Finance Committee discuss our approach to overseeing cybersecurity threats with our Chief Technology Officer and

other senior management members. We also conduct periodic assessments and testing of our policies, standards,

processes, and practices in a manner designed to address cybersecurity threats and events. The results of such

assessments, audits, and reviews are evaluated by management and reported to our Audit and Finance Committee,

and we adjust our cybersecurity policies, standards, processes, and practices as necessary based on the information

provided by these assessments, audits, and reviews. For further information regarding our oversight of cybersecurity

risks, please see the “Cybersecurity” section of our Annual Report on Form 10-K for the year ended December 31,

2024 that was filed with the SEC on February 28, 2025.

Workforce Diversity

We are a global company with employees from numerous countries around the world. We aim to hire the best talent

which includes individuals with varying educational, demographic, and geographic backgrounds. Our senior

leadership team includes leaders with diverse skills, academic training, industry experience, racial backgrounds and

genders. We aim to assemble a workforce that is reflective of the patients and caregivers we serve so we may better

understand their perspectives and needs. We have a zero-tolerance policy for discrimination.

Director Compensation

Compensation Policy

Directors who are employees do not receive any additional compensation for their service on our Board of Directors.

We reimburse our non-employee directors for their reasonable out-of-pocket costs and travel expenses in connection

with their attendance at Board of Directors and committee meetings in accordance with our travel policy. In fiscal year

2024, our non-employee directors received cash compensation, RSU awards and options to purchase shares of our

common stock pursuant to our outside director compensation policy in effect during 2024 as set forth below. Effective

December 21, 2023, our Compensation and Human Capital Committee approved an amendment and restatement of

our outside director compensation policy, pursuant to which, during fiscal year 2024, our non-employee directors

received an annual retainer of $45,000 for their service on our Board of Directors, members of our Audit and Finance

Committee, Compensation and Human Capital Committee, Governance and Nominating Committee and Technology

and Innovation Committee, other than the chairman or chairwoman of each such committee, received an additional

annual retainer of $10,000, $7,500, $5,000 and $5,000, respectively, the chairman or chairwoman of our Audit and

Finance Committee, Compensation and Human Capital Committee, Governance and Nominating Committee and

Technology and Innovation Committee each received an additional annual retainer of $20,000, $15,000, $10,000 and

$10,000, respectively, and the independent Chairman of our Board of Directors received an additional annual retainer

of $80,000. All annual retainers were paid quarterly and pro-rated for partial service in any year. Our non-employee

directors are entitled to elect the ratio of shares of our common stock to cash issuable or payable to the non-

employee director for the payment of the annual retainers.

Pursuant to our outside director compensation policy, any director first appointed to our Board going forward is

automatically granted, on a nondiscretionary basis, an option to purchase shares of our common stock having a grant

date fair value of $100,000, rounded down to the nearest whole share, at an exercise price equal to the fair market

value of our common stock on the grant date, and an award of RSUs having a grant date fair value of $100,000,

rounded down to the nearest whole share. The options vests and become exercisable in equal monthly installments

beginning with the first monthly anniversary after the grant date over the following three years, and the RSUs vests at

a rate of one-third on each one-year anniversary of the grant date. The vesting of the options and the RSUs

described above will accelerate in full upon a “change in control,” as defined in our 2024 Equity Incentive Plan (the

“2024 Plan”), effective June 13, 2024, the date of the Company’s 2024 Annual Meeting of Stockholders, our

stockholders approved the 2024 Plan. In addition, for fiscal year 2024, on the first business day after the annual

meeting of our stockholders, each non-employee director who continued to serve on our Board of Directors was

automatically granted, on a nondiscretionary basis, an option to purchase shares of our common stock having a grant

date fair value of $150,000, rounded down to the nearest whole share, at an exercise price equal to the fair market

value of our common stock on the grant date, and an award of RSUs having a grant date fair value of $150,000,

rounded down to the nearest whole share. The options vests and becomes exercisable in equal monthly installments

beginning with the first monthly anniversary after the grant date over the following one year, and the RSUs vests in full

on the one year anniversary of the grant date. The vesting of the options and the RSUs described above will

accelerate in full upon a “change in control,” as defined in our 2024 Plan.

In addition, pursuant to our outside director compensation policy, in January 2024, Mr. Goldberg, our independent

Board Chairman, received an additional one-time award of RSUs in respect of his additional responsibilities as

Chairman while we were in the process of recruiting a new Chief Executive Officer and in a period of significant

transition which had a grant date fair value of $200,000, rounded down to the nearest whole share, which vested in

full on the one-year anniversary of the grant date in January 2025. Effective January 6, 2025, our Compensation and

Human Capital Committee approved an amendment and restatement of our outside director compensation policy,

which amended the vesting schedules with respect to annual grants of options and RSUs to provide that: (i) any then-

unvested options fully vest on the day immediately before the first annual meeting of our stockholders that occurs

after the grant date, and (ii) RSUs vests on the earlier of the first anniversary of the grant date and the day

immediately before the first annual meeting our stockholders that occurs after such grant date. The amended and

restated policy also removed quarterly retainers previously provided to Mr. Goldberg for his additional efforts and

services while serving as a member of the Office of the Chief Executive Officer. Because the amended and restated

outside director compensation policy was approved after fiscal year 2024, such amendments did not impact the

compensation paid to the members of our Board of Directors during fiscal year 2024.

Notwithstanding any provisions in our outside director compensation policy, as amended and restated, pursuant to

the terms of our 2024 Plan, (a) no outside director may be granted, in any fiscal year, cash and equity-based

compensation having a value of greater than $1,500,000 in the fiscal year of such director’s initial service as an

outside director, and (b) no outside director may be granted, in any fiscal year, cash and equity-based compensation

having a value greater than $750,000.

On April 17, 2025, we amended our outside director compensation policy: (i) to increase the annual retainer payable

to our non-employee directors from $45,000 to $50,000 annually, (ii) to decrease the nondiscretionary annual award

of options to purchase shares of our common stock from a grant date fair value of $150,000 to $0, (iii) to increase the

nondiscretionary annual award of RSUs from a grant date fair value of $150,000 to $225,000, and (iv) to increase the

aggregate grant date fair value of the nondiscretionary initial equity award to non-employee directors from $200,000

to $400,000, comprising an award of RSUs with a grant date fair value of $400,000.

Director Compensation Table

The following table sets forth the compensation accrued or paid by us to our non-employee directors during the year

ended December 31, 2024 for service on our Board of Directors and its committees.

Name	Fees Earned or Paid in Cash ($)		Stock Awards ($) (1)(2)	Option Awards ($) (3)(4)	Total ($)
Michael D. Goldberg	243,340	(5)	349,985	150,049	743,374
George W. Bickerstaff, III	66,023		149,988	150,049	366,060
Fred E. Cohen, M.D., D. Phil	53,400		149,988	150,049	353,437
Grace E. Colón, Ph.D.	78,331	(6)	—	—	78,331
Christine M. Cournoyer	72,266		149,988	150,049	372,303
William A. Hagstrom	57,033		149,988	150,049	357,070
Peter Maag, Ph.D.	49,993	(7)	149,988	150,049	350,030
R. Bryan Riggsbee	52,500		249,979	250,089	552,568
Arthur A. Torres	55,000		149,988	150,049	355,037
Hannah A. Valantine, M.D.	57,734		149,988	150,049	357,771

(1) Amounts represent the aggregate fair value of the stock awards computed as of the grant date of each stock award in accordance with

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718. Our assumptions with respect

to the calculation of these values are set forth in Note 13 of the consolidated financial statements included in our Annual Report on

Form 10-K for the year ended December 31, 2024 that was filed with the SEC on February 28, 2025.

(2) As of December 31, 2024, each of our then-current non-employee directors held the following number of RSUs: Mr. Goldberg: 28,735;

Mr. Bickerstaff: 10,570; Dr. Cohen: 10,570; Ms. Cournoyer: 10,570; Mr. Hagstrom: 10,570; Dr. Maag: 13,838; Mr. Riggsbee: 17,414;

Mr. Torres: 10,570 and Dr. Valantine: 10,570.

(3) Amounts represent the aggregate fair value of the option awards computed as of the grant date of each option award in accordance

with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 13 of the consolidated

financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 that was filed with the SEC on

February 28, 2025. There can be no assurance that option awards will be exercised (in which case no value will be realized by the

individual) or that the value on exercise will approximate the fair value as computed in accordance with FASB ASC Topic 718.

(4) As of December 31, 2024, each of our then-current non-employee directors held options to purchase the following number of shares of

common stock: Mr. Goldberg: 105,231; Mr. Bickerstaff: 78,731; Dr. Cohen: 63,731; Ms. Cournoyer: 69,880; Mr. Hagstrom: 84,934; Dr.

Maag: 208,751; Mr. Riggsbee: 25,808; Mr. Torres: 55,045 and Dr. Valantine: 54,420.

(5) Amount includes (i) $108,152 in fees paid to Mr. Goldberg at a rate of $50,000 per quarter in respect of Mr. Goldberg’s additional

efforts and services while serving as a member of the Office of the Chief Executive Officer through July 15, 2024 , in accordance with

the terms of our outside director compensation policy and (ii) $20,855 representing the portion of Mr. Goldberg’s annual retainer paid in

cash and $114,333 representing the aggregate fair value of the restricted stock award granted to Mr. Goldberg in lieu of the remaining

portion of his annual cash retainer fee computed as of the grant date of each stock award in accordance with FASB ASC Topic 718.

Mr. Goldberg elected to receive such portion of his annual cash retainer fee in the form of restricted shares of our common stock

pursuant to our outside director compensation policy. Our assumptions with respect to the calculation of these values are set forth in

Note 13 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024

that was filed with the SEC on February 28, 2025.

(6) Amount includes a one-time $50,000 cash payment in respect of the potential lost value of unvested options Dr. Colon forfeited in

connection with the expiration of her service term. Dr. Colon ceased providing services as a member of our Board of Directors effective

June 13, 2024.

(7) Amount includes $25,000 representing the portion of Mr. Maag’s annual retainer paid in cash and $24,993 representing the aggregate

fair value of the restricted stock award granted to Mr. Maag in lieu of a portion of his annual cash retainer fee computed as of the grant

date of each stock award in accordance with FASB ASC Topic 718. Mr. Maag elected to receive such portion of his annual cash

retainer fee in the form of restricted shares of our common stock pursuant to our outside director compensation policy. Our

assumptions with respect to the calculation of these values are set forth in Note 13 of the consolidated financial statements included in

our Annual Report on Form 10-K for the year ended December 31, 2024 that was filed with the SEC on February 28, 2025.

Deferral Election Program

In December 2018, our Compensation and Human Capital Committee approved an RSU and performance unit

deferral election program, which is still in effect, pursuant to which our non-employee directors, executive officers and

certain other employees may elect, on an annual basis, to defer the settlement of all RSU and performance unit

awards granted to such individuals until the first to occur of (i) a “change in control,” as defined in our 2014 Equity

Incentive Plan (the “2014 Plan”) , (ii) the individual’s death, or (iii) a specified number of years following the individual’s

separation of service with us, in which case the shares will settle in a number of substantially equal annual

installments selected by the individual, on every June 30 starting in the calendar year immediately following the year

in which the individual incurs a separation of service.

Non-employee directors who elect to defer the settlement of RSU and performance units must make these deferral

elections by the end of the calendar year preceding the date of the grant of the stock award (or on such earlier date

as specified by us). As of December 31, 2024, none of our non-employee directors held any deferred stock awards,

except for Mr. Goldberg, who elected to defer the settlement of RSUs with an aggregate value of $55,944 as of

December 31, 2024, and Dr. Maag, who elected to defer the settlement of RSUs with an aggregate value of

$5,199,890 as of December 31, 2024. Not only does the RSU and performance unit deferral election program allow

our eligible participants to defer the federal income taxes otherwise payable upon the delivery of RSUs, but our

Compensation and Human Capital Committee also believes that with respect to non-employee directors and

executives who avail themselves of the deferral features, such person will necessarily hold our common stock for a

longer period of time. Accordingly, any deferred RSUs will continue to align such portion of our non-employee

directors’ and named executive officers’ compensation with the interests of our stockholders for a longer period of

time than would be provided by typical vesting periods.

Proposal No. 2

Ratification of Appointment of Independent

Registered Public Accounting Firm

Our Audit and Finance Committee has appointed Deloitte & Touche LLP (“Deloitte”) as our independent registered

public accounting firm to audit our consolidated financial statements for our fiscal year ending December 31, 2025.

Deloitte also served as our independent registered public accounting firm for our fiscal year ended December 31,

Deloitte was appointed as our independent registered public accounting firm on April 10, 2018.

At the Annual Meeting, stockholders are being asked to ratify the appointment of Deloitte as our independent

registered public accounting firm for our fiscal year ending December 31, 2025. Stockholder ratification of the

appointment of Deloitte is not required by our Bylaws or other applicable legal requirements. However, our Board of

Directors is submitting the appointment of Deloitte to our stockholders for ratification as a matter of good corporate

governance. In the event that this appointment is not ratified by the affirmative vote of a majority of the shares

present virtually or by proxy at the Annual Meeting and entitled to vote, such appointment will be reconsidered by our

Audit and Finance Committee. Even if the appointment is ratified, our Audit and Finance Committee, in its sole

discretion, may appoint another independent registered public accounting firm at any time during our fiscal year

ending December 31, 2025 if our Audit and Finance Committee believes that such a change would be in the best

interests of CareDx and its stockholders. A representative of Deloitte is expected to be present at the Annual

Meeting. Such representative will have an opportunity to make a statement if they wish to do so and is expected to

be available to respond to appropriate questions from stockholders.

Fees Paid to the Independent Registered Public Accounting Firm

The following table sets forth fees in connection with services rendered by Deloitte, our independent registered public

accounting firm, for our fiscal years ended December 31, 2024 and 2023.

	2024	2023
Audit Fees (1)	$2,422,838	$3,262,072
All Other Fees (2)	3,790	3,790
Total	$2,426,628	$3,265,862

(1) Audit Fees include fees and out-of-pocket expenses, whether or not yet invoiced, for professional services associated with the annual

audit of our financial statements, the reviews of our interim financial statements, statutory audits, and the issuance of consents in

connection with registration statement filings with the SEC.

(2) All Other Fees include any fees billed that are not audit, audit-related or tax fees. All other fees include fees for a subscription service

to a technical accounting research tool.

Auditor Independence

In 2024, there were no other professional services provided by Deloitte that would have required our Audit and

Finance Committee to consider their compatibility with maintaining the independence of Deloitte.

Audit and Finance Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of

Independent Registered Public Accounting Firm

Our Audit and Finance Committee has established a policy governing our use of the services of our independent

registered public accounting firm. Under the policy, our Audit and Finance Committee is required to pre-approve all

audit and permissible non-audit services performed by our independent registered public accounting firm to ensure

that the provision of such services does not impair such accounting firm’s independence. The policy generally pre-

approves specified services in the defined categories of audit services, audit-related services, tax services and other

services up to specified amounts. The pre-approval of services may be delegated to one or more of the Audit and

Finance Committee’s members, but the decision must be reported to the full Audit and Finance Committee at its next

scheduled meeting. In the fiscal years ended December 31, 2024 and 2023, services and related fees identified

above under the captions “Audit Fees” and “All Other Fees” that were billed by Deloitte were approved by the Audit

and Finance Committee in accordance with SEC requirements.

Vote Required; Board Recommendation

The ratification of the appointment of Deloitte requires the affirmative vote of a majority of the shares of our common

stock present virtually or by proxy at the Annual Meeting and entitled to vote thereon. Abstentions will have the effect

of a vote AGAINST the proposal. Broker non-votes will have no effect on this proposal.

OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF

DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR

FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT AND FINANCE COMMITTEE REPORT

The information contained in the following Audit and Finance Committee Report shall not be deemed to be soliciting

material or to be filed with the Securities and Exchange Commission, nor shall such information be incorporated by

reference into any future filing under the Securities Act of 1933, as amended, or the Securities Exchange Act

of 1934, as amended, except to the extent that CareDx, Inc. (the “Company”) specifically incorporates it by

reference in such filing.

The Audit and Finance Committee has reviewed and discussed the Company’s audited consolidated financial

statements with management and Deloitte & Touche LLP (“Deloitte”), the Company’s independent registered public

accounting firm. The Audit and Finance Committee has discussed with Deloitte the matters required to be discussed

by the applicable requirements of the Public Company Accounting Oversight Board and the Securities and Exchange

Commission (the “SEC”).

The Audit and Finance Committee has received and reviewed the written disclosures and the letter from Deloitte

required by the applicable requirements of the Public Company Accounting Oversight Board regarding Deloitte’s

communications with the Audit and Finance Committee concerning independence, and has discussed with Deloitte its

independence.

Based on the review and discussions referred to above, the Audit and Finance Committee recommended to the

Board of Directors that the Company’s audited consolidated financial statements be included in the Company’s

Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for filing with the SEC.

Respectfully submitted by the members of the Audit and Finance Committee of the Board of Directors:

R. Bryan Riggsbee

George W. Bickerstaff, III

Christine M. Cournoyer

Proposal No. 3

Advisory Vote on Executive Compensation

Pursuant to the proxy rules under the Exchange Act and as required by Section 951 of the Dodd-Frank Wall Street

Reform and Consumer Protection Act, we are presenting to our stockholders with a non-binding, advisory vote to

approve the compensation of our named executive officers as described in this proxy statement. This proposal is

commonly referred to as a “Say-on-Pay” proposal. In accordance with the results of the advisory vote held at

our 2020 annual meeting of stockholders on the frequency of future say-on-pay votes, we are conducting say-on-pay

votes every year. After the Annual Meeting, our next say-on-pay vote will be held at our 2026 annual meeting of

stockholders.

The compensation of our named executive officers is designed to attract, motivate and retain talented and

experienced executives, who are critical to our success. Our executive compensation contains elements of cash and

equity-based compensation. Our Board of Directors and our Compensation and Human Capital Committee believe

that our executive compensation directly and substantially link rewards to measurable corporate performance and are

designed to align the interests of our named executive officers with those of our stockholders and to reward our

named executive officers for the achievement of our near-term and longer-term financial and strategic goals. The

process for determining compensation packages requires that our Board of Directors and our Compensation and

Human Capital Committee use judgment and experience to determine the optimal components and amounts of

compensation for each named executive officer.

The Say-on-Pay vote gives you as a stockholder the opportunity to express your views regarding the compensation of

our named executive officers by voting to approve or not approve such compensation as described in this proxy

statement. This vote is advisory and will not be binding upon our Board of Directors or our Compensation and Human

Capital Committee. However, our Board of Directors and our Compensation and Human Capital Committee value the

opinion of our stockholders and will take into account the outcome of the vote when considering future executive

compensation arrangements. The vote on this resolution is not intended to address any specific element of

compensation, but rather relates to the overall compensation of our named executive officers, as described in this

proxy statement in accordance with the compensation disclosure rules of the SEC.

We encourage our stockholders to read the “Executive Compensation” section in this proxy statement, including the

compensation tables and the related narrative disclosure, which describes the structure and amounts of the

compensation of our named executive officers in fiscal year 2024.

Vote Required; Board Recommendation

The advisory approval of this Proposal No. 3 requires the affirmative vote of a majority of the shares of our common

stock present virtually or by proxy at the Annual Meeting and entitled to vote thereon. Abstentions will have the effect

of a vote AGAINST the proposal. Broker non-votes will have no effect on this proposal. Although this vote is advisory

in nature and does not impose any action on our Board of Directors or our Compensation and Human Capital

Committee, we strongly encourage all stockholders to vote on this matter.

OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE APPROVAL, ON AN ADVISORY BASIS, OF

THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT.

Proposal No. 4

Approval of Amendment to the

2024 Equity Incentive Plan

Alignment of the 2024 Plan with the Interests of the Company and Stockholders

At our Investor Day in October 2024, we laid out a three-year plan to achieve $500 Million in revenue in 2027 and

$100M in adjusted EBITDA. CareDx is a growth company in the biotechnology industry based principally in San

Francisco, California. In a highly competitive labor market, we believe equity compensation is important to attract the

talent and skills required to achieve our plan. In particular, we use equity as a long-term incentive compensation tool

to motivate and reward employees and officers to accomplish our long term plan.

To achieve our objective of recruiting the right talent to meet our long term plan, at the Annual Meeting, the

Company’s stockholders will be asked to approve an amendment to the 2024 Plan to increase the available shares

reserved thereunder by 1,600,000 shares, or approximately 3% of common shares issued and outstanding, subject to

adjustment as provided in the 2024 Plan, and an equivalent increase to the number of shares of stock available for

grant pursuant to incentive stock options (“ISOs”). The amendment to the 2024 Plan was approved unanimously by

the Board of Directors at its meeting on April 23 , 2025 . No other changes are contemplated by the amendment to the

2024 Plan.

The 2024 Plan was originally adopted by our Board of Directors on April 24, 2024 and became effective June 13,

2024, following approval by our stockholders at our 2024 Annual Meeting. The 2024 Plan has been an important

factor in attracting, retaining, motivating, and rewarding certain employees, officers, directors and consultants by

closely aligning the interests of such individuals with those of our stockholders. We believe the Amendment to the

2024 Plan as proposed aligns the interest of our employees and executive officers with that of stockholders. We also

believe that equity compensation is by its very nature performance based.

As discussed below, the Board of Directors believes the 2024 Plan is essential to the Company’s continued success

as it remains committed to the Company’s historical philosophy of incentivizing employees by tying a significant

portion of their compensation to the interests of the Company’s stockholders. As of March 31, 2025, there were

1,683,534 shares available for grant under all equity plans including 1,583,698 shares available for grant under the

2024 Plan. The Company has determined that an increase to the shares reserved under the 2024 Plan by 1,600,000

shares will allow the Company to continue providing meaningful incentives to its service providers under the 2024

Plan.

If the stockholders approve this proposal, the amendment to the 2024 Plan will become effective as of the date of

stockholder approval. If stockholders do not approve this proposal, the amendment to the 2024 Plan described in this

proposal will not take effect.

Information on Equity Compensation Plans as of March 31, 2025

As of March 31, 2025, a total of 55,462,730 shares of our common stock were outstanding and the fair market value

of our common stock was $17.75 per share based on the closing sale price of our common stock on the Nasdaq

Global Market. The following table sets forth information regarding equity awards outstanding under our equity plans

as of March 31, 2025 other than the CareDx, Inc. 2014 Employee Stock Purchase Plan (“2014 ESPP”). As of March

31, 2025, 490,040 shares of our common stock remained available for future issuance pursuant to the 2014 ESPP.

As of March 31, 2025	Equity Plans (1)
Total shares underlying outstanding stock options	2,944,438
Weighted average exercise price of outstanding stock options	$21.03
Weighted average remaining life of outstanding stock options (in years)	2.67
Total shares underlying outstanding RSUs	4,715,049
Total shares underlying outstanding PRSUs (2)	579,139
Total number of shares remaining available for future awards under our equity plans (1)	1,683,534

(1) Comprised of the 2024 Plan, the CareDx, Inc. 2016 Inducement Equity Incentive Plan and the CareDx, Inc. 2019 Inducement Equity

Incentive Plan (collectively, the “Equity Plans”) and excluding the 2014 ESPP. The number of shares remaining available for future

grant under the 2024 Plan reflects PRSUs at the target payout even though a lesser or greater number of shares may be or have been

issued. Actual shares delivered will be based on the performance results outlined in the specific plan governing the PRSUs.

(2) Assumes performance at the target performance level even though a lesser or greater number of shares may be or have been issued.

Actual shares delivered will be based on the performance results outlined in the specific plan governing the PRSUs.

Taking Action to Reduce Burn Rate and Dilution

Historical Burn Rate

Our equity plan share usage over 2022, 2023 and 2024 represented a three-year average gross burn rate (“Gross

Burn Rate”) of 9% and a net burn rate (“Net Burn Rate”) of 6%, as described in the table below.

Over the period of 2022-2023, our Net Burn Rate was more than 30% lower than our Gross Burn Rate due to the

forfeiting of stock, as well as the expiration of options, primarily related to employee turnover. We believe Net Burn

Rate is a better representation of the actual dilution to stockholders because it accounts for shares that are forfeited

or expired and not exercised due to employee turnover.

In addition, under our 2024 Plan, we retire shares that are withheld at vesting to address employee tax obligations

rather than recycling these shares into the share pool. This practice of retiring shares withheld to address employee

tax obligations further reduces the net burn rate and dilution to stockholders. In 2024, our Net Burn Rate increased

including because we hired several new executives, including our Chief Executive Officer, Chief Operating Officer,

Chief Commercial Officer, and Chief Data and AI Officer. In addition, our burn rate was impacted by agreements

entered into in connection with the departure of several former executives.

For purposes of the table below, the number of shares issuable under an award that provides for issuance of a

variable number of shares based on the extent to which performance targets are satisfied, such as PRSUs, is

deemed to be the target number of shares that may be issued on attainment of target performance, even though a

lesser or greater number of shares may be or may have been issued based on actual performance. Note that our

calculation of equity burn rate differs, or may differ, from calculations of burn rate conducted by proxy advisory or

other groups.

Year	Weighted Average Common Stock Outstanding	Time-based Stock Options Granted	Performance- based Stock Options Granted	RSUs Granted and PRSUs Granted at Target	Gross Burn Rate (1)	Expired and Forfeited Options and RSUs	Net Burn Rate (2)
2022	53,321,625	1,864,465	—	2,397,369	8%	1,370,332	5%
2023	53,764,705	680,788	—	4,028,424	9%	1,646,333	6%
2024	52,773,247	1,053,285	—	3,726,419	9%	816,550	8%

2025 Forecasted Net Burn Rate: Approximately 3 - 4%

(1) Gross Burn Rate is calculated by dividing (x) the number of stock options, RSUs and restricted shares granted to participants during a

fiscal year, plus (y) the number of PRSUs granted to participants during a fiscal year (with PRSUs included at “target” levels), by the

sum of the total common stock outstanding plus the number of equity awards outstanding (with PRSUs included at “target” levels)

during such year.

(2) Net Burn Rate excludes expired and forfeited options and RSUs primarily associated with employee turnover.

2025 Expected Burn Rate

In our 2024 proxy, we requested additional shares from investors and received their feedback concerning the need to

reduce burn rate.

We have taken the following actions to significantly reduce our burn rate and believe it will be significantly lower in

2025:

• Reduced grant sizes for employees and directors

• Shifted to a more balanced approach of cash, equity and defined contribution benefits

• Refined the parameters of employees who are eligible for stock awards

• Moved to full-value RSUs and PSUs and eliminated the use of options

We believe these actions will result in a gross burn rate below our industry benchmark for 2025 as determined by ISS.

Our 2025 industry benchmark for Pharmaceuticals, Biotechnology & Life Sciences, as determined by ISS, is 5.9% .

As shown in the chart below, in 2025 we forecast our Gross Burn Rate to be approximately 4 – 5% and our Net Burn

Rate to be approximately 3 – 4%.

~4-5%

~3-4%

The Compensation and Human Capital Committee and the Board of Directors determined that the increase to the

reserved pool under the amendment to the 2024 Plan should be 1,600,000 shares based on projected equity awards

to anticipated new hires and projected annual equity awards to existing employees and other service providers. We

anticipate that our Gross Burn Rate and Net Burn Rate for 2026 will remain below the industry benchmarks as we

have largely completed the restructuring of our executive team and have forecasted our revenue growth to outpace

operating expenses and personnel expenses. If our requested additional share reserve is approved by our

stockholders, we believe it will be sufficient to provide equity incentives to attract, retain and motivate employees for

the next year.

Our future share usage could be impacted by a number of factors such as award type mix; hiring and promotion

activity at the executive level; the rate at which shares are returned to the 2024 Plan’s reserve upon the awards’

expiration, forfeiture or cash settlement; the future performance of our stock price; the consequences of acquiring

other companies; and other factors.

Dilution

Dilution is commonly measured by “overhang,” which we calculate as the total number of equity awards outstanding

(with PRSUs included at “target” levels) plus the total number of shares available for grant under our equity plans

(other than the 2014 ESPP), divided by the sum of the total common stock outstanding, the number of equity awards

outstanding (with PRSUs included at “target” levels) and the total number of shares available for grant under our

equity plans (other than the 2014 ESPP).

As of March 31, 2025, our calculated overhang was 15%. If the amendment to the 2024 Plan to increase the share

reserve is approved, our overhang (as calculated above) will be approximately 21% (after taking into consideration

the expiration of our 2014 Plan and excluding our 2014 ESPP).

Of the 2,944,438 stock options currently outstanding, many relate to underwater stock options. Based on a closing

stock price on March 31, 2025, of $17.75, 1,368,695 stock options are currently underwater and account for 2% of our

overhang if the amendment to the 2024 Plan is approved . As we reduce our burn rate, we expect overhang to

continue to come down in 2025.

~18-19%

Key Features and Governance Practices

R 2 = 0.87

~12-13%

We have incorporated a number of provisions in the 2024 Plan that are designed to protect stockholders and that we

believe reflect strong governance practices, including the following:

• No Evergreen : The 2024 Plan does not include an automatic share reload or “evergreen” provision. Additional

stockholder approval will be required to increase the maximum number of shares reserved under the 2024 Plan.

• No Repricing : The 2024 Plan prohibits the repricing of stock options and stock appreciation rights (“SARs”)

without stockholder approval, the exchange or substitution of one award for another award that has the effect of

reducing the exercise or purchase price and the cancellation or exchange of underwater awards for cash, another

award or other property, except in the event of a capitalization adjustment (described below).

• No Dividends on Unvested Awards : Dividends or dividend equivalents credited or payable in connection with an

award under the 2024 Plan that is not yet vested will be subject to the same restrictions and risk of forfeiture as

the underlying award.

• No Liberal Share Recycling : The 2024 Plan prohibits liberal share recycling. Shares tendered by a participant or

withheld by the Company in payment of the purchase price of a stock option or to satisfy any tax withholding

obligation with respect to any option or SAR do not become available for issuance as future awards under the

2024 Plan.

• Limit on Non-Employee Director Compensation : The 2024 Plan contains an annual limit on cash and equity-

based compensation that may be paid or granted, whether under the 2024 Plan or otherwise, to our non-

employee directors of $750,000 (or $1,500,000 in the calendar year that the non-employee director first joins our

Board of Directors).

• Minimum Vesting : The 2024 Plan imposes a one-year minimum vesting requirement on awards granted

thereunder, subject to certain exceptions set forth in the 2024 Plan.

• Clawback Provision : Awards under the 2024 Plan are subject to our current clawback policy and to any future

clawback policies that we may adopt. See “—Clawback/Recovery” discussed below.

• No Automatic Single-Trigger Acceleration : In the event of a corporate transaction (described below), the 2024

Plan does not provide for automatic single trigger acceleration.

• Term and Exercise Price Limits on Options and SARs : Options and SARs granted under the 2024 Plan are

subject to a maximum term of 10 years and, with the exception of certain awards assumed in a corporate

transaction, may not be granted at a discount to the fair market value of our common stock on the grant date.

• No Change in Control/280G Tax Gross-Ups : We do not provide our employees with tax gross-ups on change in

control benefits.

• No Liberal Change in Control Definition : The definition of Change in Control in the 2024 Plan does not include

events where an actual change in control of the Company may not occur (e.g., commencement or announcement

of a tender offer or stockholder approval of a merger).

• Limited Transferability : Aw ards are not transferable except by will or by the laws of descent and distribution, or

under a domestic relations order, subject to limited approvals that may be approved by the plan administrator;

provided, unless approved by stockholders, no award can be transferred for value and no stock option or SAR

can be transferred to a third-party financial institution.

Consequences if the Amended Plan is not Approved

If the amendment to the 2024 Plan is not approved, the Company would be at a significant disadvantage relative to its

competitors for recruiting, retaining and motivating the high caliber individuals critical to our growth and profitability

and could be forced to increase cash compensation, thereby reducing resources available to meet our business

needs. Since our inception, the Board of Directors has sought to align the interests of our employees and other

service providers with the long-term interests of our stockholders through, among other things, placing a significant

emphasis on equity-based compensation as a component of our compensation programs. The Board of Directors

believes that equity compensation of the type available for grant under the 2024 Plan, a stock-based incentive plan,

furthers the Company’s goal of creating long-term value for the Company’s stockholders by fostering an ownership

culture that encourages a focus on long-term performance, retention, and stockholder value-creation, and exposes

the Company’s employees to economic diminishment if the Company’s share performance lags.

Summary of the 2024 Plan

The following summary describes the material terms of the 2024 Plan. This summary of the 2024 Plan is not a

complete description of all provisions of the 2024 Plan and is qualified in its entirety by reference to the 2024 Plan,

which is attached hereto as Appendix A. Stockholders are encouraged to read the 2024 Plan in its entirety, including

the proposed amendment to the 2024 Plan attached hereto as Appendix B.

Purpose . The purpose of the 2024 Plan is to provide incentives for our employees, directors and consultants to exert

maximum efforts for the success of the Company and our affiliates and to promote the creation of long-term value for

the stockholders of the Company by closely aligning the interests of such individuals with those of such stockholders.

Authorized Shares . As of March 31, 2025, 1,583,698 shares of common stock were available for issuance under the

2024 Plan, subject to adjustment as provided in the 2024 Plan. If the proposed amendment to the 2024 Plan is

approved by stockholders, an additional 1,600,000 shares of our common stock will be available for future issuance

under the 2024 Plan.

If any awards granted under the 2024 Plan are forfeited, expire, terminate, otherwise lapse or are surrendered

pursuant to an exchange program or otherwise settled for cash, in whole or in part, without the delivery of shares, the

shares covered by such forfeited, expired, terminated or lapsed award or award surrendered or settled in cash will be

added back to and again become available for issuance under the 2024 Plan. Any shares withheld in respect of

taxes, any shares tendered or withheld to pay the exercise price of options and any shares underlying an award of

stock appreciation rights will not be added back to or again become available for issuance under the 2024 Plan. For

the avoidance of doubt, awards granted under the 2024 Plan that by their terms settle in cash will not reduce the 2024

Plan’s share reserve.

Plan Administration . Our Board of Directors, or a duly authorized committee of our Board of Directors (referred to

collectively as the “plan administrator”), will administer the 2024 Plan. The plan administrator may, in accordance with

the terms of the 2024 Plan, delegate to one or more of our officers the authority to determine (i) award recipients, (ii)

how and when each award will be granted, (iii) the types of awards to be granted, (iv) grant dates, (v) the number of

shares subject to each award, (vi) the fair market value of our common stock, and (vii) the provisions of each award,

including the period of exercisability and the vesting schedule applicable to an award.

Under the 2024 Plan, (i) the plan administrator will not, without stockholder approval, (A) reduce the exercise or strike

price of an option or stock appreciation right (other than in connection with a capitalization adjustment), (B) at any

time when the exercise or strike price of an option or stock appreciation right is above the fair market value of a share

of our common stock, cancel and re-grant or exchange such option or stock appreciation right for a new award with a

lower (or no) purchase price or for cash and (C) institute and determine the terms and conditions of an “exchange

program” under which outstanding awards are surrendered or cancelled in exchange for awards of the same type

(which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash,

participants would have the opportunity to transfer any outstanding awards to a financial institution or other person or

entity selected by the plan administrator, and/or the exercise price of an outstanding award is increased or reduced,

and (ii) a participant’s rights under any award will not be amended to materially adversely affect such participant’s

rights thereunder without the participant’s written consent.

Our Board of Directors is the plan administrator of the 2024 Plan unless and until administration of the plan is

delegated to a committee of one or more members of our Board of Directors in accordance with the 2024 Plan.

Generally, the administration of the 2024 Plan has been delegated to the Compensation and Human Capital

Committee and, in connection with the administration of the 2024 Plan, the Compensation and Human Capital

Committee has the administrative powers and authority provided to the Board of Directors under the 2024 Plan,

concurrently with the authority retained by the Board of Directors to administer the 2024 Plan.

Awards Under the 2024 Plan

The 2024 Plan provides for the grant of incentive stock options (“ISOs”), within the meaning of Section 422 of the

Internal Revenue Code of 1986, as amended (the “ Code ”), to our employees and our parent and subsidiary

corporations’ employees, and for the grant of nonstatutory stock options (“ NSOs ”), stock appreciation rights, restricted

stock awards, restricted stock unit awards and other forms of awards to our employees, directors and consultants and

any of our affiliates’ employees and consultants.

Stock Options . ISOs and NSOs will be granted under stock option agreements adopted by the plan administrator.

The plan administrator will determine the exercise price for stock options, within the terms and conditions of the 2024

Plan, except the exercise price of a stock option (other than an option assumed or substituted in connection with a

corporate transaction) generally will not be less than 100% (or 110% in the case of ISOs granted to a person who

owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our

parent or subsidiary corporations, or a ten percent stockholder) of the fair market value of our common stock on the

date of grant. Options granted under the 2024 Plan will vest at the rate specified in the stock option agreement as will

be determined by the plan administrator. The terms and conditions of separate options need not be identical.

No option will be exercisable after the expiration of ten years (or five years in the case of ISOs granted to a ten

percent stockholder) or a shorter period specified in the applicable award agreement. Unless otherwise determined by

the plan administrator or the terms of an option holder’s stock option agreement, or other written agreement between

us and the recipient, provide otherwise, if an option holder’s service relationship with us or any of our affiliates ceases

for any reason other than disability, death, or cause, the option holder may generally exercise any vested options for

a period of three months following the cessation of service. This period may be extended in the event that exercise of

the option is prohibited by applicable securities laws. If an option holder’s service relationship with us or any of our

affiliates ceases due to death, or an option holder dies within a certain period following cessation of service, the option

holder or a beneficiary may generally exercise any vested options for a period of 12 months following the date of

death. If an option holder’s service relationship with us or any of our affiliates ceases due to disability, the option

holder may generally exercise any vested options for a period of 12 months following the cessation of service. In the

event of a termination for cause, options generally terminate upon the termination date. If a participant is suspended

pending investigation of whether their service relationship with us or any of our affiliates shall be terminated for cause,

the participant’s rights to exercise an option will be suspended during the investigation period. An option holder may

not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law.

Unless determined by the Board of Directors or provided otherwise in the option holder’s stock option agreement or

other written agreement between an option holder and us, if an option holder’s service relationship with us or any of

our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable

post-termination exercise period: (i) the exercise of the option holder’s option would be prohibited solely because the

issuance of shares upon such exercise would violate applicable law, (ii) the immediate sale of any shares issued upon

such exercise would violate our trading policy or (iii) the plan administrator has suspended exercisability of such

option holder’s option pending investigation of whether their service relationship with us or any of our affiliates shall be

terminated for cause, then the applicable post-termination exercise period will be extended to the last day of the

calendar month that begins after the date the award would otherwise expire, with an additional extension of the

exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time

during such extended exercise period. There is no limitation as to the maximum permitted number of extensions.

However, in no event may an option be exercised beyond the expiration of its term.

Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be

determined by the plan administrator and may include (i) cash, check, bank draft or money order payable to us; (ii) a

broker-assisted cashless exercise; (iii) subject to certain conditions, the tender of shares of our common stock

previously owned by the option holder; (iv) a net exercise of the option if it is an NSO; or (v) other legal consideration

approved by the plan administrator.

Unless the plan administrator provides otherwise, options or stock appreciation rights generally will not be

transferable except by will or the laws of descent and distribution. Subject to approval of the plan administrator or a

duly authorized officer, an option may be transferred pursuant to a domestic relations order.

Tax Limitations on ISOs. The aggregate fair market value, determined at the time of grant, of our common stock with

respect to ISOs that are exercisable for the first time by any participant during any calendar year under all of our stock

plans or plans of our affiliates may not exceed $100,000. Options or portions thereof that exceed such limit will

generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, is a ten percent

stockholder unless (i) the option exercise price is at least 110% of the fair market value of the stock subject to the

option on the date of grant; and (ii) the term of the ISO does not exceed five years from the date of grant.

Restricted Stock Unit Awards . Subject to the terms of the 2024 Plan, each restricted stock unit award will have such

terms and conditions as determined by the plan administrator. A restricted stock unit award represents a participant’s

right to be issued on a future date the number of shares of our common stock that is equal to the number of restricted

stock units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with

respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested

restricted stock unit award). A restricted stock unit award will generally be granted in consideration for a participant’s

services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such

services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares pursuant

to the restricted stock unit award. If, at the time of grant, the plan administrator determines that a participant must pay

consideration upon the issuance of shares pursuant to a restricted stock unit award, such consideration may be paid

in any form of legal consideration that may be acceptable to the plan administrator and permissible under applicable

law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our common stock

and cash), or in any other form of consideration determined by the plan administrator and set forth in the restricted

stock unit award agreement. At the time of grant, the plan administrator may impose such restrictions or conditions on

the award of restricted stock units that delay delivery to a date following the vesting of the award in a manner

intended to comply with Section 409A of the Code, as applicable. Additionally, dividends or dividend equivalents may

be paid or credited in respect of shares covered by a restricted stock unit award, subject to the same restrictions on

transferability and forfeitability as the underlying award with respect to which such dividends or dividend equivalents

are granted and subject to such other terms and conditions as determined by the plan administrator and specified in

the applicable restricted stock unit award agreement. Except as determined by the plan administrator or otherwise

provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock

unit awards that have not vested will be forfeited once the participant’s continuous service ends for any reason.

Restricted Stock Awards . Restricted stock awards will be granted under restricted stock award agreements adopted

by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or

money order, past or future services to us or any of our affiliates, or any other form of legal consideration that may be

acceptable to the plan administrator and permissible under applicable law. The plan administrator will determine the

terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends or dividend

equivalents may be paid or credited with respect to shares subject to a restricted stock award, subject to the same

restrictions on transferability and forfeitability as the underlying award with respect to which such dividends or

dividend equivalents are granted and subject to such other terms and conditions as determined by the plan

administrator and specified in the applicable restricted stock award agreement. If a participant’s service relationship

with us ends for any reason, we may receive any or all of the shares of our common stock held by the participant that

have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase

right.

Stock Appreciation Rights . Stock appreciation rights will be granted under stock appreciation right agreements

adopted by the plan administrator and denominated in shares of common stock equivalents. The terms of separation

stock appreciation rights need not be identical. The plan administrator will determine the purchase price or strike price

for a stock appreciation right, which generally will not be less than 100% of the fair market value of our common stock

on the date of grant. A stock appreciation right granted under the 2024 Plan will vest at the rate specified in the stock

appreciation right agreement as will be determined by the plan administrator. Stock appreciation rights may be settled

in cash or shares of our common stock (or any combination of our common stock and cash) or in any other form of

payment, as determined by the plan administrator and specified in the stock appreciation right agreement.

The plan administrator will determine the term of stock appreciation rights granted under the 2024 Plan, up to a

maximum of 10 years. If a participant’s service relationship with us or any of our affiliates ceases for any reason other

than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period

of three months following the cessation of service. This period may be further extended in the event that exercise of

the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a

participant’s service relationship with us or any of our affiliates ceases due to disability or death, or a participant dies

within a certain period following cessation of service, the participant or a beneficiary may generally exercise any

vested stock appreciation rights for a period of 18 months following the date of death. If a participant’s service

relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested

stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination for

cause, stock appreciation rights generally terminate upon the termination date. If a participant is suspended pending

investigation of whether their service relationship with us or any of our affiliates shall be terminated for cause, the

participant’s rights to exercise a stock appreciation right will be suspended during the investigation period. A holder of

a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon

such exercise would violate applicable law. Unless determined by the plan administrator or provided otherwise in the

stock appreciation right agreement or other written agreement between the participant and us, if a participant’s

service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during

the last thirty days of the applicable post-termination exercise period: (i) the exercise of the participant’s stock

appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate

applicable law, (ii) the immediate sale of any shares issued upon such exercise would violate our trading policy or (iii)

the plan administrator has suspended exercisability of such option holder’s option pending investigation of whether

their service relationship with us or any of our affiliates shall be terminated for cause, then the applicable post-

termination exercise period will be extended to the last day of the calendar month that begins after the date the award

would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month

to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no

limitation as to the maximum permitted number of extensions. However, in no event may a stock appreciation right be

exercised beyond the expiration of its term.

Other Stock Awards . The plan administrator will be permitted to grant other awards, based in whole or in part by

reference to, or otherwise based on, our common stock, either alone or in addition to other awards. The plan

administrator will have the sole and complete discretion to determine the persons to whom and the time or times at

which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent), the

form of payment (for example, shares of stock, cash or other property) and all other terms and conditions of such

awards.

Awards; Performance Criteria

Awards made pursuant to the 2024 Plan may be made subject to the attainment of performance goals relating to one

or more business criteria. For purposes of the 2024 Plan, such business criteria may include (but is not limited to) any

one or more of the following performance criteria, either individually, alternatively, or in any combination: earnings

(including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before

interest, taxes, depreciation and amortization; total stockholder return; return on equity or average stockholder’s

equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before

or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue

targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of

working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share;

share price performance; debt reduction; customer satisfaction; stockholders’ equity; capital expenditures; debt levels;

operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; pre-

clinical development related compound goals; financing; regulatory milestones, including approval of a compound;

stockholder liquidity; corporate governance and compliance; product commercialization; intellectual property;

personnel matters; progress of internal research or clinical programs; progress of partnered programs; partner

satisfaction; budget management; clinical achievements; completing phases of a clinical study (including the

treatment phase); announcing or presenting preliminary or final data from clinical studies; in each case, whether on

particular timelines or generally; timely completion of clinical trials; submission of INDs and NDAs and other regulatory

achievements; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley

Act of 2002; research progress, including the development of programs; investor relations, analysts and

communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other

measurable objectives related to process development activities); strategic partnerships or transactions (including in-

licensing and out-licensing of intellectual property; establishing relationships with commercial entities with respect to

the marketing, distribution and sale of our products (including with group purchasing organizations, distributors and

other vendors)); supply chain achievements (including establishing relationships with manufacturers or suppliers of

active pharmaceutical ingredients and other component materials and manufacturers of our products); co-

development, co-marketing, profit sharing, joint venture or other similar arrangements; individual performance goals;

corporate development and planning goals; and other measures of performance selected by our Board of Directors or

our Compensation and Human Capital Committee.

In determining performance outcomes related to such measures or criteria, the plan administrator may provide for the

exclusion of the impact of an event or occurrence which the plan administrator determines should appropriately be

excluded, including: (a) restructuring and/or other nonrecurring charges, (b) exchange rate effects, (c) the effects of

changes to generally accepted accounting principles, (d) the effects of any statutory adjustments to corporate tax

rates, (e) the effects of items that are “unusual” in nature or occur “infrequently” as determined under generally

accepted accounting principles, (f) the dilutive effects of acquisitions or joint ventures, (g) exclusions to assume that

any business divested by us achieved performance objectives at targeted levels during the balance of a performance

period following such divestiture, (h) the effect of any change in the outstanding shares of our common stock by

reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-

off, combination or exchange of shares or other similar corporate change, or any distributions to common

stockholders other than regular cash dividends, (i) the effects of stock based compensation and the award of bonuses

under the Company’s bonus plans, (j) costs incurred in connection with potential acquisitions or divestitures that are

required to be expensed under generally accepted accounting principles and (k) the goodwill and intangible asset

impairment charges that are required to be recorded under generally accepted accounting principles.

Non-Employee Director Compensation Limit

The aggregate value of all compensation granted or paid following the effective date of the 2024 Plan to any

individual for service as a non-employee director with respect to any fiscal year, including awards granted under the

2024 Plan (valued based on the grant date fair value for financial reporting purposes) and cash fees paid by us to

such non-employee director, will not exceed $750,000 in total value, except such amount will increase to $1,500,000

for the year in which a non-employee director is first appointed or elected to our Board. For the avoidance of doubt,

any awards granted and cash fees paid to a non-employee director for their service as a non-employee director in

respect of any fiscal year will count against the annual compensation limits for the fiscal year to which such awards

and fees related, regardless of any deferral of such Awards or fees.

Changes to Capital Structure

In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or

recapitalization, the plan administrator will appropriately and proportionately adjust (i) the class and maximum number

of shares subject to the 2024 Plan; (ii) the class and maximum number of shares that may be issued on the exercise

of ISOs; and (iii) the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all

outstanding awards granted under the 2024 Plan.

Corporate Transactions . In the event of a corporate transaction (as defined below), all outstanding awards as of the

date of such corporate transaction will be treated in the manner described in the definitive agreement evidencing such

corporate transaction (or, in the event that such corporate transaction is not effected pursuant to a definitive

agreement to which the Company is a party, in the manner determined by our Board of Directors). For the avoidance

of doubt, the definitive agreement (or the Board of Directors’ determination) does not need to treat all awards

outstanding under the 2024 Plan (or portions thereof) in an identical matter. Unless otherwise provided in a

participant’s award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly

provided by the plan administrator at the time of grant (and without limiting the prior sentence), any awards

outstanding under the 2024 Plan may be assumed, continued or substituted for, in whole or in part, by any surviving

or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to

our common stock issued pursuant to awards may be assigned to the successor (or its parent company). If the

surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards,

then (i) with respect to any such awards that are held by participants whose continuous service has not terminated

prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if

applicable) of such awards will be accelerated in full (or, in the case of awards with performance-based vesting with

multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award

agreement, vesting will accelerate at 100% of the target level or such greater level as determined by the Board) to a

date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate

transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the

corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse

(contingent upon the effectiveness of the corporate transaction); and (ii) any such awards that are held by persons

other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate

transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not

terminate and may continue to be exercised notwithstanding the corporate transaction.

In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, the plan

administrator may provide, in its sole discretion, that the holder of such award may not exercise such award but

instead will receive a payment, in such form as may be determined by the plan administrator, equal in value to the

excess (if any) of (i) the value of the property the participant would have received upon the exercise of the award,

over (ii) any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a

participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the

2024 Plan governing a corporate transaction involving us.

Under the 2024 Plan, a “corporate transaction” generally will be the consummation, in a single transaction or in a

series of related transactions, of (i) a sale or other disposition of all or substantially all, as determined by the plan

administrator, of our consolidated assets; (ii) a sale or other disposition of at least 50% of our outstanding securities;

(iii) a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv) a

merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our

common stock outstanding immediately prior to such transaction are converted or exchanged into other property by

virtue of the transaction.

Change in Control . Awards to be granted under the 2024 Plan may be subject to acceleration of vesting and

exercisability upon or after a change in control (as defined below) as may be provided in the applicable stock award

agreement or in any other written agreement between us or any affiliate and the participant, but in the absence of

such provision, no such acceleration will automatically occur.

Under the 2024 Plan, a “change in control” generally will be: (i) the acquisition by any person or company of more

than 50% of the combined voting power of our then outstanding stock; (ii) a merger, consolidation or similar

transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than

50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the

same proportions as their ownership immediately prior to such transaction; (iii) stockholder approval of a complete

dissolution or liquidation; (iv) a sale, lease, exclusive license or other disposition of all or substantially all of our assets

other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in

substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such

transaction; or (v) when a majority of our Board of Directors becomes comprised of individuals who were not serving

on our Board of Directors on the date of the underwriting agreement related to this offering, or the incumbent board,

or whose nomination, appointment, or election was not approved by a majority of the incumbent board still in office.

Minimum Vesting Conditions

Subject to the proviso below, awards granted under the 2024 Plan will vest no earlier than the first anniversary of the

date on which the award is granted; provided, that the following will not be subject to the foregoing minimum vesting

requirement: (i) awards to non-employee directors that vest on earlier of the one-year anniversary of the date of grant

and the next annual meeting of stockholders, which is at least 50 weeks after the immediately preceding year’s

annual meeting; (ii) additional awards the plan administrator may grant, up to a maximum of five percent (5%) of the

available share reserve authorized for issuance under the 2024 Plan (subject to the 2024 Plan’s adjustment

provisions); and (iii) any decision by our Board to provide for accelerated vesting of any award in connection with the

termination of a participant’s continuous service in exchange of a release of claims. The foregoing restriction does not

apply to the plan administrator’s discretion to provide for accelerated exercisability or vesting of any award in the

event of change in control in which the surviving corporation or acquiring corporation (or its parent company) does not

assume or continue such award or substitute a similar award.

Prohibition on Repricing

Other than pursuant to certain equitable adjustments as described in the 2024 Plan, the plan administrator will not,

without the approval of the Company’s stockholders, lower the option price per share of an option (or base price of a

SAR) after it is granted, cancel an option or SAR when the exercise price per share exceeds the fair market value of

one share in exchange for cash or another award (other than in connection with a change in control), or take any

other action with respect to an option or SAR that would be treated as a repricing under the rules and regulations of

the principal United States (“U.S.”) national securities exchange on which the shares are listed.

Deferral

In its discretion and subject to such terms and conditions as it may impose, the plan administrator may permit a

participant to elect to defer receipt of shares of common stock issuable pursuant to any equity award granted under

the 2024 Plan to a time later than the time the shares otherwise would be issued to the participant; provided that such

deferral election complies with rules adopted by the plan administrator, which comply with, or are exempt from, the

requirements of Section 409A of the Code. In such event, the plan administrator may, in its discretion, provide for the

payment by the Company of an additional amount representing interest at a reasonable rate or the actual rate of

return on one or more predetermined specific investments, as determined by the plan administrator.

Foreign Employees and Consultants

Awards may be granted to participants who are foreign nationals or employed or providing services outside the United

States, or both, on such terms and conditions different from those applicable to awards to employees or consultants

providing services in the United States as may, in the judgment of the plan administrator, be necessary or desirable in

order to recognize differences in local law or tax policy.

Transferability

Except as determined by the Board or expressly provided in the 2024 Plan or the form of award agreement, awards

granted under the 2024 Plan may not be transferred or assigned by a participant. After the vested shares subject to

an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares

have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any

interest in such shares provided that any such actions are in compliance with the terms of our trading policy and

applicable law.

Clawback/Re c overy

All awards granted under the 2024 Plan will be subject to recoupment in accordance with our current clawback policy

and as otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable

law, and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law.

See “Board of Directors and Corporate Governance—Clawback Policy”. In addition, the plan administrator may

impose such other clawback, recovery or recoupment provisions in an award agreement as the plan administrator

determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired

shares of our common stock or other cash or property upon the occurrence of cause.

Amendment or Termination

The plan administrator may accelerate the time at which an award granted under the 2024 Plan may first be exercised

or the time during which an award grant under the 2024 Plan or any part thereof will vest, notwithstanding the

provisions in the award agreement stating the time at which it may first be exercised or the time during which it will

vest. The plan administrator will have the authority to amend, suspend or terminate the 2024 Plan at any time,

provided that such action does not materially impair the existing rights of any participant without such participant’s

written consent. Certain material amendments will also require the approval of our stockholders. No ISOs may be

granted after the tenth anniversary of the effective date of the 2024 Plan. No awards may be granted under the 2024

Plan while it is suspended or after it is terminated.

Form S-8 Registration Statement

We intend to file a registration statement on Form S-8 to register the additional shares of our common stock approved

under the amendment to the 2024 Plan.

New Plan Benefits

As described above, the selection of participants who will receive awards under the 2024 Plan and the size and types

of awards will be determined by the plan administrator at its discretion. None of the shares authorized by the

amendment to the 2024 Plan have been awarded to any of the directors or employees, and no commitment has been

made to award any such shares. The plan administrator has authority to authorize future awards under the 2024 Plan

from time to time. The value of any future equity awards will ultimately depend on the nature and size of the awards,

the future price of our common stock and the exercise decisions made by the participants, among other factors, and

will be subject to such vesting conditions under the 2024 Plan as the plan administrator determines from time to time.

Therefore, the amount of any future awards under the 2024 Plan is not yet determinable and it is not possible to

predict the benefits or amounts that will be received by, or allocated to, particular individuals or groups of employees.

Currently, our non-employee directors are entitled to receive cash and equity compensation for their service as

directors as described above under “Board of Directors and Corporate Governance—Director Compensation.” For

further details on the awards granted during the fiscal year ended December 31, 2024 under the 2024 Plan, please

refer to the executive and director compensation tables beginning on page 58 and 30 , respectively, of this proxy

statement.

Certain U.S. Federal Income Tax Consequences

The following is a summary of the U.S. federal income tax treatment applicable to us and the participants who receive

awards under the 2024 Plan based on the federal income tax laws in effect on the date of this proxy statement. This

summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based

on their specific circumstances. The summary expressly does not discuss the income tax laws of any state,

municipality or non-U.S. taxing jurisdiction, or the gift, estate, excise or other tax laws other than U.S. federal income

tax law. Because individual circumstances may vary, we recommend that all participants to consult with their tax

advisor concerning the tax implications of awards granted under the 2024 Plan.

Stock Option Grants

Stock options granted under the 2024 Plan may either be ISOs, which satisfy the requirements of Section 422 of the

Code, or NSOs, which are not intended to meet such requirements. The U.S. federal income tax treatment for the two

types of options differs as follows:

Incentive Stock Options

No taxable income is recognized by the participant at the time of the grant of an ISO, and no taxable income is

recognized for ordinary income tax purposes at the time the ISO is exercised, although taxable income may arise at

that time for alternative minimum tax purposes. Unless there is a disqualifying disposition, as described below, the

participant will recognize long-term capital gain in an amount equal to the excess of (i) the amount realized upon the

sale or other disposition of the purchased shares over (ii) the exercise price paid for the shares.

A disqualifying disposition occurs if the disposition is less than two years after the date of grant or less than one year

after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i) the fair market value

of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii) the

exercise price paid for the shares will be taxable as ordinary income to the participant. Any additional gain or loss

recognized upon the disposition will be a capital gain or loss.

If the participant makes a disqualifying disposition of the purchased shares, then we will be entitled to an income tax

deduction for the taxable year in which such disposition occurs, equal to the amount of ordinary income recognized by

the participant as a result of the disposition. We will not be entitled to any income tax deduction if the participant

makes a qualifying disposition of the shares.

Non-Statutory Stock Options

No taxable income is recognized by a participant upon the grant of an NSO. The participant in general will recognize

ordinary income, in the year in which the NSO is exercised, equal to the excess of the fair market value of the

purchased shares on the exercise date over the exercise price paid for the shares. We will be entitled to an income

tax deduction equal to the amount of ordinary income recognized by the participant with respect to the exercised non-

statutory stock option.

SARs

No taxable income is recognized upon receipt of an SAR. The holder will recognize ordinary income in the year in

which the SAR is exercised, in an amount equal to the excess of (i) the fair market value of the underlying shares of

common stock on the exercise date over (ii) the base price in effect for the exercised right. We will be entitled to an

income tax deduction equal to the amount of ordinary income recognized by the holder in connection with the

exercise of the SAR.

Stock Awards

Participants will recognize ordinary income at the time unrestricted stock awards are granted in an amount equal to

the excess of (i) the fair market value of the shares on the grant date over (ii) the cash consideration (if any) paid for

the shares.

No taxable income is recognized at the time restricted stock awards are issued but the participant will have to report

as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i) the fair market

value of the shares on the vesting date over (ii) the cash consideration (if any) paid for the shares. The participant

may, however, elect under Section 83(b) of the Code to include as ordinary income in the year the unvested shares

are issued an amount equal to the excess of (a) the fair market value of those shares on the issue date over (b) the

cash consideration (if any) paid for such shares. If the Section 83(b) election is made, the participant will not

recognize any additional income as and when the shares subsequently vest.

We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at

the time such ordinary income is recognized by the participant.

Other Awards

Generally, no taxable income is recognized upon receipt of stock units (including RSUs), performance awards or cash

awards. The holder will recognize ordinary income in the year in which the shares subject to the award are actually

issued or in the year in which the award is settled in cash. The amount of that income will be equal to the fair market

value of the shares on the date of issuance or the amount of the cash paid in settlement of the award.

We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the holder at the

time the shares are issued or the cash amount is paid.

Withholding

Prior to the delivery of any shares of our common stock or cash pursuant to a 2024 Plan award (or exercise thereof),

the Company will have the power and the right to deduct or withhold, or require a participant to remit to the Company,

an amount sufficient to satisfy federal, state, and local taxes or other amounts (including the participant’s FICA

obligation) required to be withheld with respect to such award (or exercise thereof). The plan administrator, in its sole

discretion and pursuant to such procedures as it may specify from time to time, may permit a participant to satisfy

such tax withholding obligation, in whole or in part by (a) electing to have the Company withhold otherwise deliverable

shares of our common stock, or (b) delivering to the Company already-owned shares of our common stock having a

fair market value equal to the minimum amount required to be withheld. If the plan administrator permits shares of our

common stock to be withheld from the award to satisfy applicable withholding obligations, the fair market value of the

shares of our common stock withheld, as determined as of the date of withholding, will not exceed the amount

determined by the applicable minimum statutory withholding rates unless the plan administrator determines an

additional amount can be withheld and will not result in adverse accounting consequences, and the plan administrator

authorizes such additional withholding.

S ection 409A of the Code

Certain types of awards under the 2024 Plan may constitute, or provide for, a deferral of compensation subject to

Section 409A of the Code. Unless certain requirements set forth in Section 409A of the Code are complied with,

holders of such awards may be taxed earlier than would otherwise be the case (e.g., at the time of vesting instead of

the time of payment) and may be subject to an additional 20% penalty tax (and, potentially, certain interest, penalties

and additional state taxes). To the extent applicable, the 2024 Plan and awards granted under the 2024 Plan are

intended to be structured and interpreted in a manner intended to either comply with or be exempt from Section 409A

of the Code and the Department of Treasury regulations and other interpretive guidance that may be issued under

Section 409A of the Code. To the extent determined necessary or appropriate by the plan administrator, the 2024

Plan and applicable award agreements may be amended to further comply with Section 409A of the Code or to

exempt the applicable awards from Section 409A of the Code.

Deductibility of Executive Compensation

Section 162(m) of the Code limits the deductibility for federal income tax purposes of certain annual compensation

paid to any “covered employee” in excess of $1 million. For purposes of Section 162(m), the term “covered employee”

includes any individual who serves or has served as our chief executive officer, chief financial officer or one of the

other three most highly compensated executive officers for 2017 or any subsequent calendar year. It is expected that

compensation deductions for any covered employee with respect to awards under the 2024 Plan will be subject to the

$1 million annual deduction limitation.

Vote Required; Board Recommendation

Approval of the amendment to the 2024 Plan requires the affirmative vote of a majority of the shares of our common

stock present virtually or by proxy at the Annual Meeting and entitled to vote thereon. Abstentions will have the effect

of a vote AGAINST the proposal. Broker non-votes will have no effect on this proposal.

OUR BOARD OF DIREC TORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE “FOR” THE

APPROVAL OF THE AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN.

EXECUTIVE OFFICERS

The following table identifies certain information about our executive officers as of April 25, 2025. There are no family

relationships among any of our directors or executive officers.

Name	Age	Position(s)
John W. Hanna	45	President and Chief Executive Officer
Abhishek Jain	49	Chief Financial Officer
Keith Kennedy	55	Chief Operating Officer
Jessica Meng	50	Chief Commercial Officer
Jeffrey Novack	42	General Counsel and Secretary

John W. Hanna was appointed as our President and Chief Executive Officer, effective April 15, 2024. Prior to his

appointment, Mr. Hanna served as the Chief Executive Officer of Apton Biosystems, Inc., from April 2021 to August

Apton Biosystems, Inc. was acquired by Pacific Biosciences of California, Inc. in August 2023, where Mr.

Hanna served as Vice President of Corporate Development from August 2023 to March 2024. Mr. Hanna previously

served for ten years with Veracyte, Inc. from September 2011 to March 2021, where his most recent position was

Chief Commercial Officer since March 2017. Prior to Veracyte, Mr. Hanna held leadership roles at Humana and IBM.

Mr. Hanna received a B.S. in Political Science from Hampden-Sydney College in 2001 and an M.B.A. from the

University of Miami in 2008.

Abhishek Jain has served as our Chief Financial Officer since September 2022 and as a member of the Office of the

Chief Executive Officer from November 1, 2023 to April 15, 2024. Mr. Jain served as our Interim Chief Financial

Officer from May 2022 to September 2022. Prior to that, since joining us in August 2021, Mr. Jain had served as our

Vice President, Corporate Controller, where he was responsible for global accounting functions and SEC filings.

During that time, he worked closely with our Audit and Finance Committee of our Board of Directors, financial

planning and analysis team and business partners. Prior to joining us, Mr. Jain spent approximately 20 years at

Agilent Technologies, Inc., in a number of progressing finance positions and customer-facing roles, including his last

role as Global Field Controller, where he helped drive above-market growth for orders of an approximately $5 billion

business. Mr. Jain has extensive knowledge in driving channel strategy, expanding margins, scaling operations and

leading global teams. Mr. Jain is a member of the Institute of Chartered Accountants of India.

Keith Kennedy has served as our Chief Operating Officer since September 2024. Prior to joining us, Mr Kennedy

served as the Chief Financial Officer of PharmaLogic Holdings Corp from April 2022 to September 2024. Mr.

Kennedy served as Veractye, Inc.’s Chief Operating Officer from July 2019, as well as its Chief Financial Officer from

December 2016, until his retirement in May 2021, as well as its Secretary from November 2017 to July 2020. Prior to

joining Veracyte, Mr. Kennedy provided strategic counsel and consulting services from his consulting practice from

September 2015 to November 2016, including advisory services to Pennant Park Investment Advisors. Mr. Kennedy

served as President, Chief Executive Officer and Director of MCG Capital Corporation, a publicly traded business

development company, from April 2014 until its merger with Pennant Park Floating Rate Capital Ltd in August

Mr. Kennedy joined MCG Capital Corporation in February 2012 as an Executive Vice President and Managing

Director, served as its Chief Financial Officer and Treasurer from May 2012 to March 2014, and its President from

March to April 2014. Prior to MCG, Mr. Kennedy served as a Managing Director at GE Capital, a Manager of

Transaction Services at Ernst & Young LLP and as an Officer in the U.S. Air Force. Mr. Kennedy holds a B.S. in

Accounting with high distinction from Indiana University and holds an M.B.A. from the College of William & Mary. Mr.

Kennedy is a Chartered Financial Analyst and Certified Public Accountant.

Jessica Meng was appointed as our Chief Commercial Officer, effective September 12, 2024. Ms. Meng previously

served as Chief Commercial Officer at DELFI Diagnostics from July 2022 to September 2023, where she served first

as a consultant beginning January 2022. Ms. Meng served as Chief Commercial Officer and General Manager of

Women’s Health at Myovant Sciences from May 2020 to December 2021. Ms. Meng previously held roles of

increasing responsibility in sales and marketing leadership at Veracyte from November 2017 to May 2020 and

Genentech from 2004 to 2017. Prior to Genentech she worked at Progress Software and Monitor Company. Ms.

Meng received a Bachelor of Science in Finance and Bachelor of Arts in International Relations with a minor in

Mathematics from the University of Pennsylvania, and a Master’s in Business Administration, Marketing, Strategic

Management from The Wharton School.

Jeffrey Novack joined CareDx in 2021 and has served as our General Counsel since December 2023 and as our

Secretary since April 2024. Before joining CareDx, Mr. Novack served as an Assistant Attorney General in the

Investor Protection Bureau of the New York Attorney General’s Office. Prior to that, Mr. Novack practiced at two

international law firms and clerked for The Honorable Renée Marie Bumb, Chief Judge of the United States District

Court for the District of New Jersey. Mr. Novack is a graduate of New York University School of Law and Washington

University in St. Louis – Olin Business School. Mr. Novack is admitted to practice law in New York and New Jersey.

Legal Proceedings with Executive Officers

There are no legal proceedings related to any of the executive officers that require disclosure pursuant to Items 103

or 401(f) of Regulation S-K.

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

In this Compensation Discussion and Analysis (“CD&A”), we provide an overview of our executive compensation

philosophy and objectives, as well as a description of the material components of our executive compensation

program. This CD&A is intended to be read in conjunction with the tables that immediately follow this section, which

provide further historical compensation information.

During fiscal year 2024, the following executive officers constituted our named executive officers (collectively, our

“NEOs”):

Name	Position(s)
John W. Hanna (1)	President and Chief Executive Officer
Abhishek Jain	Chief Financial Officer
Keith Kennedy (2)	Chief Operating Officer
Jessica Meng (3)	Chief Commercial Officer
Jeffrey Novack	General Counsel and Secretary
Alexander Johnson (4)	Former President of Patient and Testing Services

(1) Mr. Hanna’s employment with us as our President and Chief Executive Officer commenced effective April 15, 2024.

Name	Position(s)
John W. Hanna (1)	President and Chief Executive Officer
Abhishek Jain	Chief Financial Officer
Keith Kennedy (2)	Chief Operating Officer
Jessica Meng (3)	Chief Commercial Officer
Jeffrey Novack	General Counsel and Secretary
Alexander Johnson (4)	Former President of Patient and Testing Services

(2) Mr. Kennedy’s employment with us as our Chief Operating Officer commenced effective September 12, 2024.

(3) Ms. Meng’s employment with us as our Chief Commercial Officer commenced effective September 12, 2024.

(4) Mr. Johnson served as Acting Principal Executive Officer from November 1, 2023 to April 15, 2024. Thereafter, Mr. Johnson continued

to serve as the Company’s President of Patient and Testing Services until his employment with us concluded effective September 13,

2024, at which time Mr. Johnson began serving as our consultant .

I. Executive Sum mary

2024 Business Highlights

CareDx is a leading precision medicine company focused on the discovery, development and commercialization of

clinically differentiated, high-value diagnostic solutions of transplant patients and caregivers. Over the course of 2024

we continued to further our growth by offering testing services, products, and patient and digital solutions along the

pre- and post-transplant patient journey. We are the leading provider of genomics-based information for transplant

patients. To date, we have devoted substantially all of our efforts to product development, increasing revenue and

continuing innovation to create life changing solutions that enable transplant patients to thrive. Fiscal year 2024 was

an important year for CareDx as we achieved the following:

Financials and Performance

• Reported full year revenue of $333.8 million, an increase of 19% year-over-year driven by testing services

revenue growth.

• Reported full year testing services revenue of $249.4 million, an increase of 19% year-over-year, and testing

services volume of approximately 176,000, an increase 6% year-over-year.

• Grew testing services for the sixth consecutive quarter in a row to approximately 45,500 in the fourth quarter of

2024, an increase of 14% year-over-year.

• Reported full year patient and digital solutions revenue of $43.6 million and product revenue of $40.8 million,

representing year-over-year growth of 18% and 22%, respectively.

• Reported full year GAAP net income of $52.5 million.

• Ended fiscal year 2024 with cash and cash equivalents, and marketable securities of approximately $261 million,

with no debt.

• Repurchased 3.0 million shares of common stock for $28.6 million under share buyback program in 2023 and

2024.

In achieving the above, we have continued to execute on our business objectives, improving our products and

technologies, and strengthening our financial position.

Further, our total stockholder return for 2024 outperformed the biotechnology space and the NASDAQ Composite:

K ey 2024 Compensa tion Decisions

1 YEAR

3 YEAR

5 YEAR

In 2024, the Company transitioned three of its most senior management roles, including the role of Chief Executive

Officer. The Company appointed Mr. Hanna as its president and Chief Executive Officer effective April 15, 2024,

appointed Mr. Kennedy as its Chief Operating Officer effective September 12, 2024, and hired Ms. Meng as its Chief

Commercial Officer effective September 12, 2024. Our former Principal Executive Officer, Mr. Johnson assisted with

the transition of our senior management, and effective September 13, 2024 terminated his service with the Company.

Our Compensation and Human Capital Committee was faced with the task of recruiting, retaining, and incentivizing

our leadership team and the compensation decisions for the 2024 fiscal year reflect the successful transition of the

Company’s leadership without compromising the Company’s objective of maintaining and ensuring the long-term

growth and success of the Company and the best interests of our stockholders. Aligned with our accomplishments in

2024 and continued strong business and company performance as outlined above, we onboarded and continued to

incentivize our executive officers through a compensation program that aligns our executives with the best interests of

our stockholders by placing an emphasis on pay for performance while balancing retention needs and building share

ownership among our executives. Our performance-based incentives aim to strengthen the pay-for-performance

relationship and drive fulfillment of key strategic goals. We continue to manage award design, with a goal of

delivering value that is aligned with our compensation philosophy and proactively managing our share usage as well

as dilution during a period of rapid growth. As we continued to maneuver through a period of rapid growth, we

focused on balancing retention needs and building share ownership amongst our executives, including our three most

recently hired NEOs, by granting equity awards that were inducements material to securing each of Mr. Hanna, Mr.

Kennedy, and Ms. Meng during the fiscal year 2024 as a part of our senior management team. We also granted long-

term incentives in fiscal year 2024 in the form of service-based awards of RSUs that vest over a three-year period in

order incentivize retention of our high value executives through a period of major transitions in our Company’s

leadership team.

Results of Fiscal Year 2023 Stockholder Advisory Vote

At our 2024 annual meeting of stockholders, our stockholders approved our Say-on-Pay proposal with approximately

96% of the votes in favor of the fiscal year 2023 compensation of our named executive officers. We believe that the

2023 vote approving our Say-on-Pay proposal once again conveyed our stockholders’ consistent strong support and

endorsement of our existing executive compensation program and affirmed that our overall executive compensation

program is aligned with the interests of our stockholders. Our Compensation and Human Capital Committee will

continue to consider feedback from our stockholders when making future compensation decisions, and will continue

to benchmark, against peers, our governance practices and executive compensation program.

Since we first conducted the Say-on-Pay vote, we have implemented a systematic stockholder outreach program to

seek ongoing feedback on our governance and compensation policies. We are committed to regular and transparent

communication and engagement with our current and future stockholders and reach out to our largest stockholders at

least annually.

II. Compensation Philosophy

We operate within a complex business environment in a competitive industry, which requires a very strong

management team. Our business model requires our management team to be adept at developing competitive

technologies to support multiple customers, including hospitals, all within multiple geographies. Many of our

competitors have substantially greater capital resources and larger sales forces than we do. In addition, the

diagnostics industry is characterized by rapid product development and technological advances, which require our

management team to be adept at managing these key areas of the business.

As a result, the Compensation and Human Capital Committee believes that it is critical to attract, develop and retain a

highly-qualified management team with the experience, knowledge, expertise and vision capable of not only

operating, but also excelling, in this complex and competitive business environment, including competing against

larger competitors and developing and commercializing new products, new and improved technologies and new

applications for our existing technologies.

Our executive compensation program is intended to help us achieve and foster a goal-oriented, highly-motivated

management team with a clear understanding of our business objectives and shared corporate values. To this end,

the Compensation and Human Capital Committee believes that our executive compensation program should provide

compensation that:

• attracts and retains the best executive talent;

• appropriately aligns our business objectives and stockholder interests;

• maintains a reasonable balance across types and purposes of compensation;

• motivates our executive officers to achieve our annual and long-term strategic goals and rewards performance

based on the attainment of such goals;

• appropriately considers risk and reward in the context of our business environment and long-range business

plans;

• recognizes individual value and contributions to our success;

• considers, but does not exclusively rely upon, competitive market data; and

• assists with the design and structure of our overall equity compensation practices.

We seek to achieve these objectives in a way that is consistent with the long-term interests of our company and those

of our stakeholders, including our stockholders and employees. We structure the annual compensation of our

executive officers, including our NEOs, using three principal elements: base salary, annual cash incentives and long-

term compensation opportunities in the form of equity awards.

Our Compensation and Human Capital Committee believes that our compensation program should align executive

interests with the drivers of growth and stockholder returns, and support achievement of our primary business goals.

The expertise, leadership and contributions of our executives are critical to our ability to create sustained long-term

stockholder value. Consequently, our Compensation and Human Capital Committee believes the substantial majority

of NEO compensation should be at-risk, variable pay to facilitate the successful execution of our business strategy.

III. Compensation Determination Process

Role of Compensation and Human Capital Committee

The Compensation and Human Capital Committee discharges the responsibilities of our Board of Directors relating to

the compensation of our executive officers. The Compensation and Human Capital Committee consists of directors

who are “independent” directors as required by the Nasdaq Rules and Exchange Act Rule 10C-1, and “non-employee

directors” for purposes of Exchange Act Rule 16b-3.

The Compensation and Human Capital Committee has responsibility for (i) overseeing our compensation and benefits

policies generally and (ii) overseeing, evaluating and approving the compensation plans, policies and programs

applicable to our Chief Executive Officer, as well as our other executive officers, including our other NEOs. In

carrying out its responsibilities, the Compensation and Human Capital Committee evaluates our compensation

policies and practices with a focus on the degree to which these policies and practices reflect our executive

compensation philosophy, develops recommendations, makes decisions that it believes advances our philosophy and

reviews the performance of our executive officers when making decisions with respect to their compensation.

The Compensation and Human Capital Committee conducts reviews of our compensation policies and programs on

at least an annual basis to ensure that they enhance stockholder value, align pay and performance, and attract and

retain top executive talent. This includes a review of internal pay equity among the executive team. With the

assistance of our independent compensation consultant, the Compensation and Human Capital Committee seeks to

maintain appropriate base salary, annual bonus and equity compensation plans for our executives.

Role of Chief Executive Officer & Management

For fiscal year 2024, the Compensation Committee considered executive officer compensation, other than the NEOs

who were hired in fiscal year 2024, including our current Chief Executive Officer Mr. Hanna, against the Company’s

peer group. Following Mr. Hanna’s hiring, our Compensation and Human Capital Committee reviews

recommendations from Mr. Hanna and other data and makes decisions as to total compensation for each executive

officer other than Mr. Hanna, as well as each individual compensation component. The Compensation and Human

Capital Committee makes the final decisions regarding executive compensation for our Chief Executive Officer. The

Compensation and Human Capital Committee does not delegate any of its functions to others in deciding executive

compensation.

Use of Independent Compensation Consultant

Our Compensation and Human Capital Committee is authorized to retain the services of one or more executive

compensation advisors, as it sees fit, in connection with the establishment of our compensation programs and related

policies. Since September 2023, the Compensation and Human Capital Committee has retained Alpine Rewards

(“Alpine”) as its independent outside compensation consultant to assist with setting executive compensation and the

Company’s broader employee equity strategy. The Compensation and Human Capital Committee has sole authority

to retain or replace such independent compensation consultants. The Compensation and Human Capital Committee

annually evaluates the compensation consultant’s independence and performance under the Nasdaq Rules. The

Compensation and Human Capital Committee believes that working with an independent compensation consultant

furthers our objectives to recruit and retain qualified executives, align executive interests with those of stockholders

and ensure that executive compensation packages will appropriately motivate and reward ongoing achievement of

business goals.

In 2024, Alpine provided the following services to the Compensation and Human Capital Committee:

• Provided consulting services and key insights on executive compensation based on relevant market data

throughout the process of recruiting and hiring our three newly-hired NEOs;

• Reviewed and recommended adjustments to our peer group;

• Conducted an extensive executive compensation assessment; and

• Provided other key insights on executive and outside director compensation based on relevant market data.

Alpine did not provide any services to us other than the consulting services to the Compensation and Human Capital

Committee. The Compensation and Human Capital Committee conducted a review of its relationship with Alpine in

2024 and determined that Alpine’s work for the Compensation and Human Capital Committee did not raise any

conflicts of interest. The Compensation and Human Capital Committee determined that Alpine’s work has conformed

to the independence factors and guidance provided by the SEC and The Nasdaq Stock Market LLC.

Use of a Peer Group

With the assistance and recommendations of Alpine, the Compensation and Human Capital Committee has

developed a peer group of companies as a reference group to provide a broad perspective on competitive pay levels

and practices with respect to compensation paid in fiscal year 2024.

The Compensation and Human Capital Committee approved a peer group for use in making compensation decisions.

When selecting appropriate peers, the general criteria used were:

• Industry – medical device and commercial bio pharmaceutical companies

• Revenues – between $150 million and $800 million

• Market Capitalization – between $250 million and $2.3 billion

For compensation decisions for fiscal year 2024, the following public companies were selected as our peer group:

2024 Peer Group

10x Genomics, Inc.*	Adaptive Biotechnologies Corp.	Alphatec Spine, Inc.*	AtriCure, Inc.*
Castle Biosciences, Inc.	Cerus Corporation	Cytek Biosciences, Inc.*	Fulgent Genetics, Inc.*
Guardant Health, Inc.	iRhythm Technologies, Inc.*	Maravai Lifesciences, Inc.*	Natera, Inc.*
Myriad Genetics, Inc.	NeoGenomics, Inc.	Pacific Biosciences of California, Inc.	Quanterix Corporation
Standard Bio Tools, Inc.*	TransMedics Group	Twist Bioscience Corporation	Veracyte, Inc.

New for 2024. Meridian Bioscience, Inc., Exact Science Corporation, Nanostring Technologies, Inc., Invitae

10x Genomics, Inc.*	Adaptive Biotechnologies Corp.	Alphatec Spine, Inc.*	AtriCure, Inc.*
Castle Biosciences, Inc.	Cerus Corporation	Cytek Biosciences, Inc.*	Fulgent Genetics, Inc.*
Guardant Health, Inc.	iRhythm Technologies, Inc.*	Maravai Lifesciences, Inc.*	Natera, Inc.*
Myriad Genetics, Inc.	NeoGenomics, Inc.	Pacific Biosciences of California, Inc.	Quanterix Corporation
Standard Bio Tools, Inc.*	TransMedics Group	Twist Bioscience Corporation	Veracyte, Inc.

Corporation and OraSure Technologies, Inc. were removed for 2024 from the 2023 peer group of companies.

The Compensation and Human Capital Committee does not engage in formal benchmarking against other

companies’ compensation programs or practices to establish our compensation levels or make specific compensation

decisions with respect to our executive officers, including our NEOs. Instead, in making its determinations, the

Compensation and Human Capital Committee reviews information summarizing the compensation paid at a

representative group of peer companies, to the extent that the executive positions at these companies are considered

comparable to our positions and informative of the competitive environment, as well as more broad-based

compensation surveys to gain a general understanding of market compensation levels.

Assessment of Risk

The Compensation and Human Capital Committee also evaluates and considers the potential risks in our business

when designing and administering our executive compensation program, and discusses these risks with our

management to determine whether our compensation philosophy and practices encourage excessive risk-taking. We

believe our balanced approach to performance measurement and pay delivery works to avoid misaligned incentives

for individuals to undertake excessive or inappropriate risk, and our Compensation and Human Capital Committee

has determined that the risks arising from our compensation policies and practices are not reasonably likely to have a

material adverse effect on our company.

IV. Pay Componen ts

Our executive compensation program consists of three primary elements: Base Salaries, Short-Term Incentives, and

Long-Term Incentives:

Element	Performance Period	Objective	Performance Measured / Rewarded
Base Salary	Annual	Attracts, retains, and rewards top talent and reflects an NEO’s responsibilities, performance, and relevant market data	• Provides NEOs with fixed compensation that acts as a vehicle to motivate and retain executives • Rewards executives for key performance and contributions
Short-Term Incentives	Annual	Rewards achievement of our annual goals subject to meeting individual performance expectations	• Rewards NEOs for their individual performance and our performance over the fiscal year 2024 • Cash bonuses, which are based on our financial and strategic goals, and the three metrics used for 2024 cash bonuses were: • Revenues - 40% weighting • Adjusted EBITDA - 40% weighting • Cash - 20% weighting
Long-Term Incentives	Long-Term	Aligns the interests of management and stockholders and serves as an important retention vehicle; Supports the achievement of strong stock price growth	• Certain NEOs received RSUs in 2024 that vest over three years to encourage employee retention • Because we were in the process of recruiting a new CEO, we did not grant PRSUs to our NEOs in 2024. However, our 2025 compensation incorporates PSRUs with annual equity awards comprising 70% RSUs and 30% PRSUs, with PRSUs eligible to vest based on a two-year performance period with one year of additional vesting thereafter, and based on our revenue goals. • PRSUs granted to certain of our NEOs in 2023 have a two-year performance period with one year of additional vesting thereafter, and are based on our financial and strategic goals. The two metrics used for PRSUs granted in 2023 with a two-year performance period (combined for 2023 and 2024) were: • Revenues - 50% weighting • Adjusted EBITDA - 50% weighting • Our three recently hired NEOs also received grants of stock options and RSUs that vest over four years, to encourage employee retention, align their interests with the interests of our stockholders, and reward long- term stock price growth.

We are committed to a strong performance orientation in our compensation program and effective corporate

governance practices for a company at our development stage and industry. As such we routinely review our policies

and program design. Some of our best practices in governance that we observe include:

What We Do
Pay-for-performance based on both financial and non-financial metrics Maintain an Insider Trading Policy Align compensation with stockholder interests Maintain “Double Trigger” benefits in the case of a Change in Control Annual compensation review Recommending annual stockholder advisory vote on NEO compensation Provide only very limited perquisites to executives	Director and executive officer stock ownership guidelines Balanced pay mix of fixed and variable pay Multi-year vesting requirements for stock options and certain restricted stock unit awards Robust anti-hedging and pledging policies Retain an independent compensation consultant Only independent directors serve on our board committees Maintain compensation recovery (“clawback”) policy Provide that equity awards granted under our equity incentive plans are subject to minimum vesting of at least one year
What We Don’t Do
Provide excessive severance payments Use excise tax gross-ups Utilize guaranteed bonuses Provide single trigger change-in-control severance payments Provide excessive perquisites Provide supplemental executive retirement plans	Provide special welfare benefits to our executive officers Permit the payment of dividends on RSUs or PRSUs prior to vesting Permit cash buyouts of options without stockholder consent Permit option repricings without stockholder consent

Base Salary

Base salary is the only fixed component of our executive officers’ total cash compensation and provides competitive

pay to attract and retain our executives. Generally, we use base salary to provide each executive officer with a

specified level of cash compensation during the year with the expectation that they will perform their responsibilities to

the best of their ability and in our best interests. Annual salary decisions are made in recognition of competitive data

as well as the skills and experience that each individual brings to CareDx and the performance contributions each

makes.

Base salary changes in 2024 varied by executive due either to merit increases and/or market adjustments. The

increases in 2024 were based on a review of market data from Alpine for similar roles and positions within our

compensation peer group and an assessment of the following factors:

• Peer group data and external market information;

• Individual performance;

• The level of responsibility assumed and the nature and complexity of each NEO’s role;

• The leadership demonstrated to create and promote a day-to-day working environment; and

• The desire to attract, engage and retain NEOs capable of achieving our strategic objectives and the marketability

and criticality of retention of NEOs.

Named Executive Officer*	2024	2023	Increase
John W. Hanna (1)	$675,000	—	—%
Abhishek Jain (2)	$431,600	$415,000	4%
Keith Kennedy (3)	$575,000	—	—%
Jessica Meng (4)	$475,000	—	—%
Jeffrey Novack (5)	$340,000	$340,000	—%
Alexander Johnson (6)	$431,600	$415,000	4%

The footnotes below describe the changes to base salary during fiscal year 2024. Actual amounts of salary paid to our NEOs are

described in the “Summary Compensation Table” below.

(1) Mr. Hanna’s employment with us as our Chief Executive Officer commenced effective April 15, 2024.

(2) Effective March 24, 2024, Mr. Jain’s annual base salary was increased from $415,000 to $431,600.

(3) Mr. Kennedy’s employment with us as our Chief Operating Officer commenced effective September 12, 2024.

(4) Ms. Meng’s employment with us as our Chief Commercial Officer commenced effective September 12, 2024.

(5) Mr. Novack’s annual base salary did not change during 2024.

(6) Effective March 24, 2024, Mr. Johnson’s annual base salary was increased from $415,000 to $431,600.

Mr. Johnson’s employment with us terminated effective September 13, 2024, at which time he began serving as our consultant.

Annual Incentives

Our cash bonus program is designed to provide a financial incentive to reward key executives for the achievement of

annual corporate performance objectives. Under the cash bonus program, each NEO has an award opportunity

expressed as a percentage of their base salary. Payments under the cash bonus program and vesting of the PRSUs

are ultimately based on the achievement of pre-established Company metrics. Actual performance against these

metrics determines the Company factor for purposes of calculating payments under the cash bonus program (the

“Company Factor”) and determines the level of vesting of the 2023 PRSUs. Threshold levels of performance must be

met for bonuses to be earned and vesting to occur. For purposes of our cash bonus program, in 2024, the Company

Factor could range from zero to 200%.

For fiscal year 2024, the cash bonus program used three metrics for funding: Revenue (weighted at 40%), Adjusted

EBITDA (weighted at 40%), and Cash (weighted at 20%) . We define Adjusted EBITDA as non-GAAP net income

(loss) before net interest income, income tax expense, depreciation and, other (income) expense.

For each of these three metrics, in the first quarter of fiscal year 2024, the Compensation and Human Capital

Committee established performance thresholds at the following levels: less than 50% achievement; 100%

achievement; and 200% or greater achievement. Therefore, through our cash bonus program, NEOs may earn a

significantly higher payout if target performance is exceeded. NEOs also bear the risk of a lower payout if target

performance is not achieved, and the risk of no payout for below-threshold results.

The Compensation and Human Capital Committee set the Company Factor, for purposes of the bonuses earned for

fiscal year 2024, at 200% based on our 2024 achievements in Revenue, Adjusted EBITDA, and Cash, each of which

exceeded the 200% target for each metric. The Compensation Committee elected to award all eligible employees at

this level.

To arrive at each NEO’s earned bonus for fiscal year 2024, the Compensation and Human Capital Committee

multiplied the NEO’s eligible earnings, by the NEO’s annual target bonus percentage, by the Company Factor (200%).

The annual incentive cash bonuses paid to our NEOs for 2024 were:

Named Executive Officer	Eligible Earnings for Purposes of Bonus*	2024 Annual Target Bonus (% of base)	Company Factor	Individual Performance Multiplier	2024 Earned Bonus
John W. Hanna	$480,289	100%	200%	100%	$960,577
Abhishek Jain	$411,169	60%	200%	100%	$493,403
Keith Kennedy	$170,288	60%	200%	100%	$204,346
Jessica Meng	$140,673	60%	200%	100%	$168,808
Jeffrey Novack	$340,000	40%	200%	100%	$272,000
Alexander Johnson (1)	$—	—%	—%	—%	$517,920

Eligible earnings are the actual amounts of salaries that the named executive officers received during 2024.

Named Executive Officer	Eligible Earnings for Purposes of Bonus*	2024 Annual Target Bonus (% of base)	Company Factor	Individual Performance Multiplier	2024 Earned Bonus
John W. Hanna	$480,289	100%	200%	100%	$960,577
Abhishek Jain	$411,169	60%	200%	100%	$493,403
Keith Kennedy	$170,288	60%	200%	100%	$204,346
Jessica Meng	$140,673	60%	200%	100%	$168,808
Jeffrey Novack	$340,000	40%	200%	100%	$272,000
Alexander Johnson (1)	$—	—%	—%	—%	$517,920

(1) Pursuant to our separation agreement with Mr. Johnson, dated September 31, 2024, we agreed to pay Mr. Johnson his annual bonus

for 2024 at 200% of target ($517,920), payable in accordance with our standard bonus schedule in February 2025. This amount is

included in the “All Other Compensation” column of the “Summary Compensation Table” below.

Long-Term Incentives

Our focus on long-term value creation results in our executive compensation program having a heavy weighting

toward equity compensation, which includes stock options, RSUs and PRSUs. We rely heavily on equity

compensation that vests over a multi-year period to ensure that a significant portion of a named executive officer’s

compensation opportunity is related to factors that directly or indirectly influence stockholder value. Our

Compensation and Human Capital Committee believes this serves as a reward for appreciation in our stock price and

long-term value creation, and enables us to achieve our retention objectives. Further, equity participation establishes

a sense of ownership and aligns executives’ interests with those of our stockholders.

In 2024, in connection with their commencement of service with the Company, we provided Messrs. Hanna and

Kennedy, and Ms. Meng each significant initial long-term incentives via a mix of stock options and RSUs as material

inducements to each executive’s agreeing to enter into employment with the Company. In addition, as a part of the

normal annual grant cycle, we provided each of Messrs. Jain, Novack, and Johnson a long-term incentive in the form

of RSUs. Approximately 46% of the value of the equity awards granted to our NEOs during 2024 was in the form of

long-term stock options (four-year vesting period), 32% of the value was in the form of long-term RSUs (four-year

vesting period) and 22% of the value was in the form of long-term RSUs (three-year vesting period). The

Compensation and Human Capital Committee believes this structure is appropriate for us given our current

competitive recruiting landscape and focus on retention, our current company size and our current growth trajectory.

2024 Annual Equity Grants

A summary of our regular, annual cycle grants for fiscal year 2024, which were granted on February 1, 2024, is set

forth in the table below. During a period of significant transition while we were in the process of recruiting a new CEO,

the Compensation and Human Capital Committee determined that awarding RSUs only would be the best retention

vehicle for our executive team.

Named Executive Officer (1)	RSUs — (#)	($) (2)
Abhishek Jain	174,520	$1,549,738
Jeffrey Novack	66,728	$592,545
Alexander Johnson	174,520	$1,549,738

(1) This table reflects our regular, annual cycle of grants for fiscal year 2024, which grants were awarded in February 2024 prior to the

Named Executive Officer (1)	RSUs — (#)	($) (2)
Abhishek Jain	174,520	$1,549,738
Jeffrey Novack	66,728	$592,545
Alexander Johnson	174,520	$1,549,738

commencement of Messrs. Hanna’s and Kennedy’s and Ms. Meng’s employment with the Company. Consequently, the special one-

time inducement stock options and inducement RSUs granted to each of Messrs. Hanna and Kennedy and Ms. Meng in 2024 at the

time of their commencement of service with the Company are not reflected in this table.

(2) The RSUs were granted on February 1, 2024. Amounts set forth in this column generally represent the aggregate grant date fair

value of the RSU awards granted to each listed NEO, computed in accordance with FASB ASC Topic 718. These amounts do not

represent the actual amounts paid to or realized by the NEOs.

2023 PRSUs

Our Compensation and Human Capital Committee did not grant PRSUs to our executive officers in 2024. In early

2023, our Compensation and Human Capital Committee granted PRSUs to our executive officers that include 2023

and 2024 as a performance year. The PRSUs are designed to further reward key executives for the achievement of

corporate performance objectives. The PRSUs use two metrics for funding and vesting purposes, which were

weighted equally: Total Sales and Adjusted EBITDA (defined as described above). In determining the metrics to be

used for the PRSUs, the Compensation and Human Capital Committee chose Total Sales and Adjusted EBITDA

because it determined that these were the two most important financial measures for our company to focus on for the

2023-2024 performance period. For each of these two metrics, for purposes of the PRSUs, the Compensation and

Human Capital Committee established performance thresholds at the following levels: greater than 50% achievement;

80% or greater achievement; and 100% or greater achievement. The PRSUs are long-term incentives and have a

two-year performance period with one year of additional vesting. In February 2025, the Compensation and Human

Capital Committee determined that the performance criteria for the PRSUs were achieved at 100% of target

performance levels, and 50% of the PRSUs vested at the end of the two-year performance period on February 1,

2025 and the remaining 50% will vest on December 31, 2025.

RSUs - Vesting

The RSUs granted to Messrs. Jain, Novack and Johnson in 2024 vest over three years in equal quarterly installments

commencing on the date that is three months after the date of grant, subject to the executive’s continuing service on

each vesting date.

Inducement Stock Options and Inducement RSUs - Vesting

In connection with their appointment as an executive officer, and as provided in the applicable NEO’s offer letter, each

of Messrs. Hanna and Kennedy and Ms. Meng was granted, effective as of the executive’s applicable employment

commencement date, (i) stock options that vest over four years (25% in a cliff on the one-year anniversary of the date

of grant and 1/48th vesting monthly thereafter), and (ii) an award of RSUs that vest over four years in equal annual

installments beginning on the one-year anniversary of the date of grant, in each case subject to the NEO’s continued

provision of services to the Company on each vesting date, except on certain qualifying terminations of employment

as otherwise provided in their respective Change of Control and Severance Agreement as further detailed in

“Potential Payments and Benefits upon Termination or Change of Control for Officers”.

Policies and Practices Related to the Grant of Certain Equity Awards

Following the end of each fiscal year, typically in February, the Compensation and Human Capital Committee reviews

the Company’s results and our named executive officers’ performance, and, based on those reviews, grants equity

awards to our named executive officers. In certain circumstances, including the hiring of an officer, the Compensation

and Human Capital Committee may approve grants to be effective at other times. The Compensation and Human

Capital Committee does not take material nonpublic information into account when determining the timing and terms

of equity awards granted to non-employee directors or named executive officers. The Company does not time the

disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

2024 Stock Option Award Grants

The following table contains information required by Item 402(x)(2) of Regulation S-K about stock option awards to

our NEOs in our fiscal year ending December 31, 2024 during the period from four business days before to one

business day after the filing of certain Current Reports on Form 8-K on April 16, 2024 and September 12, 2024,

disclosing the appointments of Mr. Hanna as Chief Executive Officer and Mr. Kennedy as Chief Operating Officer,

respectively. We did not grant any stock option awards to our named executive officers during our most recently

completed fiscal year during the period from four business days before to one business day after the filing of any of

the Company’s Quarterly Reports on Form 10-Q or the Company’s Annual Report on Form 10-K.

Name	Grant Date	Number of Securities Underlying Award	Exercise Price of the Award ($/Sh)	Grant Date Fair Value of the Award (1)	Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information
John W. Hanna	4/15/2024	700,706	8.2	$ 4,001,031	0.98 %
Keith Kennedy	9/12/2024	100,651	29.43	$ 2,063,346	1.19 %
Jessica Meng	9/12/2024	75,488	29.43	$ 1,547,504	1.19 %

(1) Amounts reflect the aggregate grant date fair value of the stock option awards, determined in accordance with FASB ASC Topic 718.

This amount does not reflect the actual economic value realized by the NEO.

2025 Annual Equity Grants

In March 2025, the Compensation and Human Capital Committee approved annual equity grants to our executives,

including each of our NEOs, which grants were comprised of 70% RSUs and 30% PRSUs. RSUs vest over a three-

year period subject to continued employment through each applicable vesting date, and PRSUs are eligible to

become earned and vested over a two-year performance period (including the 2025 and 2026 calendar years as the

performance years) with one year of additional vesting of earned PRSUs after the conclusion of such performance

period. The PRSUs use revenue as the metric for funding and vesting, which the Compensation and Human Capital

Committee determined to be the most important financial measure for the Company to focus on for the 2025-2026

performance period. For purposes of the PRSUs, the Compensation and Human Capital Committee established

performance thresholds at the following levels: 50% or greater achievement; 100% or greater achievement; and

200% or greater achievement.

Employment- and Service-related Agreements with our NEOs

The Company is party to “at will” agreements and Change of Control and Severance Agreements with each of our

NEOs other than Mr. Johnson whose employment with the Company terminated effective September, 13, 2024. For

a summary of the material terms of each NEO’s employment-related agreements, see “Narrative Disclosure to

Summary Compensation Table and Grant of Plan-Based Awards Table” below.

Former President of Patient and Testing Services Separation Agreement and Consulting Agreement

Our Compensation and Human Capital Committee determined that, in connection with the departure of Mr. Johnson

effective September 13, 2024, it was in our best interests to enter into a separation agreement with Mr. Johnson that

provided severance benefits and a consulting agreement that provided the Company with consulting services during

a transition period. For a summary of the materials terms of Mr. Johnson’s agreements, see “Narrative Disclosure to

Summary Compensation Table and Grant of Plan-Based Awards Table” below.

Welfare and Health Benefits

Our NEOs participate in our employee benefit plans on the same terms as all of our other eligible employees.

We maintain a tax-qualified Code Section 401(k) defined contribution plan in which all of our employees, including our

executive officers, who satisfy certain eligibility requirements, including requirements relating to age and length of

service, are entitled to participate. Employees may contribute their own funds on a pre-tax basis.

The plan permits us to make matching contributions and we have historically provided employer contributions that

match eligible employee contributions (“Employer Matching Contributions”), generally limited to 3% of the

compensation (up to a maximum matching contribution of $5,000 per year) that can be taken into account for this

purpose under federal law. On January 1, 2018, we began to make contributions to the employee plan. Employer

matching contributions vest according to a four-year graded plan at a rate of 25% per year with employees being fully

vested in Employer Matching Contributions after completing four years of service.

In addition, we provide health care, dental, vision and life insurance, an employee assistance plan and both short-

term and long-term disability and accidental death and dismemberment benefits to all full-time employees. These

benefits are subject to applicable laws and at benefit levels that we believe are generally consistent with the benefits

of companies with which we compete for talent.

Limited Perquisites

In 2024, the Company provided certain limited perquisites to our NEOs, which included electronic allowances and

gym allowances.

Hedging and Pledging Prohibitions

Our insider trading policy prohibits our directors, officers (including our executive officers), employees and agents, as

well as their immediate family members, from engaging in short sales of our securities and from engaging in

transactions in publicly-traded options and other derivative securities with respect to our securities. This prohibition

extends to any hedging or similar transactions designed to decrease the risks associated with holding our securities.

Our insider trading policy also restricts certain individuals, including our directors and executive officers, from pledging

our securities as collateral for loans absent pre-clearance and the satisfaction of other conditions.

Accounting and Tax Considerations

The Company accounts for equity-based compensation paid to employees under FASB ASC Topic 718, which

requires the Company to estimate and record an expense over the service period of an equity award. Thus, the

Company may record an expense in one year for awards granted in earlier years. Accounting rules also require the

recording of cash compensation as an expense at the time the obligation is accrued.

Section 162(m) of the Internal Revenue Code of 1986, as amended, generally disallows public companies a tax

deduction for federal income tax purposes of compensation in excess of $1 million paid to their chief executive officer,

the chief financial officer and three other most highly-compensated executive officers in any taxable year. In making

compensation decisions, the Compensation and Human Capital Committee considered the potential effects of Section

162(m) on the compensation paid our executive officers who are subject to the deduction limit (the “covered

executives”). The exemption from Section 162(m)’s deduction limit for performance-based compensation was

generally repealed for taxable years beginning after December 31, 2017, such that compensation paid to our covered

executives in excess of $1 million will generally not be deductible unless it qualifies for transition relief applicable to

certain arrangements in place as of November 2, 2017.

To maintain flexibility in compensating the NEOs in a manner designed to promote varying corporate goals, the

Compensation and Human Capital Committee has not adopted a policy that all compensation payable to the covered

executives must be deductible for federal income tax purposes. Accordingly, while the Compensation and Human

Capital Committee considers the deductibility of awards as one factor in determining executive compensation, the

Compensation and Human Capital Committee also looks at other factors in making its decisions and retains the

flexibility to award compensation that it determines to be consistent with the goals of our executive compensation

program even if the awards are not deductible by us for tax purposes.

In addition to considering the tax consequences, the Compensation and Human Capital Committee considers the

accounting consequences of its decisions, including the impact of expenses being recognized in connection with

equity-based awards, in determining the size and form of different equity-based awards.

Compensation Committee Report

The Compensation and Human Capital Committee has reviewed and discussed the Compensation Discussion and

Analysis required by Item 402(b) of Regulation S-K of the SEC’s rules and regulations with management and, based

on such review and discussions, the Compensation and Human Capital Committee recommended to the Board of

Directors that the Compensation Discussion and Analysis be included in this proxy statement.

The Compensation and Human Capital Committee:

Christine Cournoyer (Chairwoman)

George W. Bickerstaff, III

William A. Hagstrom

Summary Compensation Table

The following table provides information regarding the compensation awarded to, or earned by, our NEOs during

fiscal years 2022, 2023 and 2024.

Summary Compensation Table — Name and Principal Position	Year	Salary ($)	Bonus ($) (1)	Stock Awards ($) (2)	Option Awards ($) (3)	Non-Equity Incentive Plan Compensation ($) (4)	All Other Compensation ($)		Total ($)
John W. Hanna President and Chief Executive Officer (5)	2024	454,327	—	3,999,993	4,001,031	960,577	8,401		9,424,329
Abhishek Jain Chief Financial Officer	2024	411,169	300,000	1,549,738	—	493,403	8,400		2,762,710
	2023	405,000	100,000	1,924,614	481,973	174,300	8,820		3,094,707
	2022	318,917	—	904,723	1,013,007	104,260	2,400		2,343,307
Keith Kennedy Chief Operating Officer (5)	2024	148,173	—	2,063,072	2,063,346	204,346	33,278	(6)	4,512,215
Jessica Meng Chief Commercial Officer (5)	2024	122,404	—	1,547,312	1,547,504	168,808	6,500		3,392,528
Jeffrey Novack General Counsel and Secretary (5)	2024	326,923	75,000	592,545	—	272,000	10,376	(7)	1,276,844
Alexander Johnson Former President of Patient and Testing Services (8)	2024	335,276	—	1,549,738	—	—	1,052,557	(9)	2,937,571
	2023	408,281	100,000	1,924,614	481,973	174,300	8,270		3,097,438
	2022	384,844	—	2,519,355	2,657,432	161,510	1,080		5,724,221

(1) The amounts reported in this column for Messrs. Jain and Novack for the year ended December 31, 2024 represents the amount of the

Summary Compensation Table — Name and Principal Position	Year	Salary ($)	Bonus ($) (1)	Stock Awards ($) (2)	Option Awards ($) (3)	Non-Equity Incentive Plan Compensation ($) (4)	All Other Compensation ($)		Total ($)
John W. Hanna President and Chief Executive Officer (5)	2024	454,327	—	3,999,993	4,001,031	960,577	8,401		9,424,329
Abhishek Jain Chief Financial Officer	2024	411,169	300,000	1,549,738	—	493,403	8,400		2,762,710
	2023	405,000	100,000	1,924,614	481,973	174,300	8,820		3,094,707
	2022	318,917	—	904,723	1,013,007	104,260	2,400		2,343,307
Keith Kennedy Chief Operating Officer (5)	2024	148,173	—	2,063,072	2,063,346	204,346	33,278	(6)	4,512,215
Jessica Meng Chief Commercial Officer (5)	2024	122,404	—	1,547,312	1,547,504	168,808	6,500		3,392,528
Jeffrey Novack General Counsel and Secretary (5)	2024	326,923	75,000	592,545	—	272,000	10,376	(7)	1,276,844
Alexander Johnson Former President of Patient and Testing Services (8)	2024	335,276	—	1,549,738	—	—	1,052,557	(9)	2,937,571
	2023	408,281	100,000	1,924,614	481,973	174,300	8,270		3,097,438
	2022	384,844	—	2,519,355	2,657,432	161,510	1,080		5,724,221

retention bonus paid to each executive pursuant to the terms of their respective retention bonus agreement.

(2) The amounts in this column represent the fair value of the award computed as of the grant date of each stock award in accordance

with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 13 of the consolidated

financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 that was filed with the SEC on

February 28, 2025.

(3) The amounts in this column represent the aggregate fair value of the award computed as of the grant date of each option award in

accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 13 of the

consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 that was filed

with the SEC on February 28, 2025.

(4) Represents amounts paid as a discretionary bonus to our executive officers pursuant to our annual cash bonus programs, including

our NEOs, for their performance in 2024 as compared against the performance goals set in respect of the 2024 performance period.

The amounts reported in this column for each of Messrs. Hanna and Kennedy, and Ms. Meng are prorated for the portion of the year

each executive provided services to the Company.

(5) In accordance with SEC guidance, compensation information for Messrs. Hanna, Kennedy and Novack, and Ms. Meng, for fiscal years

2022 and 2023 have not been included in this table because each such NEO was not a named executive officer for fiscal years 2022

and 2023.

(6) All other compensation for Mr. Kennedy for the year ended December 31, 2024 includes: (i) $3,096 in employer matching contributions

under our 401(k) plan and (ii) $11,592 for Company-paid health insurance coverage. Additionally, as Mr. Kennedy works remotely and

is based in Utah, in order to facilitate Mr. Kennedy being available to work at our corporate offices on an as-needed basis, we agreed

to reimburse the cost for Mr. Kennedy to maintain an apartment in San Francisco for up to $7,500 per month. In 2024, we reimbursed

Mr. Kennedy $18,590 for the direct cost of an apartment in lieu of hotels, which is included in his all other compensation amount.

(7) All other compensation for Mr. Novack for the year ended December 31, 2024 includes: (i) $2,400 in payments in respect of a medical

waiver allowance, (ii) $6,000 in employer matching contributions under our 401(k) plan and (iii) $1,976 in payments in respect to gym

and electronics allowances.

(8) Mr. Johnson’s employment with us terminated effective September 13, 2024, and a consulting agreement was subsequently put in

place.

(9) All other compensation for Mr. Johnson for the year ended December 31, 2024 includes (i) $421 in respect to a gym allowance, (ii)

$675 in respect to a phone allowance, and (iii) $1,051,461 in severance paid and payable to Mr. Johnson pursuant to the terms of the

Johnson Separation Agreement (as defined below), including: (a) $215,800 in base salary severance, (b) $517,920 representing 200%

of Mr. Johnson’s 2024 annual target bonus, (c) $17,741 representing the cost of reimbursement for health insurance coverage under

COBRA pursuant to the Johnson Separation Agreement, and (d) $300,000 representing the amount of the unpaid portion of the

retention bonus.

Grants of Plan-Based Awards

The following table presents, for each of the NEOs, information concerning each grant of an equity award made

during the fiscal year ended December 31, 2024. This information supplements the information about these awards

set forth in the S ummary Compensation Table and the Outstanding Equity Awards at Fiscal Year-End Table.

Name	Grant Date		All Other Stock Awards: Number of shares of stock or units (#) (6)	All Other Option Awards: Number of Securities Underlying Options (#)	Exercise Price Per Share	Grant Date Fair Value of Stock and Option Awards (1)
John W. Hanna	4/15/2024	(2)(4)	487,804	—	—	$3,999,993
	4/15/2024	(3)(4)	—	700,706	$8.20	$4,001,031
Abhishek Jain	2/1/2024	(5)	174,520	—	—	$1,549,738
Keith Kennedy	9/12/2024	(2)(4)	70,101	—	—	$2,063,072
	9/12/2024	(3)(4)	—	100,651	$29.43	$2,063,346
Jessica Meng	9/12/2024	(2)(4)	52,576	—	—	$1,547,312
	9/12/2024	(3)(4)	—	75,488	$29.43	$1,547,504
Jeffrey Novack	2/1/2024	(5)	66,728	—	—	$592,545
Alexander Johnson	2/1/2024	(5)	174,520	—	—	$1,549,738

(1) Amounts reflect the aggregate grant date fair value of the RSUs and stock option awards, determined in accordance with FASB ASC

Name	Grant Date		All Other Stock Awards: Number of shares of stock or units (#) (6)	All Other Option Awards: Number of Securities Underlying Options (#)	Exercise Price Per Share	Grant Date Fair Value of Stock and Option Awards (1)
John W. Hanna	4/15/2024	(2)(4)	487,804	—	—	$3,999,993
	4/15/2024	(3)(4)	—	700,706	$8.20	$4,001,031
Abhishek Jain	2/1/2024	(5)	174,520	—	—	$1,549,738
Keith Kennedy	9/12/2024	(2)(4)	70,101	—	—	$2,063,072
	9/12/2024	(3)(4)	—	100,651	$29.43	$2,063,346
Jessica Meng	9/12/2024	(2)(4)	52,576	—	—	$1,547,312
	9/12/2024	(3)(4)	—	75,488	$29.43	$1,547,504
Jeffrey Novack	2/1/2024	(5)	66,728	—	—	$592,545
Alexander Johnson	2/1/2024	(5)	174,520	—	—	$1,549,738

Topic 718. This amount does not reflect the actual economic value realized by the NEO.

(2) Vesting of the RSU is subject to the executive’s continued service on the applicable vesting date with the following schedule: 25% of

the total number of shares vesting on the one-year anniversary of the grant date, with 25% vesting on each successive grant date

anniversary.

(3) Vesting of the option is subject to the executive’s continued service on the applicable vesting date with the following schedule: 25% of

the total number of shares vesting on the one-year anniversary of the grant date, with 1/48th vesting monthly thereafter.

(4) The RSU and stock option awards granted during 2024 to Messrs. Hanna and Kennedy and Ms. Meng were granted outside of the

2024 Plan as inducement awards (as further described in “Narrative Disclosure to Summary Compensation Table and Grants of Plan-

Based Awards Table”) material to each of Messrs. Hanna and Kennedy and Ms. Meng agreeing to enter into employment with the

Company.

(5) Vesting of the RSU is subject to the executive’s continued service on the applicable vesting date with the following schedule: 1/12th of

the total number of shares vesting on May 1, 2024, with 1/12 th of the shares vesting quarterly thereafter.

(6) Certain option and stock awards held by Mr. Johnson were modified upon termination of employment during 2024. However, the

modifications did not result in an incremental increase to the fair value of the respective awards. As a result, such modifications are

not reflected in this Grant of Plan-Based Awards table and no amounts are included in the Summary Compensation Table on account

of such modifications.

Outstanding Equity Awards at Fiscal Year-End

The following table presents certain information concerning equity awards held by our NEOs as of December 31,

2024.

Name	Grant Date		Option Awards — Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price ($)	Option Expiration Date	Stock Awards — Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested ($)*
John W. Hanna	4/15/2024	(1)	—	700,706	8.20	4/15/2034	—	—
	4/15/2024	(2)	—	—	—	—	487,804	10,443,884
Abhishek Jain	4/18/2022	(3)	1,700	850	32.55	4/18/2032	—	—
	5/6/2022	(4)	667	333	25.78	5/6/2032	—	—
	5/26/2022	(5)	6,458	3,542	24.07	5/26/2032	—	—
	9/7/2022	(6)	32,396	27,604	18.47	9/7/2032	—	—
	2/1/2023	(7)	20,212	23,888	15.66	2/1/2033	—	—
	9/10/2021	(8)	—	—	—	—	1,375	29,439
	4/18/2022	(9)	—	—	—	—	1,275	27,298
	5/6/2022	(10)	—	—	—	—	1,000	21,410
	5/26/2022	(11)	—	—	—	—	7,500	160,575
	9/7/2022	(12)	—	—	—	—	11,074	237,094
	2/1/2023	(13)	—	—	—	—	63,825	1,366,493
	2/1/2023	(14)	—	—	—	—	37,800	809,298
	2/1/2024	(15)	—	—	—	—	130,890	2,802,355
Keith Kennedy	9/12/2024	(16)	—	100,651	29.43	9/12/2034	—	—
	9/12/2024	(17)	—	—	—	—	70,101	1,500,862
Jessica Meng	9/12/2024	(16)	—	75,488	29.43	9/12/2034	—	—
	9/12/2024	(17)	—	—	—	—	52,576	1,125,652
Jeffrey Novack	4/6/2022	(18)	1,433	717	37.25	4/6/2032	—	—
	8/6/2022	(19)	1,441	944	26.29	8/6/2032	—	—
	11/6/2021	(20)	—	—	—	—	1,250	26,763
	4/6/2022	(21)	—	—	—	—	3,575	76,541
	8/6/2022	(22)	—	—	—	—	533	11,412
	11/7/2022	(23)	—	—	—	—	5,827	124,756
	4/6/2023	(24)	—	—	—	—	5,625	120,431
	6/6/2023	(25)	—	—	—	—	5,000	107,050
	7/6/2023	(26)	—	—	—	—	7,500	160,575
	2/1/2024	(15)	—	—	—	—	50,046	1,071,485
Alexander Johnson (27)	4/18/2018	(28)	2,917	—	9.13	4/18/2028	—	—
	6/29/2018	(29)	3,437	—	12.24	6/29/2028	—	—
	2/4/2019	(30)	6,667	—	27.17	2/4/2029	—	—
	2/3/2020	(31)	10,667	—	24.35	2/3/2030	—	—
	7/6/2020	(32)	2,500	—	34.49	7/6/2030	—	—
	2/3/2021	(33)	7,667	333	87.37	2/3/2031	—	—
	7/19/2021	(34)	11,839	1,944	78.02	7/19/2031	—	—
	2/2/2022	(35)	21,179	8,721	41.32	2/2/2032	—	—
	8/9/2022	(36)	9,388	42,247	23.48	8/9/2032	—	—
	2/1/2023	(7)	20,212	23,888	15.66	2/1/2033	—	—
	2/3/2021	(37)	—	—	—	—	2,000	42,820
	7/19/2021	(38)	—	—	—	—	3,333	71,360
	2/2/2022	(39)	—	—	—	—	14,925	319,544
	8/9/2022	(40)	—	—	—	—	18,256	390,861
	2/1/2023	(13)	—	—	—	—	63,825	1,366,493
	2/1/2023	(14)	—	—	—	—	37,800	809,298
	2/1/2024	(15)	—	—	—	—	130,890	2,802,355

Amounts in this column are calculated by multiplying the number of shares shown as unvested in the prior column by $21.41, the closing

price of our common stock on December 31, 2024, as reported on the Nasdaq Global Market.

(1) 25% of the total shares subject to the option will vest on April 15, 2025, and 1/48 th of the shares subject to the option will vest each

month thereafter, subject to executive’s continued employment on each applicable vesting date.

(2) 25% of the total shares subject to this inducement RSU award will vest on each of April 15, 2025, April 15, 2026, April 15, 2027 and

April 15, 2028. For further details regarding the inducement RSU award, see “Narrative Disclosure to Summary Compensation Table

and Grants of Plan-Based Awards Table.”

(3) 25% of the total shares vested on April 18, 2023 and 1/48 th of the shares subject to the option vested and will vest each month

thereafter, subject to executive’s continued employment on each applicable vesting date.

(4) 25% of the total shares vested on May 6, 2023 and 1/48 th of the shares subject to the option vested and will vest each month

thereafter, subject to executive’s continued employment on each applicable vesting date.

(5) 25% of the total shares vested on May 26, 2023 and 1/48 th of the shares subject to the option vested and will vest each month

thereafter, subject to executive’s continued employment on each applicable vesting date.

(6) 25% of the total shares vested on September 7, 2023 and 1/48 th of the shares subject to the option vested and will vest each month

thereafter, subject to executive’s continued employment on each applicable vesting date.

(7) 25% of the total shares vested on February 1, 2024 and 1/48 th of the shares subject to the option vested and will vest each month

thereafter, subject to executive’s continued employment on each applicable vesting date.

(8) 25% of the shares subject to this RSU award vested on each of September 10, 2022, September 10, 2023 and September 10, 2024.

The remaining 25% of the shares subject to this RSU award will vest on September 10, 2025, subject to executive’s continued

employment on each applicable vesting date.

(9) 25% of the shares subject to this RSU award vested on each of April 18, 2023 and April 18, 2024. An additional 25% of the shares

subject to this RSU award will vest on each of April 18, 2025 and April 18, 2026, subject to executive’s continued employment on

each applicable vesting date.

(10) 25% of the shares subject to this RSU award vested on each of May 6, 2023 and May 6, 2024. An additional 25% of the shares

subject to this RSU award will vest on each of May 6, 2025 and May 6, 2026, subject to executive’s continued employment on each

applicable vesting date.

(11) 25% of the shares subject to this RSU award vested on each of May 26, 2023 and May 26, 2024. An additional 25% of the shares

subject to this RSU award will vest on each of May 26, 2025 and May 26, 2026, subject to executive’s continued employment on each

applicable vesting date.

(12) 25% of the shares subject to this RSU award vested on each of September 7, 2023 and September 7, 2024. An additional 25% of the

shares subject to this RSU award will vest on each of September 7, 2025 and September 7, 2026, subject to executive’s continued

employment on each applicable vesting date.

(13) 25% of the shares subject to this RSU award vested on February 1, 2024. An additional 25% of the shares subject to this RSU award

will vest on each of February 1, 2025, February 1, 2026 and February 1, 2027, subject to executive’s continued employment on each

applicable vesting date.

(14) The shares subject to this PRSU will have a two-year performance period with one year of additional vesting. Upon the achievement

of certain milestones relating to Total Sales and Adjusted EBITDA, 50% of the shares subject to this PRSU vested upon the

determination of performance achievement following the completion of the two-year performance period (effective February 1, 2025),

and the remaining 50% will vest on December 31, 2025 subject to the executive’s continued service. The amounts reported in this

table represent the number of shares subject to the PRSU based on the Company’s performance results at 100% of target levels.

(15) 1/12th of the shares subject to this RSU award vested on May 1, 2024 and 1/12 th of the shares subject to the option vested and will

vest quarterly thereafter, subject to executive’s continued employment on each applicable vesting date.

(16) 25% of the total shares subject to the option will vest on September 12, 2025, and 1/48 th of the shares subject to the option will vest

monthly thereafter, subject to executive’s continued employment on each applicable vesting date.

(17) 25% of the total shares subject to this RSU award will vest on each of September 12, 2025, September 12, 2026, September 12,

2027 and September 12, 2028. For further details regarding the inducement RSU award, see “Narrative Disclosure to Summary

Compensation Table and Grants of Plan-Based Awards Table.”

(18) 25% of the total shares vested on April 6, 2023 and 1/48 th of the shares subject to the option vested and will vest each month

thereafter, subject to executive’s continued employment on each applicable vesting date.

(19) 25% of the total shares vested on August 6, 2023 and 1/48 th of the shares subject to the option vested and will vest each month

thereafter, subject to executive’s continued employment on each applicable vesting date.

(20) 25% of the shares subject to this RSU award vested on each of November 6, 2022, November 6, 2023 and November 6, 2024. The

remaining 25% of the shares subject to this RSU award will vest on November 6, 2025, subject to executive’s continued employment

on each applicable vesting date.

(21) 25% of the shares subject to this RSU award vested on each of April 6, 2023 and April 6, 2024. An additional 25% of the shares

subject to this RSU award will vest on each of April 6, 2025 and April 6, 2026, subject to executive’s continued employment on each

applicable vesting date.

(22) 25% of the shares subject to this RSU award vested on each of August 6, 2023 and August 6, 2024. An additional 25% of the shares

subject to this RSU award will vest on each of August 6, 2025 and August 6, 2026, subject to executive’s continued employment on

each applicable vesting date.

(23) 25% of the shares subject to this RSU award vested on each of November 7, 2023 and November 7, 2024. An additional 25% of the

shares subject to this RSU award will vest on each of November 7, 2025 and November 7, 2026, subject to executive’s continued

employment on each applicable vesting date.

(24) 25% of the shares subject to this RSU award vested on April 6, 2024. An additional 25% of the shares subject to this RSU award will

vest on each of April 6, 2025, April 6, 2026 and April 6, 2027, subject to executive’s continued employment on each applicable vesting

date.

(25) 50% of the shares subject to this RSU award vested on June 6, 2024 and 50% will vest on June 6, 2025, subject to executive’s

continued employment on each applicable vesting date.

(26) 25% of the shares subject to this RSU award vested on July 6, 2024. An additional 25% of the shares subject to this RSU award will

vest on each of July 6, 2025, July 6, 2026 and July 6, 2027, subject to executive’s continued employment on each applicable vesting

date.

(27) Mr. Johnson’s employment with us terminated effective September 13, 2024, at which time we entered into a consulting agreement.

With respect to Mr. Johnson, the references to continued employment in the footnotes to this Outstanding Equity Awards at Fiscal

Year-End table refer to continued service pursuant to the Johnson Consulting Agreement.

(28) 25% of the total shares subject to the option vested on April 16, 2019, and 1/48 th of the shares subject to the option vested each

month thereafter.

(29) 25% of the total shares subject to the option vested on April 16, 2019, and 1/48 th of the shares subject to the option vested each

month thereafter.

(30) 25% of the total shares subject to the option vested on January 25, 2020, and 1/48 th of the shares subject to the option vested each

month thereafter.

(31) 25% of the total shares subject to the option vested on January 29, 2021, and 1/48 th of the shares subject to the option vested each

month thereafter.

(32) 25% of the total shares subject to the option vested on July 6, 2021, and 1/48 th of the shares subject to the option vested each month

thereafter.

(33) 25% of the total shares subject to the option vested on February 3, 2022 and 1/48 th of the shares subject to the option vested and will

vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.

(34) 25% of the total shares subject to the option vested on July 19, 2022 and 1/48 th of the shares subject to the option vested and will

vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.

(35) 25% of the total shares subject to the option vested on February 2, 2023 and 1/48 th of the shares subject to the option vested and will

vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.

(36) 25% of the total shares subject to the option vested on August 9, 2023 and 1/48 th of the shares subject to the option vested and will

vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.

(37) 25% of the shares subject to this RSU award vested on each of February 3, 2022, February 3, 2023, February 3, 2024 and February

3, 2025.

(38) 25% of the shares subject to this RSU award vested on July 19, 2022, July 19, 2023 and July 19, 2024. An additional 25% of the

shares subject to this RSU award will vest on July 19, 2025, subject to executive’s continued employment through such vesting date.

(39) 25% of the shares subject to this RSU award vested on each of February 2, 2023 and February 2, 2024 and February 2, 2025. An

additional 25% of the shares subject to this RSU award will vest on February 2, 2026, subject to executive’s continued employment

through such vesting date.

(40) 33.33% of the shares subject to this RSU award vested on August 9, 2023 and August 9, 2024. An additional 33.33% of the shares

subject to this RSU award will vest August 9, 2025, subject to executive’s continued employment through such vesting date.

Narrative Disclosure to Summary Compensation Table and Grant of Plan-Based Awards Table

Employment, Separation and Consulting Agreement and Offer Letter Summaries

We have entered into employment agreements or offer letters with each of the NEOs. These agreements provide for

at-will employment and generally include the named executive officer’s initial base salary, and an indication of

eligibility for an annual cash incentive award opportunity.

John W. Hanna

In connection with appointment as our Chief Executive Officer, we entered into an offer letter with Mr. Hanna dated

March 24, 2024. The letter provides for “at-will” employment and sets forth certain agreed upon terms and conditions

of employment. During fiscal year 2024, Mr. Hanna’s initial annualized base salary was $675,000, and included

eligibility to receive an annual performance bonus of up to 100% of base salary (which was pro-rated for 2024).

In connection with his appointment and the commencement of employment with the Company, on April 15, 2024, Mr.

Hanna was granted two “inducement grants” (as such term is described in NASDAQ Listing Rule 5635(c)(4))

comprised of (i) an option to purchase shares of the Company’s common stock, having a grant date fair value of

$4,000,000 and (ii) an award of restricted stock units, having a grant date fair value of $4,000,000. Mr. Hanna’s

inducement equity awards were each granted as inducements material to Mr. Hanna agreeing to enter into

employment with the Company. Mr. Hanna has also entered into a Change of Control and Severance Agreement

with us that provides certain severance benefits upon a qualifying termination of employment as more detailed in

“Potential Payments and Benefits upon Termination or Change of Control for Officers” below .

Abhishek Jain

In connection with Mr. Jain’s promotion to our Interim Chief Financial Officer, we entered into a promotion letter with

Mr. Jain, dated May 21, 2022 that entitled Mr. Jain to an annual base salary of $305,000, and target annual

performance bonus of up to 35% of his base salary. Mr. Jain was appointed as our Chief Financial Officer effective as

of September 7, 2022 and in connection with such appointment entered into a Change of Control and Severance

Agreement with us that provides him certain severance benefits upon a qualifying termination of his employment as

more detailed in “Potential Payments and Benefits upon Termination or Change of Control for Officers” below .

On December 1, 2023, the Company entered into a retention bonus agreement with Mr. Jain, which provided a

retention bonus in an aggregate amount of $400,000. Pursuant to the terms of the retention bonus agreement, 25%

of the total retention bonus was paid in December 2023 and was subject to repayment if Mr. Jain did not remain an

employee of the Company through December 1, 2024. The remaining 75% of the retention bonus was paid on the

Company’s first payroll date in December 2024.

Keith Kennedy

In connection with appointment as our Chief Operating Officer, we entered into an offer letter with Mr. Kennedy dated

July 27, 2024. The letter provides for “at-will” employment and sets forth certain agreed upon terms and conditions of

employment, including his initial annualized based salary of $575,000, and annual performance bonus of up to 60% of

his base salary (which was pro-rated for 2024).

In connection with appointment, on September 12, 2024, Mr. Kennedy was granted two “inducement grants” (as such

term is described in NASDAQ Listing Rule 5635(c)(4)) comprised of (i) an option to purchase shares of the

Company’s common stock, having a grant date fair value of $2,000,000 and (ii) an award of restricted stock units,

having a grant date fair value of $2,000,000. Mr. Kennedy’s inducement equity awards were each granted as

inducements material to Mr. Kennedy agreeing to enter into employment with the Company. Mr. Kennedy also

entered into a Change of Control and Severance Agreement with us that provides certain severance benefits upon a

qualifying termination of his employment as more detailed in “Potential Payments and Benefits upon Termination or

Change of Control for Officers” below .

Jessica Meng

In connection with appointment as our Chief Commercial Officer, we entered into an offer letter with Ms. Meng dated

August 31, 2024. The letter provides for “at-will” employment and sets forth certain agreed upon terms and conditions

of employment, including her initial annualized base salary of $475,000, and annual performance bonus of up to 60%

of base salary (which was pro-rated for 2024).

In connection with appointment, on September 12, 2024, Ms. Meng was granted two “inducement grants” (as such

term is described in NASDAQ Listing Rule 5635(c)(4)) comprised of (i) an option to purchase shares of the

Company’s common stock, having a grant date fair value of $1,500,000 and (ii) an award of restricted stock units,

having a grant date value of $1,500,000. Ms. Meng’s inducement equity awards were each granted as inducements

material to Ms. Meng agreeing to enter into employment with the Company. Ms. Meng entered into a Change of

Control and Severance Agreement with us that provides certain severance benefits upon a qualifying termination of

employment as more detailed in “Potential Payments and Benefits upon Termination or Change of Control for

Officers” below .

Jeffrey Novack

In connection with Mr. Novack’s commencement of employment with the Company, we entered into an offer letter

with Mr. Novack dated October 6, 2021. The letter provides for “at-will” employment and sets forth certain agreed

upon terms and conditions of employment, including his initial annualized base salary of $260,000 and annual

performance bonus of up to 20% of base salary.

On December 1, 2023, the Company entered into a retention bonus agreement with Mr. Novack, which provided for a

retention bonus in an aggregate amount of $100,000. Pursuant to the terms of the retention bonus agreement, 25%

of the total retention bonus was paid in December 2023 and was subject to repayment if Mr. Novack did not remain

an employee of the Company through December 1, 2024. The remaining 75% of the retention bonus was paid on the

Company’s first payroll date in December 2024.

Mr. Novack was not party to any Change of Control and Severance Agreement with us that provides contractual

severance benefits upon a qualifying termination of employment during fiscal year 2024. For a summary of potential

payments to Mr. Novack on qualifying termination of employment, see “Potential Payments and Benefits upon

Termination or Change of Control for Officers” below .

Alexander Johnson

In connection with Mr. Johnson’s promotion to Chief Business Officer, we entered into a promotion letter with Mr.

Johnson, dated July 12, 2021. The letter provides for “at-will” employment and sets forth certain agreed upon terms

and conditions of employment. Effective September 7, 2022, Mr. Johnson transitioned from the role of Chief Business

Officer and Head of Testing Services to the role of President of Patient and Testing Services. Effective November 1,

2023, Mr. Johnson was a member of the Office of the Chief Executive Officer and assumed the duties of the

Company’s Principal Executive Officer until the appointment of Mr. Hanna on April 15, 2024, on which date Mr.

Johnson resumed the role of President of Patient and Testing Services until termination of employment and transition

to service as a consultant effective September 13, 2024.

In connection with Mr. Johnson’s termination, which was treated as a termination by the Company without “cause” for

purposes of the various agreements in place between the Company and Mr. Johnson, on September 30, 2024, we

entered into a separation agreement and release of claims with Mr. Johnson (the “Johnson Separation Agreement”).

Pursuant to the Johnson Separation Agreement, subject to Mr. Johnson’s effective release of claims in favor of us, we

agreed to provide (i) the severance payments and benefits provided under the Change of Control and Severance

Agreement, dated July 19, 2021, entered into with Mr. Johnson, which consist of continued payment of base salary

for six months from the separation date and, subject to Mr. Johnson’s election of continuation coverage under

COBRA, reimbursement of the COBRA premiums for six months from the separation date (or, if earlier, the date on

which Mr. Johnson and/or any eligible dependents become covered under similar plans), (ii) a lump sum cash

payment equal to $517,920, representing 200% of Mr. Johnson’s target bonus as in effect for the 2024 fiscal year, to

be paid at the same time 2024 annual bonuses are generally paid to our other senior executives and (iii) a lump sum

cash payment equal to $300,000, representing the unpaid portion of the retention bonus payable pursuant to that

certain letter agreement entered into with Mr. Johnson, dated December 1, 2023, to be paid on the first regularly

scheduled payroll date in December 2024. The Johnson Separation Agreement includes a mutual non-disparagement

provision and subjects Mr. Johnson to non-solicitation of our employees for 12 months following the effective date of

the Separation Agreement.

In connection with Mr. Johnson’s separation, on September 30, 2024, we also entered into a consulting agreement

with Mr. Johnson (the “Johnson Consulting Agreement”), which had retroactive effect to September 14, 2024 and

pursuant to which Mr. Johnson provides services to us as a non-employee consultant to ensure a smooth transition of

duties and responsibilities during employment with us and provide guidance as requested by the us in connection with

such transition. Pursuant to the Johnson Consulting Agreement, Mr. Johnson agreed to be available for up to 40

hours of consulting services to us in any given calendar month (and for an anticipated average of no more than 20

hours per month) for a period of six months (the “Johnson Term”), which may be extended or renewed for additional

agreed upon periods upon written agreement of the between us and Mr. Johnson. As consideration for the services to

be provided by Mr. Johnson to us pursuant to the Consulting Agreement, we agreed to pay Mr. Johnson an aggregate

fee of $107,901 (the “Johnson Fee”), payable in a lump sum at the end of the Johnson Term, and Mr. Johnson’s

outstanding equity awards will continue to vest pursuant to the terms of the applicable award agreements during the

Johnson Term. The Johnson Consulting Agreement will terminate prior to the expiration of the Johnson Term upon

Mr. Johnson’s death or disability, upon Mr. Johnson’s valid revocation of the Johnson Separation Agreement or upon

Mr. Johnson’s written request, and may be terminated by us prior to the expiration of the Johnson Term for “good

cause” (as defined in the Johnson Consulting Agreement). Under the Johnson Consulting Agreement, a termination

upon Mr. Johnson’s death or disability will result in payment of the consideration provided under the Consulting

Agreement as if services continued for the full Johnson Term, notwithstanding its earlier termination. In the event of

an automatic termination other than on account of Mr. Johnson’s death or disability or a termination by the Company

for “good cause,” we will only be obligated to pay such portion of the Johnson Fee that is pro-rated based on the

number of days that lapsed during the Johnson Term prior to the date of such termination, and any then-unvested

portion of Mr. Johnson’s stock units will automatically expire. The Johnson Consulting Agreement subjects Mr.

Johnson to non-solicitation of the our employees during the Johnson Term and six months thereafter.

Option Exercises and Stock Vested

The following table presents, for each of the NEOs, the number of shares of our common stock acquired upon the

vesting and settlement of RSUs during fiscal year 2024 and the aggregate value realized upon the vesting and

settlement of RSUs and upon the exercise of stock options during fiscal year 2024 and the aggregate value realized

upon the exercise of stock options..

Name*	Option Awards — Number of Shares Acquired on Vesting (#)	Value Realized on Exercise	Stock Awards — Number of Shares Acquired on Vesting (#)	Value Realized on Vesting
Abhishek Jain	—	$—	76,705	$1,254,265
Jeffrey Novack	—	$—	32,542	$563,591
Alexander Johnson	61,023	$578,727	99,903	$1,429,621

Messrs . Hanna and Kennedy and Ms. Meng do not hold any option awards or stock awards that vested or settled during fiscal year 2024

Name*	Option Awards — Number of Shares Acquired on Vesting (#)	Value Realized on Exercise	Stock Awards — Number of Shares Acquired on Vesting (#)	Value Realized on Vesting
Abhishek Jain	—	$—	76,705	$1,254,265
Jeffrey Novack	—	$—	32,542	$563,591
Alexander Johnson	61,023	$578,727	99,903	$1,429,621

so these NEOs have not been included in the table.

Pension Benefits

No pension benefits were paid to any of our NEOs during fiscal year 2024.

Potential Payments and Benefits upon Termination or Change of Control for Officers

John W. Hanna

Pursuant to Mr. Hanna’s Change of Control and Severance Agreement, effective March 21, 2024, if within two

months prior to, or twelve months following a change of control, we or our successor terminate Mr. Hanna’s

employment without cause, Mr. Hanna will be entitled to (a) a lump sum payment equal to eighteen months of Mr.

Hanna’s annual base salary (at the greater of the rate in effect immediately prior to the change of control or the rate in

effect immediately prior to the date of such termination), (b) acceleration of vesting equal to 100% of any unvested

equity awards (with any performance criteria being deemed achieved at target levels for the relevant performance

period(s)), (c) a lump sum payment equal to 150% of Mr. Hanna’s annual bonus (equal to the greater of target bonus

in effect for the fiscal year in which the change of control occurs or the target bonus in effect for the fiscal year in

which the termination occurs) and (d) 18 months of continued benefits, provided, that such reimbursement will cease

on the date that Mr. Hanna becomes covered under a similar plan of a new employer. Pursuant to the agreement, if

we or a successor terminates Mr. Hanna’s employment without cause and such termination occurs outside of a

change of control event, Mr. Hanna will be entitled to (a) twelve months’ severance based on Mr. Hanna’s annual

base salary, and (b) twelve months of continued benefits, provided, that such reimbursement will cease on the date

that Mr. Hanna becomes covered under a similar plan of a new employer, and (c) if such termination occurs prior to

the one year anniversary of Mr. Hanna’s start date, the inducement equity awards granted to Mr. Hanna in connection

with the initial appointment will vest pro rata based on the number of days that elapsed since starting employment

with us.

Abhishek Jain

Pursuant to Mr. Jain’s Change of Control and Severance Agreement, effective September 7, 2022, if within two

months prior to, or twelve months following a change of control, we or our successor terminate Mr. Jain’s employment

without cause, Mr. Jain will be entitled to (a) six months’ severance based on Mr. Jain’s annual base salary, (b)

acceleration of vesting equal to 100% of any unvested equity awards, (c) a lump sum payment equal to Mr. Jain’s

annual bonus (equal to the greater of target bonus or the actual bonus received for performance during the calendar

year prior to the year in which the termination occurred) and (d) six months of continued benefits, provided, that such

reimbursement will cease on the date that Mr. Jain becomes covered under a similar plan of a new employer.

Pursuant to the agreement, if we or a successor terminates Mr. Jain’s employment without cause and such

termination occurs outside of a change of control event, Mr. Jain will be entitled to (a) six months’ severance based on

Mr. Jain’s annual base salary, and (b) six months of continued benefits, provided, that such reimbursement will cease

on the date that Mr. Jain becomes covered under a similar plan of a new employer.

On March 27, 2025, we entered into an Amended and Restated Change of Control and Severance Agreement with

Mr. Jain that provides for twelve months of severance and continued benefits in the event of a qualifying termination

of employment (whether or not in the context of a change of control event), in order to better align the terms of Mr.

Jain’s severance entitlements with those of our other executive officers (other than our Chief Executive Officer). As

this agreement was not in effect on December 31, 2024, this amendment is not reflected in the table below.

Keith Kennedy

Pursuant to Mr. Kennedy’s Change of Control and Severance Agreement, effective July 27, 2024, if within two

months prior to, or twelve months following a change of control, we or our successor terminate Mr. Kennedy’s

employment without cause, Mr. Kennedy will be entitled to (a) a lump sum payment equal to twelve months of Mr.

Kennedy’s annual base salary (at the greater of the rate in effect immediately prior to the change of control or the rate

in effect immediately prior to the date of such termination), (b) acceleration of vesting equal to 100% of any unvested

equity awards (with any performance criteria being deemed achieved at target levels for the relevant performance

period(s)), (c) a lump sum payment equal to 100% of Mr. Kennedy’s annual bonus (equal to the greater of target

bonus in effect for the fiscal year in which the change of control occurs or the target bonus in effect for the fiscal year

in which the termination occurs) and (d) 12 months of continued benefits, provided, that such reimbursement will

cease on the date that Mr. Kennedy becomes covered under a similar plan of a new employer. Pursuant to the

agreement, if we or a successor terminates Mr. Kennedy’s employment without cause and such termination occurs

outside of a change of control event, Mr. Kennedy will be entitled to (a) twelve months’ severance based on Mr.

Kennedy’s annual base salary, and (b) twelve months of continued benefits, provided, that such reimbursement will

cease on the date that Mr. Kennedy becomes covered under a similar plan of a new employer, and (c) if such

termination occurs prior to the one year anniversary of Mr. Kennedy’s start date, the inducement equity awards

granted to Mr. Kennedy in connection with his initial appointment will vest pro rata based on the number of days that

elapsed since starting employment with us.

Jessica Meng

Pursuant to Ms. Meng’s Change of Control and Severance Agreement, effective August 30, 2024, if within two

months prior to, or twelve months following a change of control, we or our successor terminate Ms. Meng’s

employment without cause, Ms. Meng will be entitled to (a) lump sum payment equal to twelve months of Ms. Meng’s

annual base salary (at the greater of the rate in effect immediately prior to the change of control or the rate in effect

immediately prior to the date of such termination), (b) acceleration of vesting equal to 100% of any unvested equity

awards (with any performance criteria being deemed achieved at target levels for the relevant performance period(s)),

the fiscal year in which the change of control occurs or the target bonus in effect for the fiscal year in which the

termination occurs) and (d) 12 months of continued benefits, provided, that such reimbursement will cease on the

date that Ms. Meng becomes covered under a similar plan of a new employer. Pursuant to the agreement, if we or a

successor terminates Ms. Meng’s employment without cause and such termination occurs outside of a change of

control event, Ms. Meng will be entitled to (a) twelve months’ severance based on Ms. Meng’s annual base salary,

and (b) twelve months of continued benefits, provided, that such reimbursement will cease on the date that Ms. Meng

becomes covered under a similar plan of a new employer, and (c) if such termination occurs prior to the one year

anniversary of Ms. Meng’s start date, the inducement equity awards granted to Ms. Meng in connection with the initial

appointment will vest pro rata based on the number of days that elapsed since starting employment with us.

Jeffrey Novack

We were not party to any severance agreements or arrangements with Mr. Novack as of December 31, 2024.

Accordingly, the amounts reflected for Mr. Novack in the table below only include the value of equity acceleration in

accordance with the terms of Mr. Novack’s outstanding equity awards as of December 31, 2024.

On March 28, 2025, we entered into a Change of Control and Severance Agreement with Mr. Novack, in order to

better align the terms of Mr. Novack’s severance entitlements with those of our other executive officers (other than

our Chief Executive Officer). Pursuant to the terms of the agreement, if within two months prior to, or twelve months

following a change of control, we or our successor terminate Mr. Novack’s employment without cause, Mr. Novack will

be entitled to (a) twelve months’ severance based on Mr. Novack’s annual base salary, (b) acceleration of vesting

equal to 100% of any unvested equity awards, (c) a lump sum payment equal to Mr. Novack’s annual bonus (equal to

the greater of target bonus or the actual bonus received for performance during the calendar year prior to the year in

which the termination occurred) and (d) twelve months of continued benefits, provided, that such reimbursement will

cease on the date that Mr. Novack becomes covered under a similar plan of a new employer. Pursuant to the

agreement, if we or a successor terminates Mr. Novack’s employment without cause and such termination occurs

outside of a change of control event, Mr. Novack will be entitled to (a) nine months’ severance based on Mr. Novack’s

annual base salary, and (b) nine months of continued benefits, provided, that such reimbursement will cease on the

date that Mr. Novack becomes covered under a similar plan of a new employer. As this agreement was not in effect

on December 31, 2024, Mr. Novack’s entitlements pursuant to this agreement are not reflected in the table below.

For purposes of the Change of Control and Severance Agreements with each of our NEOs, “cause” means generally:

• executive’s material failure to perform the executive’s stated duties after a written notice of failure and a cure

period of ten days;

• executive’s material violation of our policies or any written agreement or covenant with us;

• executive’s conviction of, or entry of a plea of guilty or nolo contendere to, a felony;

• a willful act by executive that constitutes gross misconduct and which is injurious to us;

• executive’s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has

caused or is reasonably expected to result in material injury to us;

• the unauthorized use or disclosure by executive of any of our proprietary information or trade secrets or any other

party to whom they owe an obligation of nondisclosure as a result of the executive’s relationship with us; or

• executive’s willful failure to cooperate with an investigation by a governmental authority.

The following table estimates the amounts payable to our named executive officers that were serving as such as of

December 31, 2024 in the event that a change of control, termination of employment or both occurred on December

31, 2024. The closing price of our common stock on December 31, 2024, as reported on the Nasdaq Global Market,

was $21.41 per share. The following table excludes certain benefits, such as accrued vacation, that are available to

all employees generally. The actual amount of payments and benefits that would be provided can only be determined

at the time of a change of control and/or the NEOs qualifying separation from the Company:

Name*	Termination by the Company Without Cause Outside of Change of Control Window — Cash Payments	Continuation of Benefits	Value of Equity Accelerated	Termination by the Company Without Cause During Change of Control Window — Cash Payments	Continuation of Benefits	Value of Equity Accelerated
John W. Hanna	$675,000	—	$3,508,257	$1,973,077	—	$19,700,210
Abhishek Jain	$215,800	—	—	$709,203	—	$5,672,474
Keith Kennedy	$575,000	$45,985	$113,079	$779,346	$45,985	$1,500,862
Jessica Meng	$475,000	—	$84,809	$643,808	—	$1,125,652
Jeffrey Novack	—	—	—	—	—	$1,699,012

Excludes Alexander Johnson as employment terminated effective September 13, 2024 and we did not enter into any agreement to

Name*	Termination by the Company Without Cause Outside of Change of Control Window — Cash Payments	Continuation of Benefits	Value of Equity Accelerated	Termination by the Company Without Cause During Change of Control Window — Cash Payments	Continuation of Benefits	Value of Equity Accelerated
John W. Hanna	$675,000	—	$3,508,257	$1,973,077	—	$19,700,210
Abhishek Jain	$215,800	—	—	$709,203	—	$5,672,474
Keith Kennedy	$575,000	$45,985	$113,079	$779,346	$45,985	$1,500,862
Jessica Meng	$475,000	—	$84,809	$643,808	—	$1,125,652
Jeffrey Novack	—	—	—	—	—	$1,699,012

continue providing for benefits in the event of a change of control pursuant to the Johnson Consulting Agreement.

Pay Ratio Disclosure

We are a leading precision medicine company focused on the discovery, development and commercialization of

clinically differentiated, high-value diagnostic solutions for transplant patients and caregivers. We offer testing

services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and we are a

leading provider of genomics-based information for transplant patients.

As required by Item 402(u) of Regulation S-K, we are providing the following information about the relationship of the

median of the annual total compensation of all our employees (other than our Chief Executive Officer) and the annual

total compensation of John Hanna, our Chief Executive Officer and President (our “CEO”) on October 15, 2024.

Neither the Compensation and Human Capital Committee nor our management used our CEO pay ratio measure in

making compensation decisions. As explained by the SEC when it adopted Item 402(u), the rule was designed to

allow stockholders to better understand and assess our compensation practices and pay ratio disclosures rather than

to facilitate a comparison of this information from one company to another. However, the pay ratio rules provide

companies with flexibility to select the methodology and assumptions used to identify the median employee, calculate

the median employee's compensation and estimate the pay ratio. As a result, our methodology may differ from those

used by other companies, which likely will make it difficult to compare pay ratios with other companies, including

those within our industry.

There have been no changes in our employee population or employee compensation arrangements that we believe

would significantly impact the calculations of this pay ratio; accordingly, we are using the same median employee

identified in 2023.

CEO Pay Ratio for Fiscal Year 2024

• The median of the 2024 annual total compensation of all our employees, excluding our CEO, was $169,005;

• The annualized total compensation of our CEO who was hired in 2024 was $9,645,002; and

• The ratio of the annual total compensation of our CEO to the median of the annual total compensation of all our

employees was 57 to 1. This ratio is a reasonable estimate calculated in a manner consistent with SEC rules.

Methodology

The methodology, including key assumptions and estimates, used to identify the employee (excluding our Chief

Executive Officer) with compensation at the median of the annual total compensation of all our employees was based

on the following:

• In determining our employee population, we considered the individuals, excluding our Chief Executive Officer,

who were employed by us and our consolidated subsidiaries as of October 15, 2023, whether employed on a full-

time, part-time, seasonal or temporary basis. As of October 15, 2023, we had 676 employees. As permitted by

the de minimis exception contained in Item 402(u)(4)(ii) of Regulation S-K, we have excluded our 14 employees

in Belgium, Germany, Hungary, Italy and Spain, leaving us with a population of 662 employees. We did not

include any contractors or other non-employee workers in our employee population.

• To identify our median employee, we chose to use total cash and equity compensation as our consistently-

applied compensation measure, which we calculated as of October 15, 2023. After applying our methodology, our

median employee was a Sr Dev Ops Developer, based in the U.S.

• For employees paid other than in U.S. dollars, we converted their compensation to U.S. dollars using the

applicable exchange rates in effect on October 15, 2023. For permanent employees hired during 2024, we

annualized their total cash as if they had been employed for the entire measurement period. We did not make

any cost-of-living adjustments.

Calculation

Using the aforementioned methodology, the individual identified as the calculated median employee from our 2023

employee population had actual earnings consisting of base pay, bonus, equity granted and 401(k) match for 2024

annual total compensation in the amount of $169,005. Mr. Hanna’s compensation for purposes of the pay ratio

disclosure has been adjusted as follows: base salary annualized and target bonus payout included for a total of

$9,645,002.

Pay Versus Performance

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of

Regulation S-K, we are providing the following information about the relationship between executive “compensation

actually paid” (the “ CAP ”) to our principal executive officers (“ PEOs ”) and our other NEOs (the “ Non-PEO NEOs ”) and

certain financial performance of the Company. The CAP does not reflect the actual amount of compensation earned,

realized or received by the PEOs or Non-PEO NEOs during the applicable fiscal year. The following table shows the

total compensation for our NEOs for the past four fiscal years as set forth in the “Summary Compensation Table”, the

CAP to our PEOs, and on an average basis, our Non-PEO NEOs (in each case, as determined under SEC rules), our

Total Shareholder Return (“ TSR ”), the TSR for companies in the Nasdaq Biotech Index, our net income, and our

Company-Selected Measure, Revenue.

Fiscal Year (a)	Summary Compensa tion Table (“SCT”) for Mr. Hanna (PEO 1) (b) (1)	CAP to Mr. Hanna (PEO 1) (c) (2)	Summary Compensa tion Table (“SCT”) for Mr. Johnson (PEO 2) (d) (1)	CAP to Mr. Johnson (PEO 2) (e) (2)	SCT for Dr. Seeto (PEO 3) (f) (1)	CAP to Dr. Seeto (PEO 3) (g) (2)	SCT for Dr. Maag (PEO 4) (h) (1)	CAP to Dr. Maag (PEO 4) (i) (2)	Average SCT for Non- PEO NEOs (j) (3)	Average CAP to Non- PEO NEOs (k) (2)	Value of Initial Fixed $100 Investment Based On:		Net Income (in thousands ) (n)	Revenue (in thousand s) (o) (5)
											TSR (l) (4)	Peer Group TSR (m) (4)
2024	$ 9,424,329	$ 24,178,001	$ 2,937,571	$ 7,443,241	—	—	—	—	$ 2,986,074	$ 3,772,296	$ 99.26	$ 118.20	$ 52,549	$ 333,785
2023	—	—	$ 3,097,438	$ 1,923,573	$ 10,551,753	$ 6,665,898	—	—	$ 4,617,844	$ 4,412,835	$ 55.63	$ 118.87	($ 190,284 )	$ 280,324
2022	—	—	—	—	$ 12,786,270	($ 648,097 )	—	—	$ 3,784,612	$ 118,224	$ 52.90	$ 113.65	($ 76,613 )	$ 321,793
2021	—	—	—	—	$ 7,090,121	($ 50,411 )	—	—	$ 2,605,699	$ 140,603	$ 210.85	$ 126.45	($ 30,662 )	$ 296,397
2020	—	—	—	—	$ 5,618,698	$ 17,196,016	$ 6,400,015	$ 32,731,502	$ 1,979,508	$ 7,956,557	$ 335.88	$ 126.42	($ 18,714 )	$ 192,194

(1) The dollar amounts reported in columns (b), (d), and (f) are the amounts of total compensation reported for Mr. Johnson (our Principal

Executive Officer since November 1, 2023), Dr. Seeto (Chief Executive Officer and Principal Executive Officer from November 1, 2020

to November 1, 2023) and Dr. Maag (Chief Executive Officer until November 1, 2020) for each corresponding year in the “Total”

column of the Summary Compensation Table. Refer to the “Summary Compensation Table” on page 62 for additional information.

(2) The dollar amounts reported in columns (c), (e), (g), (i), and (k) represent the amount of the CAP, as computed in accordance with

SEC rules. The CAP does not necessarily represent cash and/or equity value transferred to the applicable NEO without restriction, but

rather is a value calculated under applicable SEC rules. These amounts reflect the total amount of compensation for our NEOs

reported in the Summary Compensation Table with certain adjustments as described in the table below for the most recent fiscal year.

We do not have a defined benefit plan so no adjustment for pension benefits is included. The valuation assumptions and processes

used to recalculate fair values did not materially differ from those disclosed at the time of grant.

Fiscal Year	Executives	SCT (a)	Grant Date Value of New Awards (b)	Year End Value of New Awards (i)	Change in Value of Outstandin g Awards Granted in Prior Fiscal Year (ii)	Change in Value of Vested Awards Granted in Prior Fiscal Years (iii)	Fair Value of Vested Awards Granted and Vested in Current Fiscal Year (iv)	Fair Value at Start of Fiscal Year of Awards that Failed to Meet Vesting Condition s (v)	Value of Dividend s Paid on Equity Awards not Reflecte d in Fair Value (vi)	Total Equity CAP (c)=(i)+(ii)+ (iii)+(iv)	CAP (d)= (a)-(b)+(c)
2024	PEO 1	$ 9,424,329	($ 8,001,024 )	$ 22,754,696	$ —	$ —	—	—	—	$ 22,754,696	$ 24,178,001
	PEO 2	$ 2,937,571	($ 1,549,738 )	$ 2,802,355	$ 2,262,180	$ 185,168	805,705	—	—	$ 6,055,408	$ 7,443,241
	Non-PEO NEO Avg	$ 2,986,074	($ 2,340,879 )	$ 2,220,533	$ 577,907	$ 50,217	278,444	—	—	$ 3,127,101	$ 3,772,296

(a) The dollar amounts reported in the Summary Compensation Table for the applicable year.

(b) The grant date fair value of equity awards represents the total of the amounts reported in the “Stock Awards” and “Option Awards”

columns of the Summary Compensation Table for the applicable year.

(c) The recalculated value of equity awards for each applicable year includes the addition (or subtraction, as applicable) of the following:

(d) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the

applicable year;

(e) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in

prior years that are outstanding and unvested as of the end of the applicable year;

(f) for awards that vest in the applicable year, the change in the fair value as of the vesting date from the beginning of the applicable year;

(g) for awards that failed to meet vesting conditions in the applicable year, the fair value from the end of prior fiscal year.

(h) for awards that failed to meet vesting conditions in the applicable year, the fair value from the end of prior fiscal year;

(i) value of dividend not otherwise captured in the calculation of each Fair Value used to calculate CAP

(j) The CAP does not necessarily represent cash and/or equity value transferred to the applicable NEO without restriction, but rather is a

value calculated under applicable SEC rules.

(3) The dollar amounts reported in column (j) are the average amounts of total compensation reported for the Non-PEO NEOs for each

corresponding year in the “Total” column of the Summary Compensation Table. Refer to our “Summary Compensation Table” on page

62 for additional information. For each of fiscal years in the table, the Non-PEO NEOs were:

2024	2023	2022	2021	2020
Abhishek Jain	Abhishek Jain	Abhishek Jain	Ankur Dhingra	Michael Bell
Keith Kennedy	Abraham Ronai	Alexander Johnson	Alexander Johnson	Sasha King
Jessica Meng		Abraham Ronai	Sasha King	Marcel Konrad
Jeffrey Novack		Ankur Dhingra	Peter Maag, Ph. D.
		Sasha King	Marcel Konrad

(4) TSR is determined based on the value of an initial fixed investment of $100. The TSR peer group consists of the Nasdaq Biotech Index

companies. TSR is calculated by dividing (i) the difference between the stock price at the end of each measurement period shown and

the beginning of the measurement period by (ii) the stock price at the beginning of the measurement period.

(5) We determined Revenue to be the most important financial performance measure used to link Company performance to the CAP to

our PEOs and Non-PEO NEOs in 2024, consistent with the Total Sales targets used for our short-term incentives (annual bonuses)

and long-term incentives (PRSUs). See page 50 of our CD&A for additional information.

Relationship Between the CAP and Performance Measures

We believe the table above shows the alignment between the CAP to the NEOs and the Company’s performance,

consistent with our compensation philosophy as described in our CD&A beginning on page 50 . The charts below

show the relationship between the CAP to our PEOs and Non-PEO NEOs and (i) our TSR and the Peer Group TSR;

(ii) our net income and (iii) our Company-Selected Measure, Revenue, during the five most recently completed fiscal

years.

Chart 1

Char t 2

Chart 3

2024 Most Important Performance Measures The Compensation and Human Capital Committee uses a mix of performance measures throughout our annual and long-term incentive programs to align executive pay with Company performance. As required by SEC rules, the performance measures identified as the most important for all of our NEOs’ 2024 compensation decisions are listed in the table to the right. The measures in this table are not ranked.
Most Important Performance Measures
Revenue
Adjusted EBITDA
Pipeline

Equity Compensation Plan Information

The following table provides information as of December 31, 2024 with respect to shares of our common stock that

may be issued under our existing equity compensation plans.

Plan Category	(a) Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights	(b) Weighted Average Exercise Price of Outstanding Options and Rights (1)	(c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))
Equity compensation plans approved by stockholders (2)	6,647,625	$ 26.06	5,020,052
Equity compensation plans not approved by stockholders (3)	1,604,957	$ 13.12	97,836
Total:	8,252,582	$ 22.63	5,117,888

(1) The weighted average exercise price is calculated based solely on outstanding stock options and does not reflect the shares that will be

issued upon the vesting of outstanding awards of RSUs, which have no exercise price.

(2) Includes the following plans: the 2014 Plan, the 2024 Plan and the 2014 ESPP.

(3) Consists of shares available for issuance under the CareDx, Inc. 2016 Inducement Equity Incentive Plan, the CareDx, Inc. 2019

Inducement Equity Incentive Plan and the inducement grants in connection with the appointments of Messrs. Hanna and Kennedy and

Ms. Meng.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGE MEN T

The following table sets forth certain information with respect to the beneficial ownership of our common stock as of

March 31, 2025 for:

• each of our current directors and nominees for director;

• each of our NEOs;

• all of our current directors and executive officers as a group; and

• each person or group who beneficially owned more than 5% of our common stock.

We have determined beneficial ownership in accordance with the rules of the SEC and the information is not

necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our

knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to

all shares that they beneficially owned, subject to community property laws where applicable.

We have based our calculation of the percentage of beneficial ownership on 55,462,730 shares of our common stock

outstanding as of March 31, 2025. We have deemed shares of our common stock subject to stock options that are

currently exercisable or exercisable within 60 days of March 31, 2025, or issuable pursuant to RSUs that are subject

to vesting conditions expected to occur within 60 days of March 31, 2025, to be outstanding and to be beneficially

owned by the person holding the warrants, stock option or RSUs for the purpose of computing the percentage

ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the

percentage ownership of any other person.

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o CareDx, Inc., 8000

Marina Boulevard, 4 th Floor, Brisbane, California 94005.

Name of Beneficial Owner	Number of Shares Beneficially Owned	Percentage of Shares Beneficially Owned
5% Stockholders:
Neil Gagnon (1)	4,827,623	8.7%
The Vanguard Group (2)	4,859,732	8.8%
BlackRock, Inc. (3)	4,416,324	8.0%
Bellevue Group AG. (4)	3,145,546	5.7%
Directors and Named Executive Officers:
Abhishek Jain (5)	197,260	*
Alexander Johnson (6)	376,856	*
Jeffrey Novack (7)	43,451	*
Peter Maag, Ph.D. (8)	526,867	*
George W. Bickerstaff, III (9)	169,850	*
Christine M. Cournoyer (10)	111,717	*
Fred E. Cohen, M.D., D. Phil (11)	194,985	*
Michael D. Goldberg (12)	233,251	*
William A. Hagstrom (13)	126,057	*
John W. Hanna (14)	311,726	*
R. Bryan Riggsbee (15)	20,786	*
Hannah A. Valantine (16)	79,973	*
Arthur A. Torres (17)	80,269	*
Jessica Meng (18)	—	*
Keith Kennedy (19)	—	*
All current directors and executive officers as a group (15 persons) (20)	2,473,048	4.4%

Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.

Name of Beneficial Owner	Number of Shares Beneficially Owned	Percentage of Shares Beneficially Owned
5% Stockholders:
Neil Gagnon (1)	4,827,623	8.7%
The Vanguard Group (2)	4,859,732	8.8%
BlackRock, Inc. (3)	4,416,324	8.0%
Bellevue Group AG. (4)	3,145,546	5.7%
Directors and Named Executive Officers:
Abhishek Jain (5)	197,260	*
Alexander Johnson (6)	376,856	*
Jeffrey Novack (7)	43,451	*
Peter Maag, Ph.D. (8)	526,867	*
George W. Bickerstaff, III (9)	169,850	*
Christine M. Cournoyer (10)	111,717	*
Fred E. Cohen, M.D., D. Phil (11)	194,985	*
Michael D. Goldberg (12)	233,251	*
William A. Hagstrom (13)	126,057	*
John W. Hanna (14)	311,726	*
R. Bryan Riggsbee (15)	20,786	*
Hannah A. Valantine (16)	79,973	*
Arthur A. Torres (17)	80,269	*
Jessica Meng (18)	—	*
Keith Kennedy (19)	—	*
All current directors and executive officers as a group (15 persons) (20)	2,473,048	4.4%

(1) Neil Gagnon and related entities filed a Schedule 13G on August 20, 2024, reporting that, Mr. Gagnon had sole voting and dispositive

power over 154,071 shares, shared voting power over 2,081,995 shares and shared dispositive power over 2,395,507 shares. The

Schedule 13G further reported that Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“Gagnon

Securities”), which is registered with the SEC as an investment adviser and a registered broker-dealer, in its role as investment

manager to several customer accounts, foundations, partnerships and trusts (collectively referred to as the accounts), to which it

furnishes investment advice. The Schedule 13G further reported that Mr. Gagnon and Gagnon Securities may be deemed to share

voting power with respect to 1,542,114 shares of common stock held in the accounts and dispositive power with respect to 1,847,226

shares of common stock held in the accounts. Gagnon Securities and Mr. Gagnon disclaim beneficial ownership of all securities held in

the accounts. The Schedule 13G further reported that Mr. Gagnon is the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon

Advisors”), which is registered with the SEC as an investment adviser. The Schedule 13G further reported that Mr. Gagnon and

Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), which is a private investment fund,

may be deemed to share voting and dispositive power with respect to 430,819 shares of common stock held by GIA. Gagnon Advisors

and Mr. Gagnon disclaim beneficial ownership of all securities held by GIA. The address of Mr. Gagnon and related entities is 1370

Avenue of the Americas, 24th Floor, New York, New York 10019.

(2) The Vanguard Group (“Vanguard”) filed a Schedule 13G/A on January 30, 2025 reporting that it had shared voting power with respect

to 51,695 shares, sole dispositive power with respect to 4,760,601 shares, shared dispositive power with respect to 99,131 shares and

beneficial ownership of an aggregate of 4,859,732 shares in its capacity as an investment adviser in accordance with Rule

13d-1(b)(1)(ii)(E) under the Exchange Act. Vanguard’s address is 100 Vanguard Blvd., Malvern, PA 19355.

(3) BlackRock, Inc. (“BlackRock”) filed a Schedule 13G/A on April 17, 2025, reporting that it had sole voting power with respect to

4,323,315 shares, sole dispositive power with respect to 4,416,324 shares and beneficial ownership of an aggregate of 4,416,324

shares in its capacity as a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) under the Exchange

Act. BlackRock’s address is 50 Hudson Yards, New York, New York 10001.

(4) Bellevue Group AG (“Bellevue Group”) on behalf of its wholly-owned subsidiaries, Bellevue Asset Management (UK) Ltd. (“Bellevue

Asset Management”) and Bellevue Asset Management AG (“Bellevue AG”), filed a Schedule 13G/A on November 14, 2024, reporting

that it had shared voting and dispositive power with respect to 3,145,546 shares and beneficial ownership of an aggregate of 3,145,546

shares in its capacity as a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) under the Exchange

Act. Bellevue Group’s address is Seestrasse 16, Kuesnacht, Switzerland, CH-8700. Bellevue Asset Management’s address is 32

London Bridge Street, 24 th Floor, London, England SE1 9SG.

(5) Represents 100,982 shares of common stock held by Mr. Jain, 76,847 shares subject to options that are immediately exercisable or

exercisable within 60 days of March 31, 2025, and 19,431 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31, 2025.

(6) Represents 284,983 shares of common stock held by Mr. Johnson, 91,873 shares subject to options that are immediately exercisable

or exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31 2025.

(7) Represents 30,881 shares of common stock held by Mr. Novack, 3,346 shares subject to options that are immediately exercisable or

exercisable within 60 days of March 31, 2025, and 9,224 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31 2025.

(8) Represents 319,454 shares of common stock held by Dr. Maag, 207,413 shares subject to options that are immediately exercisable or

exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions expected

to occur within 60 days of March 31, 2025.

(9) Represents 92,457 shares of common stock held by Mr. Bickerstaff, 77,393 shares subject to options that are immediately exercisable

or exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31, 2025.

(10) Represents 43,175 shares of common stock held by Ms. Cournoyer, 68,542 shares subject to options that are immediately exercisable

or exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31, 2025.

(11) Represents 132,592 shares of common stock held by Dr. Cohen, 62,393 shares subject to options that are immediately exercisable or

exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions expected

to occur within 60 days of March 31, 2025.

(12) Represents 129,358 shares of common stock held by Mr. Goldberg, 103,893 shares subject to options that are immediately

exercisable or exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting

conditions expected to occur within 60 days of March 31, 2025.

(13) Represents 43,409 shares of common stock held by Mr. Hagstrom, 82,648 shares subject to options that are immediately exercisable

or exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31, 2025.

(14) Represents 0 shares of common stock held by Mr. Hanna, 189,775 shares subject to options that are immediately exercisable or

exercisable within 60 days of March 31, 2025, and 121,951 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31 2025.

(15) Represents 2,281 shares of common stock held by Mr. Riggsbee, 18,505 shares subject to options that are immediately exercisable or

exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions expected

to occur within 60 days of March 31 2025.

(16) Represents 26,891 shares of common stock held by Dr. Valantine, 53,082 shares subject to options that are immediately exercisable

or exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31, 2025.

(17) Represents 26,562 shares of common stock held by Senator Torres, 53,707 shares subject to options that are immediately exercisable

or exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions

expected to occur within 60 days of March 31, 2025.

(18) Represents 0 shares of common stock held by Ms. Meng, 0 shares subject to options that are immediately exercisable or exercisable

within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions expected to occur

within 60 days of March 31, 2025.

(19) Represents 0 shares of common stock held by Mr. Kennedy, 0 shares subject to options that are immediately exercisable or

exercisable within 60 days of March 31, 2025, and 0 shares issuable pursuant to RSUs that are subject to vesting conditions expected

to occur within 60 days of March 31, 2025.

(20) Comprised of shares included under “Directors and Named Executive Officers”.

RELATED PARTY TRANSACTIONS

Since January 1, 2024, there have not been any transactions or series of transactions, and there is currently no

proposed transaction, to which we were or are to be a participant in which the amount involved in the transaction or

series of transactions exceeds $120,000, and in which any of our directors, executive officers or persons who we

know held more than five percent of any class of our capital stock, including their immediate family members, had or

will have a direct or indirect material interest, other than compensation arrangements that are described under

“Executive Compensation” above and the indemnification agreements described below.

Indemnification Agreements

We have also entered into indemnification agreements with our directors and certain of our executive officers. The

indemnification agreements and the Certificate of Incorporation and Bylaws require us to indemnify our directors and

officers to the fullest extent permitted by Delaware law.

Rule 10b5-1 Sales Plans

Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract

with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker

executes trades pursuant to parameters established by the director or executive officer when entering into the plan,

without further direction from them. The director or executive officer may amend a Rule 10b5-1 plan in some

circumstances and may terminate a plan at any time, subject to the terms of the plan. Our directors and executive

officers also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of

material nonpublic information, subject to compliance with the terms of our insider trading policy.

Policies and Procedures for Related Party Transactions

Our Audit and Finance Committee adopted a formal written policy that our Audit and Finance Committee is

responsible for reviewing “related party transactions.” A “related party transaction” is a transaction, arrangement, or

relationship in which we (including any of our subsidiaries) and any “related party” were, are, or will be participants

involving an amount that exceeds $120,000. For purposes of this policy, a related party is defined as a director,

nominee for director, executive officer, or greater than 5% beneficial owner of our common stock and their immediate

family members, any entity in which such person is employed or is a general partner or principal and any entity where

such person has a 5% or greater beneficial ownership interest.

Under this policy, all related party transactions may be consummated or continued only if approved or ratified by our

Audit and Finance Committee. In determining whether to approve or ratify any such proposal, our Audit and Finance

Committee will take into account, among other factors it deems appropriate, (a) whether the transaction is on terms

no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances,

and (b) the extent of the related party’s interest in the transaction. The policy grants standing pre-approval of certain

transactions, including (1) certain compensation arrangements of executive officers, (2) certain director compensation

arrangements, (3) transactions with another company at which a related party’s only relationship is as a non-

executive employee, director or beneficial owner of less than 5% of that company’s shares, (4) transactions where a

related party’s interest arises solely from the ownership of our common stock and all holders of our common stock

received the same benefit on a pro rata basis, and (5) transactions available to all U.S. employees generally.

OTHER MATTERS

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires that our executive officers and directors, and persons who own more than

10% of our common stock, file reports of ownership and changes of ownership with the SEC. Such directors,

executive officers and 10% stockholders are required by SEC regulation to furnish us with copies of all Section 16(a)

forms they file.

SEC regulations require us to identify in this proxy statement anyone who failed to file a timely required report during

the most recent fiscal year. Based solely upon our review of forms we received, or written representations from

reporting persons stating that they were not required to file these forms, we believe that during our fiscal year ended

December 31, 2024, all Section 16(a) filing requirements were satisfied on a timely basis, except for the following: on

April 9, 2024, a Form 4/A was filed by each of Abhishek Jain and Alexander Johnson to report the grant of RSUs

which were inadvertently omitted from their prior timely Form 4 filings, each reporting a transaction on February 1,

2024 ; on June 17, 2024, R. Bryan Riggsbee filed a Form 3 to report beneficial ownership as of the date he became a

director on March 11, 2024; on June 20, 2024, a Form 4 was filed by Alexander Johnson to report the withholding of

shares of Common Stock on June 17, 2024; on July 8, 2024, Christine M. Cournoyer filed a Form 4 to report

withholding of shares of Common Stock upon RSU vesting on June 14, 2024; and on December 3, 2024, each of

Jeffrey Novack and Peter K. Maag filed Form 4s to report sales pursuant to 10b5-1 trading plans on each of

November 18, 2024 and November 26, 2024, respectively.

Available Information

Our financial statements for our fiscal year ended December 31, 2024 are included in our Annual Report on Form 10-

K for the year ended December 31, 2024. This proxy statement and our annual report are posted on the Investors

section of our website at investors.caredxinc.com and are available from the SEC at its website at www.sec.gov. You

may also obtain a copy of our annual report without charge by sending a written request to CareDx, Inc., Attention:

Investor Relations, 8000 Marina Boulevard, 4 th Floor, Brisbane, California 94005.

Note About Forward-Looking Statements

This proxy statement contains forward-looking statements that involve a number of risks and uncertainties. Words

such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are

intended to identify forward-looking statements. We have based these forward-looking statements largely on our

current expectations and projections about future events and trends that we believe may affect our financial condition,

results of operations, business strategy, short-term and long-term business operations and objectives, and financial

needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including

those described in our Annual Report on Form 10-K for the year ended December 31, 2024. Moreover, we operate in

a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our

management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which

any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-

looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends

discussed in this proxy statement may not occur and actual results could differ materially and adversely from those

anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publicly release the

results of any revision to these forward-looking statements, except as required by law. Given these risks and

uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Householding

The SEC has adopted rules that permit companies and intermediaries to satisfy the delivery requirements for Notice

of Internet Availability of Proxy Materials (the “Notice”) or other proxy materials with respect to two or more

stockholders sharing the same address by delivering a single notice or other annual meeting materials addressed to

those stockholders. This process, which is commonly referred to as householding, potentially provides extra

convenience for stockholders and cost savings for companies. Stockholders who participate in householding will

continue to be able to access and receive separate proxy cards.

A Notice will be delivered in one single envelope to multiple stockholders sharing an address unless contrary

instructions have been received from one or more of the affected stockholders. If, at any time, you no longer wish to

participate in householding and would prefer to receive a separate Notice or other proxy materials, please notify your

broker or call the Company’s Secretary at (415) 287-2300 or submit a request in writing to our Corporate Secretary,

8000 Marina Boulevard, 4 th Floor, Brisbane, California 94005. Stockholders who currently receive multiple copies of

the Notice or other proxy materials at their address and would like to request householding of their communications

should contact their broker. In addition, we will promptly deliver, upon written or oral request to the address or

telephone number above, a separate copy of the Notice or other proxy materials to a stockholder at a shared address

to which a single copy of the documents was delivered.

Company Website

We maintain a website at www.caredx.com. Information contained on, or that can be accessed through, our website

is not intended to be incorporated by reference into this proxy statement, and references to our website address in

this proxy statement are inactive textual references only.

Our Board of Directors does not know of any other matters to be presented at the Annual Meeting. If any additional

matters are properly presented at the Annual Meeting, the persons named on the enclosed proxy card will have

discretion to vote the shares of common stock they represent in accordance with their own judgment on such matters.

It is important that your shares of common stock be represented at the Annual Meeting, regardless of the number of

shares that you hold. You are, therefore, urged to vote over the Internet or by telephone as instructed on the proxy

card or execute and return, at your earliest convenience, the proxy card .

THE BOARD OF DIRECTORS

Brisbane, California

April 25, 2025

A-1

APPENDIX A

2024 Equity Incentive Plan

GENERAL.

a. Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees,

Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of

the Company and any Affiliate and to promote the creation of long-term value for the stockholders of the

Company by closely aligning the interests of such individuals with those of such stockholders.

b. Available Awards. The Plan provides for the grant of the following Awards: (i) Incentive Stock Options;

(ii) Nonstatutory Stock Options; (iii) SARs; (iv) Restricted Stock Awards; (v) RSU Awards; and (vi) Other

Awards.

c. Effective Date. The Plan will come into existence on the Effective Date.

SHARES SUBJECT TO THE PLAN.

a. Share Reserve. Subject to adjustment in accordance with Section 2(c) and any adjustments as necessary to

implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be

issued pursuant to Awards will not exceed 3,500,000 shares.

b. Aggregate Incentive Stock Option Limit. Notwithstanding anything to the contrary in Section 2(a) and

subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate

maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock

Options is 3,500,000 shares.

c. Share Reserve Operation.

(i) Limit Applies to Common Stock Issued Pursuant to Awards. For clarity, the Share Reserve is a limit

on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the

granting of Awards, except that the Company will keep available at all times the number of shares of

Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards.

Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq

Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide

Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for

issuance under the Plan. For the avoidance of doubt, Awards that by their terms settle in cash shall not

reduce the Share Reserve.

(ii) Reversion of Previously Issued Shares of Common Stock to Share Reserve. If any Award is forfeited,

expires, terminates, otherwise lapses or is surrendered pursuant to an Exchange Program or otherwise

settled for cash, in whole or in part, without the delivery of Shares, then the Shares covered by such

forfeited, expired, terminated or lapsed Award or Award surrendered or settled in cash shall be added back

to the Share Reserve and again become available for issuance under the Plan. For the avoidance of

doubt, the following will not be added back to the Share Reserve or again available for issuance under the

Plan: (A) any Shares withheld in respect of taxes, (B) any Shares tendered or withheld to pay the exercise

price of Options, and (C) any Shares underlying an Award of stock-settled SARs.

ELIGIBILITY AND LIMITATIONS.

a. Eligible Award Recipients. Subject to the terms of the Plan, Employees, Directors and Consultants are

eligible to receive Awards.

b. Specific Award Limitations.

(i) Limitations on Incentive Stock Option Recipients. Incentive Stock Options may be granted only to

Employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are

defined in Sections 424(e) and (f) of the Code).

(ii) Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value

(determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are

exercisable for the first time by any Participant during any calendar year (under all plans of the Company

and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not

comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such

limit (according to the order in which they were granted) or otherwise do not comply with such rules will be

A-2

treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Award

Agreement(s).

(iii) Limitations on Incentive Stock Options Granted to Ten Percent Stockholders. A Ten Percent

Stockholder may not be granted an Incentive Stock Option unless (i) the exercise price of such Option is at

least 110% of the Fair Market Value on the date of grant of such Option and (ii) the Option is not

exercisable after the expiration of five years from the date of grant of such Option.

(iv) Limitations on Nonstatutory Stock Options and SARs. Nonstatutory Stock Options and SARs may not

be granted to Employees, Directors and Consultants who are providing Continuous Service unless the

stock underlying such Awards is treated as “service recipient stock” under Section 409A or unless such

Awards otherwise comply with the distribution requirements of Section 409A or is not subject to Section

409A.

c. Aggregate Incentive Stock Option Limit. The aggregate maximum number of shares of Common Stock that

may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in

Section 2(b).

d. Non-Employee Director Compensation Limit. The aggregate value of all compensation granted or paid, as

applicable, in each case following the Effective Date, to any individual for service as a Non-Employee Director

with respect to any fiscal year, including Awards granted and cash fees paid by the Company to such Non-

Employee Director for his or her service as a Non-Employee Director, will not exceed (i) $750,000 in total value

or (ii) in the event such Non-Employee Director is first appointed or elected to the Board during such fiscal year,

$1,500,000 in total value, in each case calculating the value of any equity awards based on the grant date fair

value of such equity awards for financial reporting purposes. For the avoidance of doubt, any Awards granted

and cash fees paid to a Non-Employee Director for his or her service as a Non-Employee Director in respect of

any fiscal year shall count against the compensation limits set forth in this Section 3(d) for the fiscal year to

which such Awards and fees relate, regardless of any deferral of such Awards or fees.

e. Minimum Vesting. Notwithstanding the Board’s discretion to determine the vesting schedule applicable to an

Award, all Awards, and all portions of Awards, shall be subject to a vesting schedule that provides that the

Award shall not vest with respect to any of the covered shares of Common Stock prior to the one year

anniversary of the date of grant of the Award (or the date of commencement of employment or service, in the

case of a grant made in connection with a Participant’s commencement of employment or service); provided,

however, that (i) Awards with respect to 5% of the aggregate number of shares subject to the Share Reserve

may be granted under the Plan to any one or more Participants (other than Officers) without respect to such

minimum vesting provisions, (ii) vesting of any Award may accelerate pursuant to Section 6(c)(ii), (iii) Awards

that vest on the earlier of the one-year anniversary of the date on which the Award was granted and the next

annual meeting of stockholders (so long as such next annual meeting of stockholders is at least 50 weeks after

the immediately preceding year’s annual meeting of stockholders) may be granted to Non-Employee Directors

without respect to such minimum vesting provisions, and (iv) nothing herein shall prohibit the Board from

accelerating the vesting of any Award in connection with the termination of a Participant’s Continuous Service

in exchange for a release of claims.

OPTIONS AND STOCK APPRECIATION RIGHTS.

Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be

designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided,

however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to

qualify as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares

purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated

in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be

identical; provided, however, that each Award Agreement will conform (through incorporation of provisions hereof

by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:

a. Term. Subject to Section 3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after

the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award

Agreement.

b. Exercise or Strike Price. Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise or strike

price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such

Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price

lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted

pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a

A-3

corporate transaction and in a manner consistent with the provisions of Sections 409A and, if applicable,

424(a) of the Code.

c. Exercise Procedure and Payment of Exercise Price for Options. In order to exercise an Option, the

Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures

specified in the Award Agreement or otherwise provided by the Company. The Board has the authority to

grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use

certain methods) and to grant Options that require the consent of the Company to utilize a particular method of

payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as

determined by the Board, by one or more of the following methods of payment to the extent set forth in the

Award Agreement:

(i) by cash or check, bank draft or money order payable to the Company;

(ii) pursuant to a “cashless exercise” program developed under Regulation T as promulgated by the

U.S. Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results

in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the

exercise price to the Company from the sales proceeds;

(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are

already owned by the Participant free and clear of any liens, claims, encumbrances or security interests,

with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that

(1) at the time of exercise the Common Stock is publicly traded, (2) any remaining balance of the exercise

price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment,

(3) such delivery would not violate any Applicable Law or agreement restricting the redemption of the

Common Stock, (4) any certificated shares are endorsed or accompanied by an executed assignment

separate from certificate and (5) such shares have been held by the Participant for any minimum period

necessary to avoid adverse accounting treatment as a result of such delivery;

(iv) if the Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the

Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole

number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise

price, provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and

(2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the

Participant in cash or other permitted form of payment; or

(v) in any other form of consideration that may be acceptable to the Board and permissible under Applicable

Law.

d. Exercise Procedure and Payment of Appreciation Distribution for SARs. In order to exercise any SAR,

the Participant must provide notice of exercise to the Plan Administrator in accordance with the Award

Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be

greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of exercise of a

number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and

being exercised under such SAR, over (ii) the strike price of such SAR. Such appreciation distribution may be

paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash)

or in any other form of payment, as determined by the Board and specified in the Award Agreement.

e. Transferability. Options and SARs may not be transferred to third-party financial institutions for value. The

Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In

the absence of any such determination by the Board, the following restrictions on the transferability of Options

and SARs will apply, provided that, except as explicitly provided herein, neither an Option nor a SAR may be

transferred for consideration, and provided, further, that if an Option is an Incentive Stock Option, such Option

may be deemed to be a Nonstatutory Stock Option as a result of such transfer:

(i) Restrictions on Transfer. An Option or SAR will not be transferable, except by will or by the laws of

descent and distribution, and will be exercisable during the lifetime of the Participant only by the

Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is

not prohibited by applicable tax and securities laws upon the Participant’s request, including to a trust if the

Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of

the Code and applicable U.S. state law) while such Option or SAR is held in such trust, provided that the

Participant and the trustee enter into a transfer and other agreements required by the Company.

A-4

(ii) Domestic Relations Orders. Notwithstanding the foregoing, subject to the execution of transfer

documentation in a format acceptable to the Company and subject to the approval of the Board or a duly

authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order.

f. Vesting. The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an

Option or SAR as determined by the Board and vesting conditions may include achievement of one or more

Performance Goals. Except as otherwise determined by the Board or provided in the applicable Award

Agreement or other written agreement between a Participant and the Company, vesting of Options and SARs

will cease upon termination of the Participant’s Continuous Service.

g. Termination of Continuous Service for Cause. Except as otherwise determined by the Board or explicitly

provided in the Award Agreement or other written agreement between a Participant and the Company, if a

Participant’s Continuous Service is terminated for Cause, the Participant’s Options and SARs will terminate

and be forfeited immediately upon such termination of Continuous Service, and the Participant will be

prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of

such termination of Continuous Service and the Participant will have no further right, title or interest in such

forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of

the forfeited Award. If a Participant is suspended pending investigation of whether his or her Continuous

Service shall be terminated for Cause, the Participant’s rights to exercise an Option or SAR shall be

suspended during the investigation period.

h. Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other

than Cause. Subject to Section 4(i), if a Participant’s Continuous Service terminates for any reason other

than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the

following period of time or, if applicable, such other period of time determined by the Board or provided in the

Award Agreement or other written agreement between a Participant and the Company; provided, however,

that in no event may such Award be exercised after the expiration of its maximum term (as set forth in

Section 4(a)):

(i) 3 months following the date of such termination if such termination is a termination without Cause (other

than any termination due to the Participant’s Disability or death); or

(ii) 12 months following the date of such termination if such termination is due to the Participant’s Disability or

the Participant’s death (or if the Participant’s death occurs following the date of such termination but

during the period such Award is otherwise exercisable (as provided in (i) above)).

Following the date of such termination, to the extent the Participant does not exercise such Award within

the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term

of such Award), such unexercised portion of the Award will terminate, and the Participant will have no

further right, title or interest in terminated Award, the shares of Common Stock subject to the terminated

Award, or any consideration in respect of the terminated Award.

i. Restrictions on Exercise; Extension of Exercisability. A Participant may not exercise an Option or SAR at

any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law.

Except as otherwise determined by the Board or provided in the Award Agreement or other written agreement

between a Participant and the Company, if a Participant’s Continuous Service terminates for any reason other

than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period:

(i) the exercise of the Participant’s Option or SAR would be prohibited solely because the issuance of shares

of Common Stock upon such exercise would violate Applicable Law, (ii) the immediate sale of any shares of

Common Stock issued upon such exercise would violate the Company’s Trading Policy or (iii) the Board has

suspended exercisability under Section 7(b), then the applicable Post-Termination Exercise Period will be

extended to the last day of the calendar month that commences following the date the Award would otherwise

expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if

any of the foregoing restrictions apply at any time during such extended exercise period, generally without

limitation as to the maximum permitted number of extensions; provided, however, that in no event may such

Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).

j. Non-Exempt Employees. No Option or SAR, whether or not vested, granted to an Employee who is a non-

exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable

for any shares of Common Stock until at least six months following the date of grant of such Award.

Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any

vested portion of such Award may be exercised earlier than six months following the date of grant of such

Award in the event of (i) such Participant’s death or Disability, (ii) a corporate transaction in which such Award

is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant’s retirement (as

A-5

such term may be defined in the Award Agreement or another applicable agreement between the Employee

and the Company or one of its Affiliates or, in the absence of any such definition, in accordance with the

Company’s then current employment policies and guidelines). This Section 4(j) is intended to operate so that

any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR

will be exempt from his or her regular rate of pay.

k. Whole Shares. Options and SARs may be exercised only with respect to whole shares of Common Stock or

their equivalents.

l. Rights as a Stockholder. Dividends and dividend equivalents may not be paid or credited to Options or

SARs, and a Participant shall have no rights to dividends, dividend equivalents or distributions or any other

rights of a stockholder with respect to the Shares subject to an Option or SAR until the Participant has given

written notice of the exercise thereof, has paid in full for such Shares and has satisfied the requirements of

Section 4(c) or 4(d), as applicable.

AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS.

a. Restricted Stock Awards and RSU Awards. Each Restricted Stock Award and RSU Award will have such

terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award

Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by

reference in the Award Agreement or otherwise) to the substance of each of the following provisions:

(i) Form of Award.

(1) RSAs: To the extent consistent with the Company’s Bylaws, at the Board’s election, shares of Common

Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company’s

instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a

certificate, which certificate will be held in such form and manner as determined by the Board. Unless

otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of

the Company with respect to any shares subject to a Restricted Stock Award.

(2) RSUs: A RSU Award represents a Participant’s right to be issued on a future date the number of shares

of Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a

holder of a RSU Award, a Participant is an unsecured creditor of the Company with respect to the

Company’s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award

and nothing contained in the Plan or any Award Agreement, and no action taken pursuant to its

provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a

Participant and the Company or an Affiliate or any other person. A Participant will not have voting or

any other rights as a stockholder of the Company with respect to any RSU Award (unless and until

shares are actually issued in settlement of a vested RSU Award).

(ii) Consideration.

(1) RSA: A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or

money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other

form of consideration as the Board may determine and permissible under Applicable Law.

(2) RSU: Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in

consideration for the Participant’s services to the Company or an Affiliate, such that the Participant will

not be required to make any payment to the Company (other than such services) with respect to the

grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the

RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the

Participant (in a form other than the Participant’s services to the Company or an Affiliate) upon the

issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be

paid in any form of consideration as the Board may determine and permissible under Applicable Law.

(iii) Vesting. The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock

Award or RSU Award as determined by the Board, which may include achievement of one or more

Performance Goals. Except as otherwise determined by the Board or provided in the Award Agreement

or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted

Stock Awards and RSU Awards will cease upon termination of the Participant’s Continuous Service.

(iv) Termination of Continuous Service. Except as otherwise determined by the Board or provided in the

Award Agreement or other written agreement between a Participant and the Company, if a Participant’s

Continuous Service terminates for any reason, (i) the Company may receive through a forfeiture condition

A-6

or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her

Restricted Stock Award that have not vested as of the date of such termination as set forth in the

Restricted Stock Award Agreement and (ii) any portion of his or her RSU Award that has not vested will

be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU

Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect

of the RSU Award; provided, however, that if the Company has a contingent contractual obligation to

provide for accelerated vesting of a Participant’s Restricted Stock Award or RSU Award after termination

of the Participant’s Continuous Service, the unvested portion of such Award subject to potential

acceleration shall remain outstanding until the maximum contractual time for determining whether such

contingency will occur, and terminate at such time if the contingency has not then occurred.

(v) Dividends and Dividend Equivalents. Dividends or dividend equivalents may be paid or credited, as

applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU

Award, subject to the same restrictions on transferability and forfeitability as the underlying Award with

respect to which such dividends or dividend equivalents are granted and subject to such other terms and

conditions as determined by the Board and specified in the Award Agreement.

(vi) Settlement of RSU Awards. A RSU Award may be settled by the issuance of shares of Common Stock

or cash (or any combination thereof) or in any other form of payment, as determined by the Board and

specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such

restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award in a

manner intended to comply with Section 409A, as applicable.

b. Other Awards. Other Awards may be granted either alone or in addition to Awards provided for under

Section 4 and the preceding provisions of this Section 5. Subject to the provisions of the Plan, the Board will

have sole and complete discretion to determine the persons to whom and the time or times at which such

Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be

granted pursuant to such Other Awards and all other terms and conditions of such Other Awards (including

the form of settlement, which may be in the form of Common Stock, cash or other form of payment).

ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

a. Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board shall appropriately and

proportionately adjust: (i) the class(es) and maximum number of shares of Common Stock subject to the Plan,

(ii) the class(es) and maximum number of shares that may be issued pursuant to the exercise of Incentive

Stock Options pursuant to Section 2(b), and (iii) the class(es) and number of securities and exercise price,

strike price or purchase price of Common Stock subject to outstanding Awards. The Board shall make such

adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no

fractional shares or rights for fractional shares of Common Stock shall be created in order to implement any

Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any

fractional shares or rights to fractional shares that might be created by the adjustments referred to in the

preceding provisions of this Section.

b. Dissolution or Liquidation. Except as otherwise determined by the Board or provided in the Award

Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than

Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or

the Company’s right of repurchase) will terminate immediately prior to the completion of such dissolution or

liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a

forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the

holder of such Award is providing Continuous Service, provided, however, that the Board may determine to

cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or

forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or

liquidation is completed but contingent on its completion.

c. Change in Control. All Awards outstanding on the effective date of a Change in Control shall be treated in

the manner described in the definitive agreement evidencing the Change in Control (or, in the event that the

Change in Control is not effected pursuant to a definitive agreement to which the Company is party, in the

manner determined by the Board, with such determination having final and binding effect on all parties),

which agreement or determination need not treat all Awards (or portions thereof) in an identical manner.

Unless an Award Agreement provides otherwise, without limiting the prior sentence, the treatment specified

in the transaction agreement or by the Board may include (without limitation) one or more of the following

with respect to each outstanding Award:

A-7

(i) Awards May Be Assumed. In the event of a Change in Control, any surviving corporation or acquiring

corporation (or the surviving or acquiring corporation’s parent company) may assume or continue any or

all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the

Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the

Company pursuant to the Change in Control), and any reacquisition or repurchase rights held by the

Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to

the successor of the Company (or the successor’s parent company, if any), in connection with such

Change in Control. A surviving corporation or acquiring corporation (or its parent) may choose to assume

or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may

choose to assume or continue the Awards held by some, but not all Participants. The terms of any

assumption, continuation or substitution will be set by the Board.

(ii) Awards Held by Current Participants. In the event of a Change in Control in which the surviving

corporation or acquiring corporation (or its parent company) does not assume or continue such

outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards

that have not been assumed, continued or substituted and that are held by Participants whose Continuous

Service has not terminated prior to the effective time of the Change in Control (referred to as the “Current

Participants” ), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights,

the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective

time of such Change in Control (contingent upon the effectiveness of the Change in Control) as the Board

determines (or, if the Board does not determine such a date, to the date that is five days prior to the

effective time of the Change in Control), and such Awards will terminate if not exercised (if applicable) at

or prior to the effective time of the Change in Control, and any reacquisition or repurchase rights held by

the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Change in

Control). With respect to the vesting of Awards with performance-based vesting that will accelerate upon

the occurrence of a Change in Control pursuant to this subsection (ii) and that have multiple vesting levels

depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of

such Awards will accelerate at 100% of the target level upon the occurrence of the Change in Control (or

such greater level as determined by the Board). With respect to the vesting of Awards that will accelerate

upon the occurrence of a Change in Control pursuant to this subsection (ii) and are settled in the form of a

cash payment, such cash payment will be made no later than 30 days following the occurrence of the

Change in Control or such later date as required to comply with Section 409A.

(iii) Awards Held by Persons other than Current Participants. In the event of a Change in Control in

which the surviving corporation or acquiring corporation (or its parent company) does not assume or

continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with

respect to Awards that have not been assumed, continued or substituted and that are held by persons

other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the

occurrence of the Change in Control; provided, however, that any reacquisition or repurchase rights held

by the Company with respect to such Awards will not terminate and may continue to be exercised

notwithstanding the Change in Control.

(iv) Payment for Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event an Award will

terminate if not exercised prior to the effective time of a Change in Control, the Board may provide, in its

sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in

such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any,

of (1) the value of the property the Participant would have received upon the exercise of the Award

(including, at the discretion of the Board, any unvested portion of such Award), over (2) any exercise

price payable by such holder in connection with such exercise; for clarity, an Award may be cancelled

without payment of any consideration if the value of such property is equal to or less than the exercise

price.

d. Appointment of Stockholder Representative. As a condition to the receipt of an Award under this Plan, a

Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement

governing a Change in Control involving the Company, including, without limitation, a provision for the

appointment of a stockholder representative that is authorized to act on the Participant’s behalf with respect

to any escrow, indemnities and any contingent consideration.

e. No Restriction on Right to Undertake Transactions. The grant of any Award under the Plan and the

issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the

Company or the stockholders of the Company to make or authorize any adjustment, recapitalization,

reorganization or other change in the Company’s capital structure or its business, any merger or

consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of

A-8

bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common

Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the

dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or

any other corporate act or proceeding, whether of a similar character or otherwise.

ADMINISTRATION.

a. Administration by Board. The Board will administer the Plan unless and until the Board delegates

administration of the Plan to a Committee or Committees, as provided in subsection (c) below.

b. Powers of Board. The Board will have the power, subject to, and within the limitations of, the express

provisions of the Plan:

(i) To determine from time to time: (1) which of the persons eligible under the Plan will be granted Awards;

(2) when and how each Award will be granted; (3) what type or combination of types of Award will be

granted; (4) the provisions of each Award granted (which need not be identical), including the time or

times when a person will be permitted to receive an issuance of Common Stock or other payment

pursuant to an Award (and whether and to what degree any applicable Performance Goals have been

attained); (5) the number of shares of Common Stock or cash equivalent with respect to which an Award

will be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms

of any Award with performance-based vesting that is not valued in whole or in part by reference to, or

otherwise based on, the Common Stock, including the amount of cash payment or other property that

may be earned and the timing of payment.

(ii) To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke

rules and regulations for its administration. The Board, in the exercise of this power, may correct any

defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it

deems necessary or expedient to make the Plan or Award fully effective.

(iii) To settle all controversies regarding the Plan and Awards granted under it.

(iv) To accelerate the time at which an Award may first be exercised or the time during which an Award or

any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at

which it may first be exercised or the time during which it will vest.

(v) To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days

prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares,

merger, consolidation or other distribution (other than normal cash dividends) of Company assets to

stockholders, or any other change affecting the shares of Common Stock or the share price of the

Common Stock including any Change in Control, for reasons of administrative convenience or in

connection with any other event pursuant to which the Board determines prohibition of exercise is

necessary or reasonable.

(vi) To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially

Impair rights and obligations under any Award granted while the Plan is in effect except with the written

consent of the affected Participant.

(vii) To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that

stockholder approval will be required for any amendment to the extent required by Applicable Law.

Except as provided above, rights under any Award granted before amendment of the Plan will not be

Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the

affected Participant, and (2) such Participant consents in writing.

(viii) To submit any amendment to the Plan for stockholder approval.

(ix) To institute and determine the terms and conditions of an Exchange Program; provided that the Board

shall not implement an Exchange Program without stockholder approval.

(x) To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or

more Awards, including, but not limited to, amendments to provide terms more favorable to the

Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan

that are not subject to Board discretion; provided however, that, (1) the Board shall not, without

stockholder approval, reduce the exercise or strike price of an Option or SAR (other than in connection

with a Capitalization Adjustment) and, at any time when the exercise or strike price of an Option or SAR

is above the Fair Market Value of a share of Common Stock, the Board shall not, without stockholder

A-9

approval, cancel and re-grant or exchange such Option or SAR for a new Award with a lower (or no)

purchase price or for cash, and (2) a Participant’s rights under any Award will not be Materially Impaired

by any such amendment unless (A) the Company requests the consent of the affected Participant, and

(B) such Participant consents in writing.

(xi) Generally, to exercise such powers and to perform such acts as the Board deems necessary or

expedient to promote the best interests of the Company and that are not in conflict with the provisions of

the Plan or Awards.

(xii) To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate

participation in the Plan by, or take advantage of specific tax treatment for Awards granted to,

Employees, Directors or Consultants who are non-U.S. nationals or employed outside the United States

(provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award

Agreement to ensure or facilitate compliance with the laws of the relevant non-U.S. jurisdiction).

c. Delegation to Committee.

(i) General. The Board may delegate some or all of the administration of the Plan to a Committee or

Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in

connection with the administration of the Plan, the powers theretofore possessed by the Board that have

been delegated to the Committee, including the power to delegate to another Committee or a

subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise

(and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject,

however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time

to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the

Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest

in such Committee some or all of the powers previously delegated. The Board will retain the authority to

concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all

of the powers previously delegated.

(ii) Rule 16b-3 Compliance. To the extent an Award is intended to qualify for the exemption from

Section 16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will

be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as

determined under Rule 16b-3(b)(3) of the Exchange Act, and, thereafter, any action establishing or

modifying the terms of the Award will be approved by the Board or a Committee meeting such

requirements to the extent necessary for such exemption to remain available.

d. Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board or

any Committee in good faith will not be subject to review by any person and will be final, binding and

conclusive on all persons.

e. Delegation to an Officer. The Board or any Committee may delegate to one or more Officers the authority

to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options

and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent

permitted by Applicable Law, the terms thereof, and (ii) determine the number of shares of Common Stock

to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter

adopted by the Board or any Committee evidencing such delegation will specify the total number of shares

of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not

grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award

Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the

resolutions approving the delegation of authority. Notwithstanding anything to the contrary herein, neither

the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer

(and not also as a Director) the authority to determine the Fair Market Value.

TAX WITHHOLDING

a. Withholding Authorization. As a condition to acceptance of any Award under the Plan, a Participant

authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees

to make adequate provision for (including), any sums required to satisfy any U.S. and/or non-U.S. federal,

state, or local tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any,

which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a

Participant may not be able to exercise an Award even though the Award is vested, and the Company shall

A-10

have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations

are satisfied.

b. Satisfaction of Withholding Obligation. To the extent permitted by the terms of an Award Agreement, the

Company may, in its sole discretion, satisfy any U.S. and/or non-U.S. federal, state or local tax or social

insurance withholding obligation relating to an Award by any of the following means or by a combination of

such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock

from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the

Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts

otherwise payable to the Participant; (v) by allowing a Participant to effectuate a “cashless exercise” pursuant

to a program developed under Regulation T as promulgated by the U.S. Federal Reserve Board or (vi) by

such other method as may be set forth in the Award Agreement.

c. No Obligation to Notify or Minimize Taxes; No Liability to Claims. Except as required by Applicable Law,

the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of

exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise

such holder of a pending termination or expiration of an Award or a possible period in which the Award may

not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to

the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to

such holder in connection with an Award. As a condition to accepting an Award under the Plan, each

Participant (i) agrees not to make any claim against the Company, or any of its Officers, Directors, Employees

or Affiliates related to tax liabilities arising from such Award or other Company compensation and

(ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and

other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and

voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under

the Plan is exempt from Section 409A only if the exercise or strike price is at least equal to the “fair market

value” of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is

no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to

accepting an Option or SAR granted under the Plan, each Participant agrees not to make any claim against

the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the U.S. Internal

Revenue Service asserts that such exercise price or strike price is less than the “fair market value” of the

Common Stock on the date of grant as subsequently determined by the U.S. Internal Revenue Service.

d. Withholding Indemnification. As a condition to accepting an Award under the Plan, in the event that the

amount of the Company’s and/or its Affiliate’s withholding obligation in connection with such Award was

greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to

indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its

Affiliates to withhold the proper amount.

MISCELLANEOUS.

a. Source of Shares; Fractional Shares. The stock issuable under the Plan will be shares of authorized but

unissued or reacquired Common Stock, including shares repurchased by the Company on the open market

or otherwise. No fractional shares of Common Stock will be issued or delivered pursuant to this Plan or any

Award. The Board may determine whether cash, other Awards or other securities or property will be issued

or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto will be forfeited

or otherwise eliminated.

b. Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock

pursuant to Awards will constitute general funds of the Company.

c. Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of

an Award to any Participant will be deemed completed as of the date of such corporate action, unless

otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the

Award is communicated to, or actually received or accepted by, the Participant. In the event that the

corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving

the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with

those in the Award Agreement or related grant documents as a result of a clerical error in the Award

Agreement or related grant documents, the corporate records will control and the Participant will have no

legally binding right to the incorrect term in the Award Agreement or related grant documents.

A-11

d. Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a

holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such

Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and

(ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.

e. No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other

instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon

any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time

the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without

regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the

employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant

pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate or (iii) the service of a

Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate

law of the U.S. state or non-U.S. jurisdiction in which the Company or the Affiliate is incorporated, as the

case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed

thereunder or in connection with any Award will constitute any promise or commitment by the Company or an

Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any

other term or condition of employment or service or confer any right or benefit under the Award or the Plan

unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan.

f. Change in Time Commitment. In the event a Participant’s regular level of time commitment in the

performance of his or her services for the Company and any Affiliates is reduced (for example, and without

limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a

full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of

any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law and

without the affected Participant’s consent, to (i) make a corresponding reduction in the number of shares or

cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date

of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the

vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant

will have no right with respect to any portion of the Award that is so reduced or extended.

g. Execution of Additional Documents. As a condition to accepting an Award under the Plan, the Participant

agrees to execute any additional documents or instruments necessary or desirable, as determined in the

Plan Administrator’s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance

with securities and/or other regulatory requirements, in each case at the Plan Administrator’s request.

h. Electronic Delivery and Participation. Any reference herein or in an Award Agreement to a “written”

agreement or document will include any agreement or document delivered electronically, filed publicly at

www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared

electronic medium controlled by the Company to which the Participant has access). By accepting any Award

the Participant consents to receive documents by electronic delivery and to participate in the Plan through

any on-line electronic system established and maintained by the Plan Administrator or another third party

selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or

electronic entry evidencing such shares) shall be determined by the Company.

i. Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance

with any clawback policy that the Company is required to adopt pursuant to the listing standards of any

national securities exchange or association on which the Company’s securities are listed or as is

otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other

Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable

and permissible under Applicable Law. In addition, the Board may impose such other clawback,

recovery or recoupment provisions in an Award Agreement as the Board determines necessary or

appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of

Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation

under such a clawback policy will be an event giving rise to a Participant’s right to voluntarily terminate

employment upon a “resignation for good reason,” or for a “constructive termination” or any similar term

under any plan of or agreement with the Company or any of its Affiliates.

j. Securities Law Compliance. A Participant will not be issued any shares in respect of an Award unless either

(i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance

would be exempt from the registration requirements of the Securities Act. Each Award also must comply with

A-12

other Applicable Law governing the Award, and a Participant will not receive such shares if the Company

determines that such receipt would not be in material compliance with Applicable Law.

k. Transfer or Assignment of Awards; Issued Shares. Except as otherwise determined by the Board or

expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be

transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or

in the case of Restricted Stock Awards and similar awards, after the issued shares have vested, the holder of

such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such

shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading

Policy and Applicable Law.

l. Effect on Other Employee Benefit Plans. The value of any Award granted under the Plan, as determined

upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar

terms used when calculating any Participant’s benefits under any employee benefit plan sponsored by the

Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly

reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit

plans.

m. Deferrals. To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that

the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a

portion of any Award may be deferred and may establish programs and procedures for deferral elections to

be made by Participants. Deferrals will be made in accordance with the requirements of Section 409A.

n. Section 409A. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award

Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the

Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with

the requirements of Section 409A. If the Board determines that any Award granted hereunder is not exempt

from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate

the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code,

and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby

incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan

(and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are

publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under

Section 409A is a “specified employee” for purposes of Section 409A, no distribution or payment of any

amount that is due because of a “separation from service” (as defined in Section 409A without regard to

alternative definitions thereunder) will be issued or paid before the date that is six months and one day

following the date of such Participant’s “separation from service” or, if earlier, the date of the Participant’s

death, unless such distribution or payment can be made in a manner that complies with Section 409A, and

any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the

balance paid thereafter on the original schedule.

o. Choice of Law. This Plan and any controversy arising out of or relating to this Plan shall be governed by,

and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law

principles that would result in any application of any law other than the law of the State of Delaware.

p. Data Privacy. As a condition of receipt of any Award, each Participant explicitly and unambiguously

acknowledges that the Company and its Affiliates will process certain personal information about the

Participant in accordance with the provisions of the Company’s privacy notice, a copy of which can be

obtained by the Participant by contacting his or her local human resources representative. Such personal

information may include, but is not limited to, the Participant’s name, home address, email address and

telephone number, date of birth, social security or insurance number, passport number or other identification

number, salary, nationality, job title, any shares or directorships held in the Company, and details of all

Awards or any other entitlement to shares of Common Stock awarded, canceled, exercised, vested,

unvested or outstanding in Participant’s favor (“ Data ”), for the exclusive purpose of implementing,

administering and managing the Plan. In certain jurisdictions, the Participant’s consent is required in order

for the parties to process Participant’s personal information for the purpose of implementing, administering

and managing Participant’s participation in the Plan pursuant to and in accordance with his or her Award

Agreement. Where such consent is required and without limiting any other specific consent provided by the

Participant, including in any consent provided in a separate document, the Participant explicitly and

unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s

personal data as described herein and any other applicable Award grant materials by and among, as

applicable, the Company or any of its Affiliates for the exclusive purpose of implementing, administering and

A-13

managing the Participant’s participation in the Plan. The Participant understands that Data will be transferred

to a stock plan service provider as may be selected by the Company from time-to-time (the “ Designated

Broker ”), which is assisting the Company with the implementation, administration and management of the

Plan. The Participant understands that the recipients of the Data may be located in the United States or

elsewhere, and that the recipient’s country of operation may have different data privacy laws and protections

than the Participant’s country. The Participant understands that if he or she resides outside the United

States, he or she may request a list with the names and addresses of any potential recipients of the Data by

contacting his or her local human resources representative. The Participant authorizes (where such

authorization is required) the Company, the Designated Broker and any other possible recipients which may

assist the Company (presently or in the future) with implementing, administering and managing the Plan to

receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of

implementing, administering and managing his or her participation in the Plan. The Participant understands

that Data will be held only as long as is necessary to implement, administer and manage his or her

participation in the Plan. The Participant understands that if he or she resides outside the United States, he

or she may, at any time, view Data, request additional information about the storage and processing of Data,

require any necessary amendments to Data or, where applicable, refuse or withdraw the consents herein, in

any case without cost, by contacting in writing his or her local human resources representative. Further, the

Participant understands that where his or her consent is required by applicable law, he or she is providing the

consents on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to

revoke his or her consent, his or her status as an Employee, Consultant or Director and career with the

Company and its Affiliates will not be adversely affected; the only adverse consequence of refusing or

withdrawing the Participant’s consent is that the Company would not be able to grant Awards to the

Participant or administer or maintain such Awards. Therefore, the Participant understands that refusing or

withdrawing his or her consent may affect the Participant’s ability to participate in the Plan. For more

information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the

Participant understands that he or she may contact his or her local human resources representative.

COMPLIANCE WITH LAW.

The Company will seek to obtain from each regulatory commission or agency, as may be deemed necessary,

having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares

of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not

require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or

issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is

unable to obtain from any such regulatory commission or agency the authority that counsel for the Company

deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company

will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such

Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the

subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of

any Applicable Law.

SEVERABILITY.

If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be

unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award

Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of

such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give

effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and

valid.

TERMINATION OF THE PLAN.

The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the

tenth anniversary of the Effective Date. No Awards may be granted under the Plan while the Plan is suspended

or after it is terminated.

DEFINITIONS.

As used in the Plan, the following definitions apply to the capitalized terms indicated below:

(a) “Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms

are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at

which “parent” or “subsidiary” status is determined within the foregoing definition.

A-14

(b) “Applicable Law” means the Code and any applicable U.S. or non-U.S. securities, federal, state, material

local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code,

edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted,

promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body

(including under the authority of any applicable self-regulating organization such as The Nasdaq Stock

Market LLC, the New York Stock Exchange or the Financial Industry Regulatory Authority, Inc.).

(including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a RSU Award,

a SAR or any Other Award).

(d) “Award Agreement” means a written agreement between the Company and a Participant evidencing the

terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the

agreement containing the written summary of the general terms and conditions applicable to the Award and

which is provided to a Participant along with the Grant Notice.

(e) “Board” means the board of directors of the Company (or its designee). Any decision or determination

made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its

designee), and such decision or determination shall be final and binding on all Participants.

(f) “Capitalization Adjustment” means any change that is made in, or other events that occur with respect to,

the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of

consideration by the Company through merger, consolidation, reorganization, recapitalization,

reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock

split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in

corporate structure or any similar equity restructuring transaction, as that term is used in Statement of

Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor

thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not

be treated as a Capitalization Adjustment.

(g) “Cause” has the meaning ascribed to such term in any written agreement between the Participant and the

Company defining such term and, in the absence of such agreement, such term means, with respect to a

Participant, the occurrence of any of the following events: (i) the Participant’s theft, dishonesty, willful

misconduct, breach of fiduciary duty for personal profit, or intentional falsification of any Company or Affiliate

documents or records; (ii) the Participant’s material failure to abide by the Company’s Code of Conduct or

other policies (including, without limitation, policies relating to confidentiality and reasonable workplace

conduct and policies of any Affiliate, as applicable); (iii) the Participant’s unauthorized use, misappropriation,

destruction or diversion of any tangible or intangible asset or corporate opportunity of the Company or any of

its Affiliates (including, without limitation, the Participant’s improper use or disclosure of Company or Affiliate

confidential or proprietary information); (iv) any intentional act by the Participant which has a material

detrimental effect on the Company’s or its Affiliate’s reputation or business; (v) the Participant’s repeated

failure or inability to perform any reasonable assigned duties after written notice from the Company (or its

Affiliate, as applicable) of, and a reasonable opportunity to cure, such failure or inability; (vi) any material

breach by the Participant of any employment or service agreement between the Participant and the

Company (or its Affiliate, as applicable), which breach is not cured pursuant to the terms of such agreement;

or (vii) the Participant’s conviction (including any plea of guilty or nolo contendere) of any criminal act

involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs the Participant’s ability to

perform his or her duties with the Company (or its Affiliate, as applicable). The determination that a

termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the

Board with respect to Participants who are executive officers of the Company or members of the Board and

by the Company’s Chief Executive Officer or his or her designee with respect to all other Participants. Any

determination by the Company that the Continuous Service of a Participant was terminated with or without

Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any

determination of the rights or obligations of the Company or such Participant for any other purpose.

(h) “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of

any one or more of the following events; provided, however, to the extent necessary to avoid adverse

personal income tax consequences to the Participant in connection with an Award, also constitutes a

Section 409A Change in Control:

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company

representing more than 50% of the combined voting power of the Company’s then outstanding securities

other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a

A-15

Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the

Company directly from the Company, (B) on account of the acquisition of securities of the Company by

an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s

securities in a transaction or series of related transactions the primary purpose of which is to obtain

financing for the Company through the issuance of equity securities, or (C) solely because the level of

Ownership held by any Exchange Act Person (the “ Subject Person ”) exceeds the designated

percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition

of voting securities by the Company reducing the number of shares outstanding, provided that if a

Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of

voting securities by the Company, and after such share acquisition, the Subject Person becomes the

Owner of any additional voting securities that, assuming the repurchase or other acquisition had not

occurred, increases the percentage of the then outstanding voting securities Owned by the Subject

Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;

(ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the

Company and, immediately after the consummation of such merger, consolidation or similar transaction,

the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either

(A) outstanding voting securities representing more than 50% of the combined outstanding voting power

of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the

combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or

similar transaction, in each case in substantially the same proportions as their Ownership of the

outstanding voting securities of the Company immediately prior to such transaction;

(iii) the stockholders of the Company approve or the Board approves a plan of complete dissolution or

liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise

occur, except for a liquidation into a parent corporation;

(iv) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the

consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other

disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an

Entity, at least 50% of the combined voting power of the voting securities of which are Owned by

stockholders of the Company in substantially the same proportions as their Ownership of the outstanding

voting securities of the Company immediately prior to such sale, lease, license or other disposition; or

(v) during any period of 12 consecutive months, individuals who, on the date the Plan is adopted by the

Board, are members of the Board (the “ Incumbent Board ”) cease for any reason to constitute at least a

majority of the members of the Board; provided, however, that if the appointment or election (or

nomination for election) of any new Board member was approved or recommended by a majority vote of

the members of the Incumbent Board then still in office, such new member shall, for purposes of this

Plan, be considered as a member of the Incumbent Board and that no individual initially elected or

nominated as a member of the Board as a result of an actual or threatened election contest with respect

to the election or removal of directors or other actual or threatened solicitation of proxies or consents by

or on behalf of any person other than the Board (a “ Proxy Contest ”), including by reason of any

agreement intended to avoid or settle any Proxy Contest, shall be considered to be a member of the

Incumbent Board.

Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall

not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing

the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an

individual written agreement between the Company or any Affiliate and the Participant shall supersede

the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no

definition of Change in Control or any analogous term is set forth in such an individual written agreement,

the foregoing definition shall apply.

(i) “Code” means the U.S. Internal Revenue Code of 1986, as amended, including any applicable

regulations and guidance thereunder.

(j) “Committee” means the Compensation Committee and any other committee of one or more Directors to

whom authority has been delegated by the Board or Compensation Committee in accordance with the

Plan.

(k) “Common Stock” means the common stock, par value $0.001 per share, of the Company.

(l) “Company” means CareDx, Inc., a Delaware corporation, and any successor corporation thereto.

A-16

(m) “Compensation Committee” means the Compensation Committee of the Board.

(n) “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate

to render consulting or advisory services and is compensated for such services, or (ii) serving as a

member of the board of directors of an Affiliate and is compensated for such services. However, service

solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a

“Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a

Consultant under this Plan only if a Registration Statement on Form S-8 under the Securities Act is

available to register either the offer or the sale of the Company’s securities to such person.

(o) “Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as

an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which

the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or

a change in the Entity for which the Participant renders such service, provided that there is no

interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate

a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is

rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant’s

Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an

Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an

Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted

by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may

determine whether Continuous Service will be considered interrupted in the case of (i) any leave of

absence approved by the Board or chief executive officer, including sick leave, military leave or any other

personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding

the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an

Award only to such extent as may be provided in the Company’s leave of absence policy, in the written

terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required

by law. In addition, to the extent required for exemption from or compliance with Section 409A, the

determination of whether there has been a termination of Continuous Service will be made, and such

term will be construed, in a manner that is consistent with the definition of “separation from service” as

defined under U.S. Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition

thereunder).

(p) “determine” or “determined” means as determined by the Board or the Committee (or its designee) in its

sole discretion.

(q) “Director” means a member of the Board.

(r) “Disability” means, with respect to a Participant, such Participant is unable to engage in any substantial

gainful activity after accounting for reasonable accommodations (if applicable and required by Applicable

Law) by reason of any medically determinable physical or mental impairment which can be expected to

result in death or which has lasted or can be expected to last for a continuous period of not less

than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the

basis of such medical evidence as the Board deems warranted under the circumstances.

(s) “Effective Date” means the date on which the Company’s stockholders approve the adoption of the

Plan.

(t) “Employee” means any person employed by the Company or an Affiliate. However, service solely as a

Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee”

for purposes of the Plan.

(u) “Employer” means the Company or the Affiliate that employs the Participant.

(v) “Entity” means a corporation, partnership, limited liability company or other entity.

(w) “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and

regulations promulgated thereunder.

(x) “Exchange Act Person” means any natural person, Entity or “group” (within the meaning of

Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the

Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any

Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit

plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities

pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by

A-17

the stockholders of the Company in substantially the same proportions as their Ownership of stock of the

Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the

Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the

Company representing more than 50% of the combined voting power of the Company’s then outstanding

securities.

(y) “Exchange Program” means a program subject to stockholder approval as set forth in Section 7(b)(ix)

under which (i) outstanding Awards are surrendered or cancelled in exchange for awards of the same

type (which may have higher or lower exercise prices and different terms), awards of a different type,

and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial

institution or other person or entity selected by the Board or the Committee, and/or (iii) the exercise price

of an outstanding Award is increased or reduced. The Board or the Committee will determine the terms

and conditions of any Exchange Program in its sole discretion.

(z) “Fair Market Value” means, as of any date, unless otherwise determined by the Board, the value of the

Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows:

(i) if the Common Stock is listed on any established stock exchange or traded on any established

market, the Fair Market Value will be the closing sales price for such stock as quoted on such

exchange or market (or the exchange or market with the greatest volume of trading in the Common

Stock) on the date of determination, as reported in a source the Board deems reliable;

(ii) if there is no closing sales price for the Common Stock on the date of determination, then the Fair

Market Value will be the closing selling price on the last preceding date for which such quotation

exists; or

(iii) in the absence of such markets for the Common Stock, or if otherwise determined by the Board, the

Fair Market Value will be determined by the Board in good faith and in a manner that complies with

Sections 409A and 422 of the Code.

(aa) “Governmental Body” means any: (a) nation, state, commonwealth, province, territory, county,

municipality, district or other jurisdiction of any nature; (b) U.S. or non-U.S. federal, state, local,

municipal, or other government; (c) governmental or regulatory body, or quasi-governmental body of

any nature (including any governmental division, department, administrative agency or bureau,

commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit,

body or Entity and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other

body exercising similar powers or authority; or (d) self-regulatory organization (including The Nasdaq

Stock Market LLC, the New York Stock Exchange, and the Financial Industry Regulatory Authority,

Inc.).

(bb) “Grant Notice” means the notice provided to a Participant that he or she has been granted an Award

under the Plan and which includes the name of the Participant, the type of Award, the date of grant of

the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if

any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.

(cc) “Incentive Stock Option” means an option granted pursuant to Section 4 of the Plan that is intended

to be, and qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.

(dd) “Materially Impair” means any amendment to the terms of the Award that materially adversely affects

the Participant’s rights under the Award. A Participant’s rights under an Award will not be deemed to

have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines

that the amendment, taken as a whole, does not materially impair the Participant’s rights. For example,

the following types of amendments to the terms of an Award do not Materially Impair the Participant’s

rights under the Award: (i) imposition of reasonable restrictions on the minimum number of shares

subject to an Option that may be exercised; (ii) to maintain the qualified status of the Award as an

Incentive Stock Option under Section 422 of the Code; (iii) to change the terms of an Incentive Stock

Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an

Incentive Stock Option under Section 422 of the Code; (iv) to clarify the manner of exemption from, or to

bring the Award into compliance with or qualify it for an exemption from, Section 409A; or (v) to comply

with other Applicable Laws.

(ee) “Non-Employee Director” means a Director who either (i) is not a current employee or officer of the

Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company

or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except

A-18

for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K

promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any

other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not

engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of

Regulation S-K; or (ii) is otherwise considered a “non-employee director” for purposes of Rule 16b-3.

(ff) “Nonstatutory Stock Option” means any option granted pursuant to Section 4 of the Plan that does

not qualify as an Incentive Stock Option.

(gg) “Officer” means a person who is an officer of the Company within the meaning of Section 16 of the

Exchange Act.

(hh) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of

Common Stock granted pursuant to the Plan.

(ii) “Other Award” means an award valued in whole or in part by reference to, or otherwise based on,

Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise

price or strike price less than 100% of the Fair Market Value at the time of grant) that is not an Incentive

Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award or RSU Award.

(jj) “Other Award Agreement” means a written agreement between the Company and a holder of an

Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award

Agreement will be subject to the terms and conditions of the Plan.

(kk) “Own,” “Owned,” “Owner,” “Ownership” means that a person or Entity will be deemed to “Own,” to

have “Owned,” to be the “Owner” of or to have acquired “Ownership” of securities if such person or

Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or

otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with

respect to such securities.

(ll) “Participant” means an Employee, Director or Consultant to whom an Award is granted pursuant to the

Plan or, if applicable, such other person who holds an outstanding Award.

(mm) “Performance Criteria” means the one or more criteria that the Board will select for purposes of

establishing the Performance Goals for a Performance Period. The Performance Criteria that will be

used to establish such Performance Goals may include (but is not limited to) any one of, or

combination of, the following as determined by the Board: earnings (including earnings per share and

net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes,

depreciation and amortization; total stockholder return; return on equity or average stockholder’s

equity; return on assets, investment, or capital employed; stock price; margin (including gross margin);

income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating

cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost

reduction goals; improvement in or attainment of working capital levels; economic value added (or an

equivalent metric); market share; cash flow; cash flow per share; share price performance; debt

reduction; customer satisfaction; stockholders’ equity; capital expenditures; debt levels; operating profit

or net operating profit; workforce diversity; growth of net income or operating income; billings; pre-

clinical development related compound goals; financing; regulatory milestones, including approval of a

compound; stockholder liquidity; corporate governance and compliance; product commercialization;

intellectual property; personnel matters; progress of internal research or clinical programs; progress of

partnered programs; partner satisfaction; budget management; clinical achievements; completing

phases of a clinical study (including the treatment phase); announcing or presenting preliminary or final

data from clinical studies; in each case, whether on particular timelines or generally; timely completion

of clinical trials; submission of INDs and NDAs and other regulatory achievements; partner or

collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act

of 2002; research progress, including the development of programs; investor relations, analysts and

communication; manufacturing achievements (including obtaining particular yields from manufacturing

runs and other measurable objectives related to process development activities); strategic partnerships

or transactions (including in-licensing and out-licensing of intellectual property; establishing

relationships with commercial entities with respect to the marketing, distribution and sale of the

Company’s products (including with group purchasing organizations, distributors and other vendors));

supply chain achievements (including establishing relationships with manufacturers or suppliers of

active pharmaceutical ingredients and other component materials and manufacturers of the

Company’s products); co-development, co-marketing, profit sharing, joint venture or other similar

A-19

arrangements; individual performance goals; corporate development and planning goals; and other

measures of performance selected by the Board.

(nn) “Performance Goals” means, for a Performance Period, the one or more goals established by the

Board for the Performance Period based upon the Performance Criteria. Performance Goals may be

based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or

business segments, and in either absolute terms or relative to the performance of one or more

comparable companies or the performance of one or more relevant indices. Unless specified

otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other

document setting forth the Performance Goals at the time the Performance Goals are established, the

Board will appropriately make adjustments in the method of calculating the attainment of Performance

Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring

charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally

accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax

rates; (5) to exclude the effects of items that are “unusual” in nature or occur “infrequently” as

determined under generally accepted accounting principles; (6) to exclude the dilutive effects of

acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved

performance objectives at targeted levels during the balance of a Performance Period following such

divestiture; (8) to exclude the effect of any change in the outstanding shares of Common Stock of the

Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization,

merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change,

or any distributions to common stockholders other than regular cash dividends; (9) to exclude the

effects of stock based compensation and the award of bonuses under the Company’s bonus plans;

(10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required

to be expensed under generally accepted accounting principles; and (11) to exclude the goodwill and

intangible asset impairment charges that are required to be recorded under generally accepted

accounting principles. In addition, the Board retains the discretion to reduce or eliminate the

compensation or economic benefit due upon attainment of Performance Goals and to define the

manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial

achievement of the specified criteria may result in the payment or vesting corresponding to the degree

of achievement as specified in the Award Agreement.

(oo) “Performance Period” means the period of time selected by the Board over which the attainment of

one or more Performance Goals will be measured for the purpose of determining a Participant’s right

to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration,

at the sole discretion of the Board.

(pp) “Plan” means this CareDx, Inc. 2024 Equity Incentive Plan, as amended from time to time.

(qq) “Plan Administrator” means the person, persons, and/or third-party administrator designated by the

Company to administer the day-to-day operations of the Plan and the Company’s other equity

incentive programs.

(rr) “Post-Termination Exercise Period” means the period following termination of a Participant’s

Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(h).

(ss) “Restricted Stock Award” or “RSA” means an Award of shares of Common Stock granted pursuant

to the terms and conditions of Section 5(a).

(tt) “Restricted Stock Award Agreement” means a written agreement between the Company and a

holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award

grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock

Award and the agreement containing the written summary of the general terms and conditions

applicable to the Restricted Stock Award and which is provided to a Participant along with the Grant

Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the

Plan.

(uu) “RSU Award” or “RSU” means an Award of restricted stock units representing the right to receive an

issuance of shares of Common Stock which is granted pursuant to the terms and conditions of

Section 5(a).

(vv) “RSU Award Agreement” means a written agreement between the Company and a holder of a RSU

Award evidencing the terms and conditions of a RSU Award. The RSU Award Agreement includes the

Grant Notice for the RSU Award and the agreement containing the written summary of the general

A-20

terms and conditions applicable to the RSU Award and which is provided to a Participant along with

the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan.

(ww) “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to

Rule 16b-3, as in effect from time to time.

(xx) “Rule 405” means Rule 405 promulgated under the Securities Act.

(yy) “Section 409A” means Section 409A of the Code and the regulations and other guidance thereunder.

(zz) “Section 409A Change in Control” means a change in the ownership or effective control of the

Company, or in the ownership of a substantial portion of the Company’s assets, as provided in

Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without regard

to any alternative definition thereunder).

(aaa) “Securities Act” means the U.S. Securities Act of 1933, as amended.

(bbb) “Share” means a share of Common Stock, as adjusted in accordance with Section 6 of the Plan.

(ccc) “Share Reserve” means the number of shares available for issuance under the Plan as set forth in

Section 2(a).

(ddd) “Stock Appreciation Right” or “SAR” means a right to receive the appreciation on Common Stock

that is granted pursuant to the terms and conditions of Section 4.

(eee) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the

outstanding Common Stock having ordinary voting power to elect a majority of the board of directors of

such corporation (irrespective of whether, at the time, stock of any other class or classes of such

corporation will have or might have voting power by reason of the happening of any contingency) is at

the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability

company or other entity in which the Company has a direct or indirect interest (whether in the form of

voting or participation in profits or capital contribution) of more than 50%.

(fff) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to

Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all

classes of stock of the Company or any Affiliate.

(ggg) “Trading Policy” means the Company’s policy permitting certain individuals to sell Company shares

only during certain “window” periods and/or otherwise restricts the ability of certain individuals to

transfer or encumber Company shares, as in effect from time to time.

Adopted by the Board of Directors (contingent on approval by the Stockholders) on April 24, 2024

Approved by the Stockholders on June 13, 2024

B-1

APPENDIX B

Amendment No. 1

to the

Caredx, Inc.

2024 Equity Incentive Plan

April 23, 2025

This Amendment No 1. (this “ Amendment ”) to the CareDx, Inc. 2024 Equity Incentive Plan (the “ Plan ”) was

adopted by the Board of Directors (the “ Board ”) of CareDx, Inc. (the “ Company ”), and following the Board’s approval

of this Amendment as of the date first written above, will be effective as of the date on which this Amendment is

approved by the stockholders of the Company (the “ Amendment Effective Date ”).

WHEREAS , the Company maintains the Plan, and pursuant to Section 7(b) of the Plan, the Board is

authorized to amend the Plan;

WHEREAS , the Board desires to amend the Plan to increase the number of shares of the Company’s

Common Stock reserved and available for issuance thereunder; and

WHEREAS , following approval by the Board, this Amendment will become effective as of and contingent

upon approval by the Company’s stockholders and if, for any reason, the Company’s stockholders fail to approve this

Amendment, this Amendment shall be void ab initio and the existing Plan shall continue in full force and effect.

NOW , THEREFORE , the Plan is hereby amended as follows, subject to and effective upon the Amendment

Effective Date:

Capitalized Terms . Capitalized terms that are not defined in this Amendment shall have the meanings

ascribed thereto in the Plan.

Amendments to the Plan .

i. Section 2(a) of the Plan is hereby amended in its entirety to read as follows :

“ (a) Share Reserve . Subject to adjustment in accordance with Section 2(c)

and any adjustments as necessary to implement any Capitalization

Adjustments, the aggregate number of shares of Common Stock that may

be issued pursuant to Awards will not exceed 5,100,000 shares.”

ii. Section 2(b) of the Plan is hereby amended in its entirety to read as follows:

“ (b) Aggregate Incentive Stock Option Limit . Notwithstanding anything to

the contrary in Section 2(a) and subject to any adjustments as necessary to

implement any Capitalization Adjustments, the aggregate maximum number

of shares of Common Stock that may be issued pursuant to the exercise of

Incentive Stock Options is 5,100,000 shares.”

Ratification and Confirmation . Except as specifically amended by this Amendment, the Plan is hereby

ratified and confirmed in all respects and remains valid and in full force and effect.

Choice of Law . This Amendment shall be governed by and construed in accordance with the laws of the

State of Delaware, without reference to the principles of conflicts of laws thereof.

Headings . Section headings are for convenience only and shall not be considered a part of this

Amendment.

AI Terminal

More from CareDx, Inc.

Talk to a Data Expert